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Fibroblast growth factor 10 (FGF10) is a mesenchymal paracrine-acting factor that
stimulates epithelial growth and is involved in the development of several branched
organs, including the lungs, lachrymal glands and prostate. During branching
morphogenesis in the lung, FGF10 is expressed in discrete areas of mesenchyme
juxtaposed to branching epithelial tips. It has been proposed that paracrine factors
produced in the epithelium and by differentiated stroma, such as sonic hedgehog (SHH)
and transforming growth factor beta 1 (TGFbetal) regulate the discrete expression
pattern of FGF10. In the prostate, FGF10 expression is also confined to the mesenchyme
that surrounds growing epithelial buds. In the prostate it has been proposed that FGF10
is involved in prostatic induction and epithelial branching morphogenesis. However,
little is known about how FgflO is regulated in the prostate, and the aim of this thesis
was to investigate some of these regulatory mechanisms. This was done by developing a
primary mesenchymal cell system in which to study FgflO regulation; investigating how
TGFbetal and testosterone affect FgflO transcript expression in prostate cells and
organs, and analysing the FgflO promoter. In addition the effects of TGFbetal on
prostate growth were assessed to determine if TGFbetal might have opposing effects to
that of FGF10.
A primary stromal cell system, derived from the Ventral Mesenchymal Pad (VMP) was
established and characterised. The VMP is a condensed area of mesenchyme found in
both males and females that is required for prostatic induction in males, and is known to
express FgflO. After the first passage in vitro, primary VMP cells (VMPC) became
larger and their growth rate slowed, suggesting that primary VMPC senesced after being
plated out. VMPC maintained expression of FgflO, Tgfbetal, 2, and 3 transcripts at
levels similar to those in the VMP in vivo. VMPC also expressed androgen receptor but
did not show androgen responsive growth in vitro. It was concluded that primary VMPC
were a good cellular system in which to study the regulation of FgflO gene expression,
and were used on their first passage.
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It has been shown that TGFbetal and testosterone regulate FgflO transcript expression
in cells in culture. In studies presented here treatment of both cells and organs showed
no direct regulation of FgflO by testosterone. However, treatment of primary VMPC
with TGFbetal reduced FgflO expression fourteen-fold after 3 hours, but levels returned
to control levels after 48 hours. A seven-hour TGFbetal treatment of VMP organ
rudiments grown in vitro also decreased FgflO transcript levels by three-fold, similar to
the decrease in expression after seven hours in primary VMPC. Furthermore, regulation
of FgflO transcripts by TGFbetal was found to be specific for cells of the VMP and was
not observed in urethral stroma. We next sought to extend our study into ventral prostate
(VP) to determine if TGFbetal could regulate FgflO transcript levels in the prostate.
TGFbetal only decreased FgflO transcript levels in the VP by approximately 1.5-fold, in
contrast to VMP and VMPC that showed over a 3-fold repression. The reasons for the
lower response of FgflO to TGFbetal in VPs were not determined but may be due to
epithelium inhibiting TGFbetal repression of FgflO. This implies that factors present in
the epithelium regulate the temporal and spatial expression of FgflO in the prostate,
similar to observations in the lung.
To further analyse FgflO regulation, 6 kb of mouse genomic sequence 5' to the
translation start, which was thought to contain the FgflO promoter, was characterised. A
transcription start site for FgflO was mapped 704 nts 5' to the translation start site, by
RNase protection assay. Comparisons of the mouse and human genomic sequences 5' to
the FgflO gene revealed several regions of high homology, suggestive of sites that
control FgflO gene expression. Deletion analysis of the FgflO promoter identified a
conserved element that mediated the majority of FgflO promoter activity above basal
core promoter activity, as well as mediating promoter downregulation by TGFbetal.
This element was located between nucleotides -50/-198, and contained a consensus Spl
binding site. The promoter study provided further evidence that suggests TGFbetal
regulates FgflO gene expression in the prostate, as well as identifying a potential
mechanism.
Next the effect of TGFbetal on VP development was characterised. The addition of
TGFbetal to VPs inhibited 86% of testosterone-induced growth in vitro and
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significantly increased numbers of epithelial-branched tips. After a six day TGFbetal
treatment in the presence of testosterone, TGFbetal decreased proliferation of epithelial
(67%) and stromal (70%) cells in the proximal to urethra region of the VP, but increased
proliferation of epithelial (89%) and stromal (40%) cells in the distal to urethra region of
the VP. This suggested that TGFbetal has different effects on proliferation depending on
the location of the cells within the prostate and perhaps the level of cellular
differentiation.
Previously it has been demonstrated that testosterone and TGFbetas regulate expression
of Tgfbeta transcripts in adult prostates. To determine if the same effect was observed
during development, VPs and VMPs were treated with testosterone and TGFbetal and
Tgfbeta transcript levels were analysed by RPA. Testosterone and TGFbetal regulated
Tgfbetal, Tgfbeta2, and Tgfbeta3 transcript levels in VPs and female VMPs cultured for
three days, but the same effects were not observed over a six-day culture. As a previous
study has shown that testosterone and TGFbetal did not affect Tgfbeta transcript levels
in isolated prostatic stromal or epithelial cells it can be suggested that interactions
between stroma and epithelium may be involved in the regulation of Tgfbeta transcript
levels in prostatic rudiments.
Overall, I have provided an insight into the regulation of FgflO and identified a possible
mechanism involved in branching morphogenesis in the prostate. However, these data
suggests that complex regulatory pathways, involving interactions between TGFbeta,
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1 Introduction
Prostate development is dependent on androgens and mesenchymal-epithelial
interactions (Chung et al., 1991; Cunha and Chung, 1981; Tenniswood, 1986).
Androgens bind to pad of condensed mesenchymal cells (called the ventral
mesenchymal pad, VMP) of the male urogenital sinus resulting in paracrine signalling
that regulates epithelial budding and branching. Epithelial budding can also be induced
in the female VMP in the presence of testosterone (Lasnitzki and Mizuno, 1977; Takeda
et al., 1986; Timms et al., 1995). This suggests that the VMP expresses the necessary
paracrine factors that regulate prostate development. A mesenchymal paracrine factor
expressed in the male and female VMP is fibroblast growth factor 10 (FGF10). FgflO
transcripts are expressed during periods of prostatic growth suggesting that FgflO plays
an important role in prostate organogenesis (Thomson and Cunha, 1999). In fact FGF10
may be acting as a paracrine factor that regulates epithelial branching morphogenesis
(Thomson and Cunha, 1999). FGF10 also plays a role in the branching morphogenesis
and growth of many organs (table 1.1). As androgens act on the VMP to induce prostate
development and FgflO is expressed in the VMP it could be suggested that FgflO may
be regulated by testosterone. Testosterone has been shown to stimulate FgflO
expression in prostate cells (Fu et al., 1999) although some controversy surrounds this
result (Thomson, 2001). Also in other systems, such as the lung, numerous factors have
been shown to regulate FgflO during branching morphogenesis (Bellusci et al., 1997b;
Febeche et al., 1999). Thus, as the regulation of FgflO has not been thoroughly
investigated in the prostate, the aim of this thesis was to investigate the regulation of
FgflO transcript levels during prostatic development.
This thesis has addressed the regulation of FgflO gene expression in primary prostate
cells and organ cultures. TGFbetal has been identified as a factor that regulates FgflO
transcript levels in these systems. Also the regulation of FgflO transcription was
investigated by promoter analysis. An Spl binding site was shown to mediate basal
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levels of FgflO transcription and TGFbetal appeared to repress FgflO transcription
through this site. Tgfbeta transcript isoforms have been implicated in prostate
development and we have demonstrated that although TGFbetal inhibits prostate
growth, it has differential effects on prostate cell proliferation. These studies have
examined prostate development and this chapter will discuss prostate anatomy and
function, followed by an in depth review of prostate development. Finally as the
regulation of FgflO transcript levels by TGFbetal was examined the next part of this
chapter will discuss the role of FGFs and TGFbetas in prostate development.
1.1 The Prostate
1.1.1 The Adult Prostate
The prostate gland is found exclusively in mammals and functions by contributing
secretory proteins and other factors to seminal fluid. In adult human males the prostate
is a small oval shaped organ located surrounding the urethra at the base of the bladder.
The structure of the human prostate lacks distinct lobular organization and has been
studied extensively to be defined as three discrete morphological regions; the peripheral
zone, the transition zone, and the central zone (Fig. 1.1 A) (McNeal, 1969; McNeal,
1988). Unlike human, the rodent prostate gland has distinct lobular organisation and is
made up of four distinct lobes, the anterior, dorsal, lateral (and dorsolateral) and ventral
(Fig. 1.1 B). There is no clear correlation between the structures found in the rodent
prostate than those in the human prostate, although primarily descriptive evidence
suggests the rodent dorsolateral lobe is most similar to the human peripheral zone
(Abate-Shen and Shen, 2000). Also similar to the human prostate, these lobes are found
circumventing the neck of the bladder and have characteristic features of ductal
branching and secretory protein production (Hayashi et al., 1991; Sugimura et ah,





Fig. 1.1 Schematic illustration of the anatomy of the human (A) and rat (B) prostate (adapted
from Abate-Shen 2000 and Thomson 2001, respectively).
The glandular component of the prostate is made up of at least three distinct cell types
that differ in morphological appearance, functional significance and relative abundance
(Fig. 1.2). The main glandular epithelial cell is the luminal cell. These cells are
differentiated androgen-dependent cells that produce prostatic secreted proteins. Basal
cells are the second key epithelial cell type found in the prostate and are located between
luminal cells and the basement membrane, which surrounds the prostatic duct. Basal
cells do not produce secretory proteins and might function to protect cells against DNA
damage (Bui and Reiter, 1998; De Marzo et al., 1998). Interspersed between basal and
luminal cells are neuroendocrine cells that are believed to support the growth of luminal
cells by paracrine signalling (Abrahamsson, 1999; di Sant'Agnese, 1992; di Sant'Agnese,
1998). The glandular epithelial cells are juxtaposed with an underlying stromal
compartment consisting of smooth muscle cells, fibroblasts, endothelial cells, nerves and
extracellular matrix (ECM). Interactions between stromal and epithelial cells play an
important role in maintaining prostate architecture and prostate function (Chung and
Davies, 1996; Lee, 1996). In fact stromal cell paracrine signalling is involved in
androgen induced growth of normal prostatic epithelial cells (Gao et al, 2001).
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1.1.2 Development of the Rat Prostate
The development of the rat prostate is a complex process involving interactions between
steroids and the urogenital sinus (UGS) tissue (Chung et al., 1991; Cunha and Chung,
1981; Tenniswood, 1986). Primitive UGS originates from the terminal hindgut, through
the division of the cloaca by the urorectal septum during mid-gestation in rodents (this
occurs earlier in humans). The bladder and the penile urethra form from the cranial and
caudal ends of the primitive UGS, respectively. The prostate gland forms in the
intermediate region. This region is referred to as the UGS and consists of urogenital
mesenchyme (UGM) and urogenital epithelium (UGE). Development of the prostate
requires the presence of androgens and signalling between UGM and UGE (Cunha and
Donjacour, 1987). The rat urogenital structures can first be seen at el4, and first visually
distinguished as bladder and urogenital tissue at el7 (Hayward et al., 1996a). The first
signs of prostate formation in the rat were thought to occur when solid cords of
epithelium from the UGE bud into the UGM at el9 (Fig. 1.3B) (Hayward et al., 1996a).
However more recently, molecular insights into the earliest stages of prostate formation
were derived from the analysis of the Nkx3.1 homeobox gene in the mouse (Bhatia-Gaur
et al., 1999; Sciavolino et al., 1997). The expression of Nkx3.1 first appeared in the
mouse UGE two days prior to the formation of prostatic lobes (Fig. 1.3A). On the day
preceding the development of prostatic lobes Nkx3.1 became more intense in the urethra
epithelium that forms prostatic buds. When prostatic buds emerge, Nkx3.1 expression
became more restricted to the epithelium of all the outgrowing buds in the different
prostatic lobes (Fig. 1.3C). Thus, expression of Nkx3.1 transcripts may demarcate
regions where prostatic buds will arise from the UGE.
During prostate organogenesis the epithelial buds grow at their tips (Sugimura et al.,
1986b) and become highly branched. Numerous reports have demonstrated that
epithelial bud induction and growth during prostate development are due to androgens
acting via the mesenchyme (Cunha and Lung, 1978; Lasnitzki and Mizuno, 1980;














Fig. 1.3 Diagram showing the distribution of UGS tissue and factors involved in prostate
morphogenesis. At el7 (A) the male UGS consists of UGE (blue), SM (brown), UGM (pink) and AR
(red dots). The green regions represent UGE that expresses Nkx3.1. No epithelial budding has occurred
and a SM gap (discussed later) is apparent. At el9 (B) the UGE that expressed Nkx3.1 has budded
through the SM gap into the VMP. Note the lack of AR in the epithelia, but AR is still expressed in the
mesenchyme. At this stage androgens promote prostate development via interactions with the VMR
By PO (C) the epithelia has branched into the mesenchyme and now expresses AR. Also mesenchyme
adjacent to the epithelia has differentiated into SM expressing cells. On closer inspection (D) the SM
runs along the epithelia branches but SM expression becomes less apparent towards the distal tip, and
does not cover the tip. Also D demonstrates the distribution of differentiated epithelial cells.
Differentiated cells are shown in light blue dots that are located in the proximal region and
undifferentiated cells (dark blue spots) are shown in the distal regions.
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reports have therefore postulated that androgens regulate paracrine factors produced by
the mesenchyme that influence epithelial proliferation leading to prostatic bud formation
and branching morphogenesis. Androgens also appear to regulate the differentiation of
epithelial cells during prostate development. At birth, prostate epithelia uniformly
express cytokeratins 5, 7, 8, 14, 18, and 19 (Hayward et al., 1996a). During
development of the prostate and differentiation of the epithelia, cytokeratins segregate to
the basal and luminal subtypes. In the rat prostate, this process occurs initially in the
epithelium proximal to urethra proceeding towards the distal region (Fig. 1.3D). The
adult prostate contains both luminal cells (expressing cytokeratins 8, 18, and 19) and
basal cells (expressing cytokeratins 5, 7, 14, and 19). In adulthood, androgens have been
postulated as being involved in maintaining prostatic differentiation and secretions
(Cunha and Chung, 1981; Hayward et ah, 1996a).
The patterns of branching morphogenesis in the prostate may be similar in mechanism to
branching observed in other branched organs (Bellusci et ah, 1997b; Mailleux et ah,
2002). Numerous similarities between branching and expressed factors have been
observed between the lung and the prostate. Fibroblast growth factor signalling in the
lung has been extensively examined (Bellusci et ah, 1997b; Peters et ah, 1994) and
FGF7 and FGF10 appear to be involved in both lung (Bellusci et ah, 1997b; Post et ah,
1996) and prostate development (Sugimura et ah, 1996; Thomson and Cunha, 1999;
Thomson et ah, 1997). Figure 1.4 shows the factors that may be involved in prostate
development of which some will be discussed now. FgflO is expressed in the UGM
around the elongating epithelial buds (Thomson and Cunha, 1999) and may be involved
in regulating ductal branching. Fgf7 is also expressed in the UGM (Finch et ah, 1995a)
and stimulates ductal branching (Sugimura et ah, 1996). Tgfbetal is expressed
predominantly in the UGM and TGFbetal protein has been localised around the growing
tips (Timme et ah, 1994). The transcription factor Gli is expressed in the mesenchyme
and has been associated with Shh signalling (Podlasek et ah, 1999a). Hox genes are
expressed in both the epithelial and mesenchymal compartments of the UGS and
abnormalities in prostate development are observed in Hox gene mutations (Oefelein et
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al., 1996; Podlasek et al., 1999b; Podlasek et al., 1999c). Other factors expressed in the
epithelium include Nkx3.1 and Shh. Nkx3.1 gene expression is localised to emerging
prostatic epithelial buds (Sciavolino et al., 1997) and defects in the Nkx3.1 gene have
been linked to prostatic epithelial hyperplasia and defects in branching morphogenesis
(Bhatia-Gaur et al., 1999). Shh has been postulated as being involved in prostate
development by regulating branching morphogenesis and ductal bud formation (Lamm
et al., 2002; Podlasek et al., 1999a). As many of these factors play a role in development
of the lung (Fig. 1.7) it is possible that there are numerous conserved mechanisms
between prostatic and lung branching morphogenesis.
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UGS Lumen
□ Epithelium □ Mesenchyme
□ Shh □ Tgfbeta^
□ Nkx3.1 □ Fgf10
I□ Bmp4
Fig 1.4 Factors that have been postulated as being involved in regulating budding and branching
morphogenesis in the prostate. (Figure adapted from (Lamm et al., 2001))
We have addressed prostate development and briefly described the roles of androgens
and cellular interactions in this process. So next I will discuss the endocrinology and
mesenchymal-epithelial interactions of prostate development in more detail. Also
factors postulated as being involved in prostate development and branching
morphogenesis, such as FGF10 and TGFbetal, will be discussed.
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1.1.3 Endocrinology of Prostate Induction and Growth
The major steroids involved in development of the prostate are androgens. Androgens
are C19 steroids characterised by their ability to stimulate and maintain the development
of secondary sexual characteristics. Testosterone is the principal androgen and is mainly
secreted by androgen producing cells in the testis; Leydig cells. The testis is an
endocrine gland where androgen secretion is primarily driven by luteinizing hormone
(LH) and spermatogenesis by follicular stimulating hormone (FSH) produced in the
pituitary (Fig. 1.5). LH and FSH secretion is under the control of LH releasing hormone
(LHRH) secreted from the hypothalamus. Testosterone exerts a negative feedback
regulation on LH and FSH production by the pituitary gland and paracrine regulation of
Sertoli cell function. FSH and androgen stimulate inhibin production by Sertoli cells that
selectively suppresses FSH production (Fig. 1.5).
Fig. 1.5 The hypothalamic-pituitary-gonadal axis
Most secreted androgens (>98 %) circulate in the blood bound to albumin and steroid
binding globulins. The steroid binding capacity of these proteins determines the
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proportion of androgen that circulates freely. Only free testosterone is able to enter the
cell and hence free testosterone is the biologically active form. More than 90% of
testosterone in the cell is converted to 5a-dihydrotestosterone (DHT) through the action
of the enzyme 5a-reductase. DHT binds at a higher affinity (five times) to the AR than
testosterone and is a more potent androgen (Wilbert et al., 1983). Although DHT binds
at a higher affinity to AR than testosterone data supports the idea that prostate
development does not absolutely require DHT; androgens that cannot be converted to
DHT will elicit the growth of prostatic rudiments in vitro (Foster and Cunha, 1999).
Also, inhibition of 5a-reductase does not completely impair prostate development
(Imperato-McGinley et al., 1992).
The levels of circulating androgens correlate with prostate development and production
of prostatic fluid during adulthood; androgen levels are relatively high towards the end
of gestation, decrease one day after birth and increase again during puberty in rats
(Corpechot et al., 1981). Hence androgens may be involved in numerous processes
during prostate organogenesis. In fact during development, androgens may promote
epithelial bud induction from the UGE into the UGM in the male. Androgens may
induce UGE budding by acting on the UGM to instructively induce the morphogenesis
and differentiation of adjacent UGE in vivo (described below) (Cunha and Lung, 1978;
Lasnitzki and Mizuno, 1980; Shannon and Cunha, 1983; Takeda and Mizuno, 1984;
Takeda et al., 1985). Also, administration of androgens to female urogenital tracts in
vitro results in prostatic budding (Lasnitzki and Mizuno, 1977; Takeda et al., 1986).
Surprisingly the formation of the VMP is independent of androgens, as the VMP is
found in females, but it is clear that the VMP has the ability to induce prostate
organogenesis in the presence of androgens (Timms et al., 1995). This might suggest
that paracrine factors are secreted by the VMP in response to androgens, which regulate
prostatic budding. Several growth factors that are produced by stromal cells in response
to androgens have been identified and shown to influence prostatic epithelial cells
(reviewed in Cunha et al., 1992). Epidermal growth factor (EGF), basic fibroblast
growth factor (bFGF), keratinocyte growth factor (KGF; FGF7), FGF10, transforming
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growth factor a (TGFa) and insulin-like growth factors I and II can all stimulate growth
of prostatic epithelial cells (Cohen et al., 1991; Culig et al., 1996; Itoh et al., 1998b;
Marengo and Chung, 1994; Peehl and Rubin, 1995; Sugimura et ah, 1996; Thomson and
Cunha, 1999). However some controversy surrounds the effect of androgens on the
regulation of some of these genes (Thomson, 2001), but there is no doubt that they
positively regulate the proliferation of prostate epithelial cells. Also androgens have
been shown to repress gene expression of factors that have inhibitory effects on prostatic
epithelial and stromal cells, such as transforming growth factor beta (TGFbeta) (Itoh et
ah, 1998a; Kyprianou and Isaacs, 1989). Androgens are not only involved in epithelial
bud induction but are also important in promoting epithelial differentiation (discussed
later) (Cunha and Chung, 1981).
Another function of testosterone during development of the prostate may be its
regulation of smooth muscle (SM) expression along the UGT. It has been reported that
the position of the VMP coincides with a gap in the SM at the junction of the urethra and
bladder (Thomson et al., 2002). The gap in SM was consistent in the male and female
urogenital tracts from el7 to el9, after which a sexually dimorphic difference became
apparent. After el9, the layer of SM was reported to be continuous in females, but an
obvious gap in SM remained in the male (Fig. 1.3). The SM layer may act as a barrier to
epithelial buds and thus prevent prostate development. Thus the closure of SM gap in
females may prevent epithelial budding while maintenance of a gap in males provides an
area that allows epithelial buds to grow into the VMP. Therefore this report suggests an
alternative pathway that androgens can regulate development of the prostate. Hence
androgens appear to have multifunctional roles in prostate organogenesis.
Other steroids potentially involved in prostate development are oestrogens. Exposure to
low doses of oestrogens during mouse development have been reported to increase adult
prostate weight and AR levels, as well as significantly increasing prostatic glandular
budding (Nonneman et al., 1992; Timms et al., 1999; vom Saal et al., 1997). In contrast,
higher doses of oestrogen administered to neonates have caused a permanent
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suppression of prostate growth, a reduced response to androgens and increased epithelial
and stromal hyperplasia (Naslund and Coffey, 1986; Prins, 1992; Singh and
Handelsman, 1999; Turner et al., 1989). It has been shown that the reduction in
response to androgens is due to a decrease in AR levels, and could possibly be linked to
a reduction in circulating androgen (Prins, 1992). More recent research has suggested
that the effect of oestrogens on development of the prostate may be due not only to a
repression of the hypothalamic-pituitary-gonadal axis (Fig. 1.3), but also oestrogens may
have a direct effect on prostate development (Jarred et al., 2000).
1.1.4 Stromal-Epithelial Interactions
1.1.4.1 Mesenchymal-Epithelial Interactions during Development
The role of mesenchymal-epithelial interactions in prostate formation has been
extensively defined through tissue recombination studies, performed by Cunha and
colleagues (Cunha, 1996; Cunha and Chung, 1981; Cunha et al., 1987; Cunha and Lung,
1978; Hayward et al., 1997). Tissue recombination experiments used dissection and
enzymatic isolation of epithelium and mesenchyme from embryonic UGS and/or from
other tissues. The tissues are recombined and transplanted into adult rodent male hosts.
Tissue architecture and proteins normally secreted by the prostate were examined.
Tissue recombination studies have led to the conclusion that prostatic differentiation
requires the interaction of epithelia and mesenchyme. However, although a prostate will
only form using mesenchyme from embryonic UGS, a wide range of epithelia of
endodermal origin, including those from differentiated male of female adult tissue, can
form prostates when recombined.
Tissue recombination experiments have been performed using tissue combinations from
mutant animals. In particular, recombination experiments using Testicular-feminized
(Tfin) mutant mouse strains have been thoroughly examined. The Tfm mouse strain
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carries a defective AR that results in premature termination of AR synthesis and loss of
function of androgen signalling (He et ah, 1991). As would be expected male Tfm mice
have no prostate and recombination experiments of epithelial and mesenchyme from Tfm
mice with wildtype examined the role of AR in prostatic development (Fig. 1.6) (Cunha
and Lung, 1978; Lasnitzki and Mizuno, 1980). Prostatic structures appeared when Tfin
epithelium was recombined with wild-type mesenchyme suggesting that AR in the
mesenchyme was necessary for prostate development. Prostatic structures did not form
when wild-type epithelium was recombined with Tfin mesenchyme, suggesting that
expression of AR only in the epithelium was not enough to induce prostatic formation.
Overall these results determined that androgens act on the mesenchyme of developing
prostates to induce prostate development and that AR expression in the epithelium is not
required to initiate prostatic budding. However, although Tfm UGE combined with
wild-type mesenchyme forms prostatic ducts, the epithelium lacked production of
prostatic secretory proteins. This suggested that following development androgens act
on the epithelium to promote prostatic secretory proteins. The conclusions derived from
Tfin recombination experiments correlated with studies examining the expression pattern
of AR (Hayward et ah, 1996a; Hayward et al., 1996b) and autoradiographic studies of
androgen binding sites (Shannon and Cunha, 1983; Takeda and Mizuno, 1984; Takeda
et al., 1985) in the developing prostate. AR expression was restricted to the
mesenchyme preceding and during initial stages of prostatic budding. After prostatic
buds have formed and begun to develop, the epithelium expresses AR. This suggests
that an androgen-induced mesenchymal paracrine factor regulates epithelial budding and
androgen-regulated factors are not produced in the epithelium. However the function of













— no prostate structures
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— no prostate structures
Fig. 1.6 depicting results from recombination experiments performed by Cunha et al. 1981, using
Tfin and wild type mice tissues.
Signalling can also occur from the epithelium to the mesenchyme. As the epithelial bud
grows into the VMP it becomes obvious that cellular changes occur in the mesenchyme
(Hayward et al., 1996b). Mesenchyme cells start expressing smooth muscle a actin (a
smooth muscle marker) around the periphery of the epithelial bud. The expression of
SM a actin is followed by vinculin, myosin, desmin, and laminin in an orderly sequence
in a distal to proximal manner along the prostatic ducts (Hayward et al., 1996b). Also
by using tissue recombination techniques it was demonstrated that different prostatic
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epithelium elicit different patterns of stromal development (Hayward et al., 1998).
Tissue recombination experiments consisting of adult human prostatic epithelium and rat
UGM, grafted beneath the renal capsule of a rodent host, revealed that the rat
mesenchyme differentiated into thick sheets of smooth muscle, characteristic of the
human and not the rat prostate (Hayward et al., 1998). Also a solid cord of human
epithelium grew into the surrounding mesenchyme and canalised expressing markers for
basal and luminal cells. Hence epithelial to mesenchyme signalling is most likely to
regulate the differentiation of the mesenchyme into smooth muscle cells and the
reciprocal interactions regulate epithelial growth and differentiation.
1.1.4.2 Stromal-Epithelial Interactions during Adulthood
A similar mesenchymal-epithelial interaction that occurs during prostatic organogenesis
also occurs during adulthood between smooth muscle and epithelial cells. It has been
hypothesised that adult prostatic smooth muscle maintains epithelial structure and
function and, in a reciprocal fashion, prostatic epithelium maintains smooth muscle
differentiation (Hayward et al., 1996c). It is likely that aberrant interactions between the
epithelium and smooth muscle play an important role in prostate carcinoma and
although neoplastic changes occur in the epithelium compartment, the role of the stromal
compartment has been relatively neglected. However it has been demonstrated that
smooth muscle failed to differentiate in tissue recombinants of neoplastic prostatic
epithelium and UGM (Hayward et al., 1996c) demonstrating that neoplastic epithelium
regulates the pattern of SM expression. Also tissue recombination experiments have
suggested that paracrine signalling from the stromal compartment may play an important
role in cancer progression (Hayward et al., 1997; Olumi et al., 1999). The paracrine
signals that mediate stromal-epithelial interactions in prostate carcinoma have not yet
been identified, but may include, members of the FGF family or TGFbeta family
(Cunha, 1996; Djakiew, 2000). Members of these growth factor families have been
investigated in development, not only in the prostate but also in other systems. Some of
these factors thought to be important during prostate development and that have been
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examined in this thesis will be discussed next, not only in the context of prostate biology
but also their role in development of similar branched organs such as the lung, and
disease.
1.2 Fibroblast Growth Factors in the Development of
the Prostate
Numerous FGFs have been identified and the family contains at least 23 proteins. FGFs
induce mitogenic, chemotactic, and angiogenic activity in cells derived from
mesodermal and neuroectodermal origins (reviewed in (Basilico and Moscatelli, 1992)).
The FGF family members play key roles in the development of several organs including
the limbs, lung, brain, and prostate (reviewed in (Ornitz and Itoh, 2001; Powers et al.,
2000)). FGFs are involved in developmental processes from the earliest time points of
embryogenesis to after birth. In fact there are probably very few organs in which FGFs
are not involved in some developmental role. FGF gene expression and function has
been extensively examined in both limb and lung organogenesis (Bellusci et al., 1997b;
Lebeche et al., 1999; Ohuchi et al., 1999; Ohuchi et al., 1997; Yonei-Tamura et al.,
1999) and FGFs serve as an essential regulator of their development (Min et al., 1998;
Sekine et al., 1999). It is therefore no surprise that FGFs function in the development of
the prostate (Lu et al., 1999; Nemeth et al., 1998; Thomson and Cunha, 1999; Thomson
et al., 1997), as key processes have been shown to be similar between lung and prostate
formation (Lamm et al., 2001; Lebeche et al., 1999). FGF7 (KGF) and FGF10 play
important roles in the development of the prostate (Thomson and Cunha, 1999;
Thomson et al., 1997) and it remains to be seen if other FGFs e.g. FGF8 or FGF9 are
involved in regulation of prostatic growth. However as this thesis has examined the
regulation of FgflO gene expression, FGF10 will be discussed in more detail than any
other FGF. Also it is important to discuss the role that FGF10 plays in lung formation
since more research has been performed on these processes than in prostate
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development. However initially a general overview of the role that FGF10 plays in
development will be discussed.
1.2.1 FGF10
The FgflO gene was first isolated from rat embryos by homology-based polymerase
chain reaction (Yamasaki et al., 1996). Yamasaki et al. discovered that the expression
pattern of FgflO mRNA was quite different from other FGFs. FgflO transcript
expression was more restricted than other members of the FGF family and was
predominantly expressed in the rat embryo and adult lung. However no function was
described for the protein. The next reported FgflO gene isolation was cloned from
mouse tissue (Beer et ah, 1997). Beer et al. investigated the function of FgflO by
examining the characteristics of the FGF10 protein, the expression pattern of FgflO
transcripts in isolated tissues and during wound repair, and also the regulation of FgflO
transcript expression in fibroblast cells. It was shown that FGF10 is most homologous
to FGF7 (57 % identity at the amino acid level). FGF10 was predicted to encode a
protein with a predicted mass of 23.6 kDa (Beer et ah, 1997). The FGF10 protein was
also predicted to express a leader sequence necessary for ER-Golgi secretion. FGF7
also has a leader sequence (Finch et ah, 1989) and is efficiently secreted from cells
(Brauchle et ah, 1994; Chedid et ah, 1994). Beer et al. demonstrated that the FGF10
protein was not in the media suggesting the mouse FGF 10 protein could be either inside
the cell, associated with cell surface, or associated with the ECM. It was hypothesised
that the mouse FGF10 protein enters the secretory pathway but remains associated with
either the cell or ECM for two reasons; 1) at least one form of the protein is N-
glycosylated and glycosylation occurs in the ER-Golgi apparatus and not in the cytosol,
and 2) heparin, which is known to compete for binding of FGFs to the ECM and cell
surface proteoglycans (Burgess and Maciag, 1989), releases mouse FGF10 proteins into
the media (Beer et al., 1997; Igarashi et al., 1998).
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FGF7 and FGF10 have been shown to have similar paracrine mechanisms. FGF7 is
predominantly expressed in mesenchymal cells (Finch et ah, 1989), while the receptor
for FGF7 is expressed in epithelial cells (Finch et ah, 1989). FGF10 also acts in a
paracrine manner as FgflO transcripts have been detected in the mesenchyme of
numerous organs (Bellusci et ah, 1997b; Ohuchi et ah, 1997; Thomson and Cunha,
1999) and its receptor (FGFR2 Illb) in epithelium (Igarashi et ah, 1998). It has also been
demonstrated that FGF7 and FGF10 have similar receptor binding properties and target
cell specificities during development (Igarashi et ah, 1998).
Although FGF7 and FGF10 act on similar cells and are mainly expressed in same organs
the regulation of Fgf7 and FgflO is vastly different. Fgfl transcripts were strongly up
regulated by numerous cytokines (Brauchle et ah, 1994; Chedid et ah, 1994) but most of
these factors did not have the same affect on FgflO transcript levels (Beer et ah, 1997).
In fact TGFbetal and TNFa both repressed the levels of FgflO transcripts in 3T3
fibroblasts suggesting that Fgfl and FgflO transcript levels could be oppositely regulated
under conditions where high levels of these cytokines are expressed. FGF7 and FGF10
are also involved in lung development and were differentially regulated in that system
(Lebeche et ah, 1999). SHH, FGF1, and FGF2 appeared to stimulate expression of Fgf7
transcripts, while FGF1 and FGF2 had no effect on FgflO transcript levels but SF1H
decreased FgflO gene expression. This suggests that although Fgf7 and FgflO have a
high sequence homology and similar functions their gene expression is differentially
regulated. Also Beer et al. (1997) demonstrated that FgflO transcripts were rapidly
decreased indicating a short half-life of the mRNA, typical features of highly regulated
genes.
FGF7 and FGF10 are also regulated differently at their protein level (Igarashi et ah,
1998). Members of the FGF family interact with ECM components after secretion and
during receptor signalling (described below) (Flaumenhaft et ah, 1990; Mansukhani et
ah, 1992; Moscatelli, 1987; Yayon et ah, 1991). Important components of the ECM that
have been shown to bind and regulate distribution of these proteins are heparin and
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heparan-like glycosaminoglycans (HLGAGs). Heparin exerts differential effects on
FGF10 and FGF7, by stimulating FGF10 and inhibiting FGF7 mitogenic activity
(Igarashi et al., 1998). These effects could be one possible mechanism through which
different responses to FGF10 and FGF7 may be mediated although they signal through
the same receptor. Also FGF10 is glycosylated and remains predominantly cell or ECM
associated (Beer et al., 1997), while FGF7, which is also glycosylated, is readily
secreted into the medium of producing cells (Finch et al., 1989).
The original expression study performed by Beer at al. (1997) demonstrated the
presence of FgflO transcripts in various adult mouse tissues. FgflO transcripts were
mainly expressed in the lung, brain and dermis. More extensive studies on FgflO
transcript expression have been performed and have shown that FGF10 may play
important roles in a variety of different systems (Table 1.1).
Table 1.1 Summary of the role of FGF10 in different processes
Organ System The Role of FGL10 References
Lung Localised sources of FGF10 in the mesoderm
regulate endoderm proliferation and bud
outgrowth
(Bellusci et al., 1997b; Min et al.,
1998; Ohuchi et al., 2000; Sekine
et al., 1999)
Limb FGF10 is a mesenchymal factor involved in the
initial budding as well as the continuous
outgrowth of vertebrate limbs
(Min et al., 1998; Ohuchi et al.,
1997; Sekine et al., 1999; Yonei-
Tamura et al., 1999)
Reproductive
tract
FGF10 identified as an essential factor in
prostate development, involved in bud outgrowth
and branching morphogenesis. Also it has been
shown to be important during development of the
glans penis and glans clitoridis
(Lu et al., 1999; Nakano et al.,
1999; Perriton et al., 2002;
Thomson and Cunha, 1999)
Brain The spatial expression of FGF10 in the brain
indicates that it has a distinct role in the brain
(Hattori et al., 1997)
Lacrimal
glands
FGFlOs role in induction of lacrimal gland
budding is to stimulate proliferation and, in turn,
FGF10 combines with other factors to provide
the instructive signals required for lacrimal gland
development
(Makarenkova et al., 2000)
Kidney FGF10 appeared to be important in ureteric bud
branching and branch elongation, and thus may
play a role in the determination of nephron
(Cancilla et al., 2001; Qiao et al.,
2001)
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number and patterning of the kidneys
Mammary FGF10 important in mammary gland
development
(Mailleux et al., 2002)
Thymus FGF10 important in thymic epithelial signalling (Revest et al., 2001)
Pancreas FGF10 plays an essential role in the
mesenchymal interaction required for the proper
development of the pancreas
(Bhushan et al., 2001; Miralles et
al., 1999; Yamaoka et al., 2002)
Heart The arterial pole of the mouse heart forms from
FGFlO-expressing cells in pharyngeal mesoderm
(Kelly et al., 2001)
Colorectal
cancer
Findings indicate that FGF 10 and FGFR Illb
may contribute to the growth of colorectal cancer
cells
(Matsuike et al., 2001)
Uterus The in vivo spatial expression pattern suggests
that FGF10 is a endometrial stromal cell-derived
mediator of uterine epithelial function
(Chen et al., 2000)
Teeth FGF10 suggested to be a survival factor that
maintains the stem cell population in developing
incisor germ cells in mice
(Harada et al., 2002)
Adipose tissue FGF10 plays an important role in adipogenesis
by regulating expression of factors by
autocrine/paracrine mechanisms
(Sakaue et al., 2002; Yonei-
Tamura et al., 1999)
Skin FGF10 is required for embryonic epidermal
morphogenesis in the skin but is not essential for
hair follicle development. May be involved in
wound healing
(Beer et al., 1997; Suzuki et al.,
2000; Tagashira et al., 1997; Tao
et al., 2002)
Ear FGF10 signalling important for inner ear
morphogenesis
(Pirvola et al., 2000)
Bladder May have an important role in regulating growth,
differentiation and repair of urothelium cells in
the bladder
(Bagai et al., 2002)
1.2.2 FGF10 Signalling
Members of the FGF family have a central core of 140 amino acids, which fold into
twelve antiparallel B-strands forming a cylindrical barrel and is highly homologous
between different family members (reviewed in (Powers et al., 2000)). The amino- and
carboxy-terminal stretches are more variable between members of the family. The
amino terminus of most FGFs contains a leader sequence, including FGF10, and this
sequence is involved in secretion (Blobel, 1980). The regions involved in receptor and
heparin binding are located in the B-strands, and a defining feature of the FGF family is
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a strong affinity for heparin and HLGAGs (Burgess and Maciag, 1989) of the ECM.
This interaction between FGF and HLGAG may be involved in regulation of FGFR
signalling (Plotnikov et al., 1999; Venkataraman et al., 1999) and thus FGF activity. In
fact the interactions between FGFs and these factors may not only limit their diffusion
and release into interstitial spaces but also stabilize FGFs against denaturation and
proteolysis (Flaumenhaft et al., 1990; Moscatelli, 1987). Also cell surface HLGAGs are
physiologically significant as they were originally shown to be required for the high
affinity binding of FGFs to their receptors (Mansukhani et al., 1992; Yayon et al., 1991).
The high affinity binding caused by the presence of HLGAGs mediates mitogenesis and
angiogenesis caused by FGF signaling (Aviezer et al., 1994; Rapraeger et al., 1991).
These results led to an hypothesis that HLGAGs not only mediates the recruitment of
FGFs to the cell surface and stabilized FGFs against denaturation but also induced a
change in the presentation of the FGFs or FGFR that promotes binding of the two
(Klagsbrun and Baird, 1991). Research has been focused on the later hypothesis and it
is now a common understanding that HLGAGs promote FGFs ability to activate
receptors and that they induce receptor dimerization (Ornitz and Itoh, 2001; Ornitz et al.,
1992; Powers et al., 2000; Spivak-Kroizman et al., 1994).
There are four different genes encoding FGF receptors (FGFR), designated FGFR1-4,
which are responsible for FGF-mediated signal transduction (Johnson and Williams,
1993). These receptors are characterised by two or three immunoglobulin (Ig)-like
domains in the extracellular region and a tyrosine kinase domain in the intracellular
regions. Additional diversity of the FGFR family is generated by alternative splicing
that results in differing ligand specificity (Chellaiah et al., 1994; Miki et al., 1992).
FGF10 can act on two types of FGFR: FGFR1 Illb and FGFR2 Illb (Beer et al., 2000;
Igarashi et al., 1998). Numerous FGFR signalling pathways have been identified
(Goldschmidt-Clermont et al., 1991; Larsson et al., 1999; Mohammadi et al., 1996; Zhan
et al., 1994). However signalling pathways of different FGFRs are very similar, which
is probably due to the high degree of homology between the different receptor proteins
(Johnson and Williams, 1993). Also this may be due to the fact that the principal
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difference between FGFRs has been postulated as being in the level of tyrosine kinase
activity and that this level is important in determining the response to ligand activation
of the receptor (Raffioni et ah, 1999).
One of the most characterised systems on which FGF10 plays a key role is during
development of the lung. Next I will discuss the role that FGF10 plays in lung growth
and development, as the processes of lung branching morphogenesis appear to be similar
to that of the prostate.
1.2.3 The Role of FGF10 in Development of the Lung
Development of lungs in mice begins at e9.5 by lung buds emerging from each ventro¬
lateral side of the foregut endoderm. The buds then grow in a caudal direction away
from the gut endoderm. The two primary buds elongate and undergo branching
morphogenesis to give rise to five lobes, four on the right and one on the left. It has
been shown that branching morphogenesis of the lung, as well as other organs, depends
on epithelial-mesenchymal interactions that are mediated by a complex network of
interactions including those of transcription factors, peptide growth factors, and their
receptors (Fig. 1.7) (reviewed in (Cardoso, 2000; Cardoso, 2001)).
23
Fig. 1.7 The spatial distribution of gene expression in the developing lung. Epithelial expression is
represented in yellow boxes and all other genes are expressed in the mesenchyme with exception of








New insights into development of the lung have been derived from other developing
structures such as the limb or the respiratory system of the Drosophila (Klambt et al.,
1992; Sutherland et al., 1996). There are key differences between the Drosophila
respiratory system and mouse lung. In particular cells migrate in the Drosophila trachea
system but cell proliferation promotes lung airway development. However factors
involved in regulating the Drosophila respiratory system have proved to be very similar
to those in the mouse lung. The Drosophila gene, branchless (bnl), is critical for
patterning of tracheal branching (Sutherland et al., 1996). The secreted bnl binds to the
breathless receptor (btl) on nearby tracheal cells, stimulating receptor signalling and
promoting budding of primary branches. As each primary branch grows towards a patch
of cells that express bnl, expression of bnl is inhibited. Occasionally expression of bnl
turns on at a different site and the primary branch continues to grow towards the new
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site. Hence bnl is important for the initial patterning of tracheal branching. The bnl-btl
interactions are also important for secondary budding pattern and terminal branching.
Mutant analyses of the bnl and btl genes have demonstrated the necessity of the ligand
and receptor during tracheal development (Klambt et al., 1992; Sutherland et al., 1996).
Bnl is an Fg/homolog and a 99 amino acid stretch of bnl is 30 % - 40 % identical to
several vertebrate Fgfs (Sutherland et al., 1996). The bnl mutant (Sutherland et al., 1996)
has a similar phenotype to that of the FgflO knockout mutant mice (Min et al., 1998;
Sekine et al., 1999). FgflO mutant mice demonstrated that FGF10 was required for the
initial branching of the primordial buds during the early phase of embryonic lung
development (Min et al., 1998; Sekine et al., 1999). Hence the function of FgflO in
mice and bnl in Drosophila are very similar in that both are critical for initial pulmonary
branching events. FGF10 signals via FGFR2 Illb (Igarashi et al., 1998) and this
interaction was considered to be similar to the bnl-btl signalling processes in the
Drosophila (Sutherland et al., 1996). In fact the initial breakthrough in identifying
mesodermal factors that regulated branching morphogenesis controlling mammalian
lung development initially came with the targeted expression of the dominant expression
of Fgfr2 111b (Peters et al., 1994). FGFR2 Illb is expressed in the endoderm of
developing lungs (Cardoso, 2001) and numerous FGFs have been shown to signal via
this receptor (Table 1.2). The dominant negative Fgfr2 Illb completely blocked airway
branching and epithelial differentiation, without prohibiting outgrowth, establishing a
specific role for FGFs in branching morphogenesis in the mammalian lung (Peters et al.,
1994). FGF10 appeared to be the most likely member of FGF family involved in this
process, based on its expression and localisation within the lung mesenchyme (Bellusci
et al., 1997a; Park et al., 1998).
FgflO transcripts have been shown to be mesenchymal-expressed in a localised fashion
surrounding the epithelial buds (Bellusci et al., 1997b). FgflO gene expression appears
to precede formation of lung buds, and its expression is down regulated once the bud has
formed (Bellusci et al., 1997b). Hence FgflO gene expression is dynamically regulated
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during lung organogenesis. If the mesenchyme is removed from the epithelial bud,
recombinant FGF10 can substitute the effect caused by the mesenchyme by inducing
generalised budding (Bellusci et al., 1997b; Park et ah, 1998). This suggested that
FGF10 produced by the mesenchyme was necessary for lung budding during
development. However creating a gradient of FGF10 protein by implanting a heparin
bead soaked in FGF10 caused the lung bud to grow towards and engulf the bead (Park et
ah, 1998; Weaver et ah, 2000). Park et al. also grafted an FGFlO-soaked bead into intact
el 1.5 lung explants, in an organ culture system, to produce similar results (Park et ah,
1998). The FGFlO-soaked bead appeared to augment endogenous FGF10 signalling
causing bud growth to be redirected towards the bead. Also it was demonstrated that
FGF10 acts over relatively short distances in lung explants and that the chemotactic
effect of FGF10 was reduced (from 150 /xm to between 50 to 75 /xm) in lung explants
with mesenchyme attached, compared to buds without mesenchyme (Park et ah, 1998;
Weaver et ah, 2000).
1.2.4 Modulation of FGF10 Signalling in the Lung
The dynamic expression of bnl in Drosophila development and FgflO in the mouse lung
suggests that branching morphogenesis might require FGF10 levels to be precisely
controlled by factors expressed in both the mesenchyme and epithelium. Numerous
factors have been identified that might play important roles in regulating branching
morphogenesis and therefore postulated as modulating FGF10 signalling in the lung.
These include FGFs, sonic hedgehog (SHH), bone morphogenetic protein 4 (BMP4),
and TGFbetal.
FGFs Numerous FGFs were identified as being expressed in development of
the lung and shown to influence lung development by treatment of embryonic lungs in
organ cultures. A complex regulatory network between FGF1, FGF2 and FGF7 has
been proposed (Lebeche et ah, 1999). However, FGF9 and FGF10 are the first known
FGFs to be detected in the developing lung and research has suggested that FGF9 could
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act as a potential regulator of FGF10, via activation of FGFR1 signalling in early lung
development (Arman et al., 1999).
SHH Shh is expressed in the endoderm by e9.5 and expression is continued in
the developing lung epithelium (Bellusci et al., 1996). As in FGF10 knockout mice, Shh
expression is essential for branching morphogenesis but not for the initial budding of the
foregut endoderm in the developing lung (Litingtung et al., 1998; Pepicelli et al., 1998).
Also lung mesenchyme in Shh knockout mice diffusely expressed FgflO contrasting
with the restricted pattern of expression in wild-type mice (Pepicelli et al., 1998). This
suggests that Shh not only inhibits FgflO gene expression but it regulates the spatial
distribution of FGF10 and this regulation is required for the proper patterning of the
lungs during development. Other data supports this hypothesis as over-expression of
Shh in transgenic mice increased mesenchymal proliferation and decreased expression of
FgflO (Bellusci et al., 1997a; Bellusci et al., 1997b).
BMP4 Bmp4 is initially expressed in the foregut mesenchyme suggesting it plays
a role in start of lung development (Weaver et al., 1999). During branching
morphogenesis BMP4 is expressed in the epithelium of branching airways (Weaver et
al., 2000). Increasing gradients of FGF10 in the mesenchyme induces levels of Bmp4
expression during branching morphogenesis. Also as BMP4 inhibits epithelial cell
proliferation and prevents budding, BMP4 expression antagonizes the effect of FGF10
(Weaver et al., 2000). Therefore BMP4-FGF10 interaction served to limit bud
outgrowth during budding in development of the lung.
TGFbetal Tgfbetal transcripts are expressed in the subepithelial mesenchyme
during embryonic lung development and TGFbetal protein accumulates along proximal
airways and in cleft formation (Lebeche et al., 1999). In the clefts, TGFbetal was shown
to promote synthesis of ECM which is thought to prevent local branching (Heine et al.,
1990). Also the addition of TGFbetal to lung explants in culture inhibited branching
morphogenesis (Serra and Moses, 1995) and when Tgfbetal is mis-expressed in the
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distal lung epithelium of transgenic mice, lungs did not develop beyond late
pseudoglandular stage of development (Zhou et al., 1996). Hence TGFbetal has been
implicated as an inhibitor of cell proliferation and differentiation. An important fact
about TGFbetal is that it has been shown to repress FgflO gene expression both in a
primary lung mesenchyme cells and in lung organ cultures (Lebeche et ah, 1999).
Therefore TGFbetal is another important factor that may play a vital role in modulation
of FGF10 signalling in the lung, and as the regulation of FgflO transcripts was studied in
this thesis the TGFbeta superfamily will be discussed later.
1.2.5 FGFs in the Prostate
Member of the FGF family are key regulators of organogenesis so it is not surprising
that FGFs play key roles in the development of the prostate. Both FGF7 and FGF10
play important roles in the growth and development of the prostate (Thomson and
Cunha, 1999; Thomson et ah, 1997), but little has been reported on the role of other
FGFs during prostate organogenesis. The similarities of FGF7 and FGF10 led to the
conclusion that these proteins are interchangeable. In fact Fgf7 knockout mice have no
reported change in reproductive tract development (Guo et ah, 1996) suggesting that
FGF10 might substitute for the lack of FGF7 protein. However in the reverse situation,
FgflO knockout mice do not have a prostate (Donjacour, Thomson and Cunha,
manuscript in preparation) therefore FGF7 protein does not compensate for the lack of
FGF10 protein. FGF7 therefore cannot replace the function of FGF10 during
development of the prostate. This suggests that FGF10 is a vital factor in prostate
development.
1.2.5.1 FGF7 in the Prostate
During development of the VP, Fgf7 transcripts are expressed during periods of active
growth suggesting that FGF7 is a key regulator of VP growth and development
(Thomson et ah, 1997). FGF7 is expressed in the mesenchyme cells and its receptor
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(FGFR2 Illb) in the epithelium of rodent prostates during development (Sugimura et al.,
1996), FGF7 therefore acts in a paracrine fashion to regulate growth. FGF7 stimulates
the development of VPs grown using a serum free organ culture system and FGF7
protein is mitogenic for epithelial cells (Sugimura et al., 1996). Also, addition of an
anti-FGF7 antibody to a serum free organ culture system partially inhibits growth of the
VP suggesting that FGF7 is required for VP growth and development (Sugimura et al.,
1996). However, in Fgfl knockout mice no changes in the reproductive tract have been
reported (Guo et al., 1996). This observation is probably due to regulatory redundancies
in the processes performed by FGF7 i.e. other family members may be able to
compensate in processes involving FGF7, such as FGF10. This has also been observed
in Fgf2 and Fgf6 knockout mice as they are not only viable and fertile but are
phenotypically indistinguishable from wild-type animals by gross examination (Fiore et
al., 1997; Ortega et al., 1998).
1.2.5.2 FGF8 in the Prostate
FGF8 and its isoforms may play a key role in prostate carcinogenesis. Over-expression
of FGF8 (Kouhara et al., 1994; MacArthur et al., 1995; Rudra-Ganguly et al., 1998) and
generation of Fgf8 transgenic mice (Daphna-Iken et al., 1998) have demonstrated the
tumourigenic effect of FGF8. In a proportion of prostate cancer patients FGF8 protein
(Tanaka et al., 1998) and Fgf8 transcripts (Leung et al., 1996) may be over-expressed in
the prostate. Also in prostate cancer cells Fgf8 was regulated by testosterone at the
promoter level and at the protein level (Gnanapragasam et al., 2002). It remains to be
investigated whether FGF8 plays an important role in prostate development.
1.2.5.3 FGF10 in the Prostate
FGF10 plays an essential role as a paracrine regulator in the VP. Like FGF7, FGF10 is
expressed in mesenchyme cells (Thomson and Cunha, 1999) and its receptor (again
FGFR Illb) in epithelial cells (Igarashi et al., 1998). During development of the VP,
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FgflO transcripts were expressed in periods of rapid growth (Thomson and Cunha,
1999), suggesting that FGF10 is a key regulator of prostatic growth and development.
The expression pattern of FgflO transcripts was also shown to be more restricted than
that of Fgfl; FgflO transcripts were expressed in fewer organs compared to Fgf7
transcripts (Bellusci et al., 1997b; Thomson and Cunha, 1999). However more recent
data has identified FGF10 a key regulator in numerous processes (see table 1.1), the
majority of which involve either regulation of proliferation of cells and highly folded or
branched organs.
The expression pattern of FgflO in the prostate (Thomson and Cunha, 1999) is similar
both to the expression of FgflO in the lung (Bellusci et al., 1997b) and Bnl, an Fgf
homologue, in the Drosophila (Sutherland et al., 1996). This suggests that FgflO is
playing a similar role in the prostate as that observed in lung and tracheal airway
development. The addition of FGF10 protein to VP organ rudiments in serum free organ
culture, resulted in the growth and development of the prostate similar to that observed
by the addition of testosterone alone (Thomson and Cunha, 1999). Recombinant FGF10
protein also stimulated the growth of prostatic epithelial cell lines, but did not stimulate
the growth of prostatic stromal cells (Thomson and Cunha, 1999). Overall these results
suggest that FGF10 functions as a paracrine regulator of prostate growth and
development.
1.2.5.4 Regulation of FGF7 and FGF10 in the Prostate
FGF7 and FGF10 are expressed in the prostate during development and have been
postulated as being regulators of branching morphogenesis (Thomson and Cunha, 1999;
Thomson et al., 1997). Many studies have addressed their regulation in this system and
as testosterone is essential for prostate development numerous studies have examined
the regulation of FGF7 and FGF10 by testosterone.
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Fgf7 transcripts were up regulated by androgens in prostate cells grown in vitro (Yan et
al., 1992). However Fgf7 transcript levels were inversely proportional to androgen
concentrations in vivo (Nishi et al., 1996) and were repressed in response to testosterone
in VPs grown in vitro (Thomson et al., 1997). These results concurred with studies on
FGF7 protein distribution in the prostate, which showed a broad distribution of FGF7
and no significant changes in concentration as a result of androgen treatment (Nemeth et
al., 1998).
It has been postulated that testosterone may regulate FgflO transcript levels in the
prostate (Lu et al., 1999). If testosterone increases FgflO transcript levels, and thus
FGF10 protein levels, it can be suggested that the addition of FGF10 protein to an organ
culture system would substitute for the effect observed in VPs caused by androgens.
The addition of FGF10 protein to VP organ rudiments in serum free organ culture,
resulted in the growth and development of the prostate similar to that observed by the
addition of testosterone alone (Thomson and Cunha, 1999). Hence these results suggest
that the effect of androgens on prostate development acts via the regulation of FgflO
transcripts. However FgflO transcript levels were not directly regulated by testosterone
in VPs grown in vitro, and are not only inversely related to levels of circulating
androgens but are also expressed in female VMPs (Thomson and Cunha, 1999). Thus it
is unlikely that androgens directly regulate FgflO transcript levels, however to resolve
this problem the regulation of FgflO transcript levels by testosterone was investigated in
this thesis.
If androgens do not regulate FgflO transcripts but FGF10 protein induces a similar
response to androgens in organ cultures, suggesting they may act on the same pathways,
how might androgens be regulating FGF10 signalling? During development of the
prostate, it has been proposed that mesenchymal paracrine factors are produced
constitutively and that androgens act via indirect mechanisms to control the availability
or activity of these paracrine factors (Thomson, 2001). FGF10 is required for prostate
development and is a mesenchymal paracrine factor. FGF10 protein may be modulated
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by androgens via an indirect mechanism. In fact androgens may alter the availability of
FGF10 protein by affecting FGF-heparin/HLGAG interactions. A recent study has
suggested that heparin-like molecules are intimately involved in the androgen-mediated
proliferation of mouse mammary tumour cells (Borgenstrom et al., 2001). Also another
study has addressed a possible mechanism for androgen and heparin interaction
involving FGFR signalling (Kassen et al., 2000). This study demonstrated that in the
absence of DHT, FGF2 in culture was trapped in the ECM and was not available to
interact with LNCaP cells. However in the presence of DHT, heparinase activity in the
culture was elevated and as a result, it liberated the trapped FGF2, which stimulated the
proliferation of LNCaP cells. As FGF10 has been shown to be associated with ECM
(Beer et al., 1997), it is possible that an increase in heparinase caused by androgens may
release the FGF10 protein and thus result in FGFR signalling.
Other factors possibly involved in modulating FGF signalling during development of the
prostate are shown in Fig. 1.4. As some of these factors have been shown to regulate
FgflO gene expression in the lung it would be highly likely that they are involved in
regulating its expression in the prostate. Numerous studies have already demonstrated
that these factors are involved in prostate organogenesis (Lamm et al., 2001; Podlasek et
al., 1999a; Timme et al., 1995) and in the future the mechanisms of their interactions
will most probably be elucidated. However as this thesis has concentrated on the
regulation of FgflO gene expression by TGFbetal, this cytokine will be discussed in
more detail than the others that are briefly mentioned above. Also as the regulation of
FgflO gene transcription was investigated the next part of this chapter will briefly
discuss gene transcription and the role that TGFbetal may play in regulating gene
transcription.
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1.3 TGFbeta in Development of the Prostate
Members of the transforming growth factor beta (TGFbeta) superfamily have been
implicated in the biological processes ranging from specification of cell fate during
embryogenesis to inhibition of cell proliferation during adulthood (reviewed in
(Massague et ah, 1992b)). In mammals there are three different Tgfbetas, Tgfbetal,
Tgfbeta2 and Tgfbeta3 (Derynck et ah, 1985; Madisen et ah, 1988), which are encoded
by different genes and which all function through the same receptor (Massague, 1998).
TGFbetas have been implicated in playing a role in adult prostate homeostasis and
ablation of androgens by castration demonstrated a role for TGFbetas during prostate
regression (Kyprianou and Isaacs, 1989; Bacher et al., 1993; Itoh et al., 1998). However
in the prostate it has been demonstrated that TGFbetal isoform is the most abundantly
expressed and is also the best characterised (Timme et al., 1994). Hence the
experiments performed in this thesis used recombinant TGFbetal protein and as a result
the rest of this chapter will mainly discuss the role that TGFbetal plays in prostate
development and disease.
1.3.1 TGFbetal
TGFbetal protein is a 25 kDa homodimer composed of two disulfide linked subunits.
The subunit remains associated with its N-terminal propeptide, also called latency-
associated peptide (LAP), through non-covalent interactions (Munger et al., 1997).
TGFbetal is secreted in a latent form and the mechanism by which TGFbetal is
activated in vivo is not well understood. However in vitro culture experiments suggest
that proteases play an important role in the activation of TGFbetal (Munger et al.,
1997). In order to elicit a biological response, TGFbetal must be released from the
latent complex so latency is one mechanism to control growth factor activity. Latency
also regulates the availability of TGFbetas by limiting the diffusion from the secreting
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cell thus modulating the autocrine or paracrine actions of the growth factor (Arrick et al.,
1992).
In mice, targeted disruption of the Tgfbetal gene results in lethal inflammation, resulting
in death at approximately three weeks of age (Kulkarni et al., 1993; Shull et al., 1992).
However up to about two weeks of age Tgfbeta 1 null mice appear indistinguishable from
their heterozygotes and wild-type littermates. Analysis of organs revealed a marked
infiltration of lymphocytes and macrophages and tissue necrosis resulting in lesions in
numerous organs (Boivin et al., 1995; Kulkarni et al., 1993; Kulkarni et al., 1995; Shull
et al., 1992). Many of these lesions appeared to resemble those found in autoimmune
diseases, suggesting that TGFbetal plays a vital role in regulating immune responses in
tissues. Tgfbetal knockout mice have also been used to demonstrate a role for
TGFbetal in bone (Geiser et al., 1998), hair follicle (Foitzik et al., 2000) and teeth
(D'Souza et al., 1998) development and production of Langerhans cells in the skin
(Borkowski et al., 1996). Recently Abate-Shen and Shen, 2000, stated that mutant mice
also have defects in prostatic duct formation although there is no published data to
support this (Abate-Shen and Shen, 2000).
1.3.2 TGFbetal Signalling
The basic signalling pathway of TGFbeta's consists of two membrane receptors and a
family of receptor substrates that move into the nucleus (Fig. 1.8) (Attisano and Wrana,
2002). TGFbetas signal through a family of transmembrane serine/threonine kinases
called the TGFbeta receptor family (reviewed in (Massague, 1992)). TGFbetal signals
through and interaction of two types of TGFbeta receptor (TGFbetaR): TGFbetaRI and
TGFbetaRII (Massague, 1992; Massague et al., 1992a; Massague and Chen, 2000;
Wrana, 1998; Wrana et al., 1994). Both TGFbetaRI and TGFbetaRII are required for
cell signalling and work together as a heteromeric complex. Initially TGFbetal binds to
TGFbetaRII, which facilitates TGFbetaRI to recognize the ligand and TGFbetaRI is
recruited into the ligand/receptor complex. Upon RI/RII/TGFbeta binding TGFbetaRI
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is activated by TGFbetaRII phosphorylation, which results in downstream signalling
(Fig. 1.8).
Substrates involved in the signalling of TGFbetal include the SMAD family of proteins



















Fig. 1.8 Depicting TGFbetal signalling in cells as described in the text
8S
activation) inducing the release of R-SMADs (SMAD2/-3). Phospholyation of R-
SMADs results in the accumulation of the proteins in the nucleus that aids the binding of
R-SMADs to SMAD4 (a second class of SMADs, referred to as Co-SMADs) (Lagna et
ah, 1996; Nakao et ah, 1997b). In the nucleus the R-SMAD/Co-SMAD complex
associates with one of many DNA binding partners and numerous transcriptional
coactivalors or compressors, thus mediating repression 01 activation of gene expression
(Wrana, 2000; Wrana and Attisano, 1996; Wrana and Attisano, 2000). A third class of
SMAD proteins, inhibitor SMADs, inhibits the effects of the other SMADs (Hayashi et
ah, 1997; Imamura et ah, 1997; Nakao et ah, 1997a).
To summarize, in the basal state SMADs reside in the cytoplasm and upon TGFbetal
activation of TGFbetaR SMAD2/3 are phosphorylated and form a complex with
SMAD4. These complexes move into the nucleus and either alone or in conjunction
with other factors, activate target genes by binding to specific promoter elements.
SMADs and proteins that associate with SMADs may prove to an important mechanism
by which TGFbetal may regulate FgflO gene expression. As this thesis has examined
the regulation of the FgflO transcript levels by TGFbetal it is important to understand
the mechanisms of TGFbeta-mediated transcription. Therefore, next, an overview of
factors involved in gene transcription, and the role of TGFbeta signalling in gene
transcription will be discussed.
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1.3.3 Gene Transcription and the Role of TGFbetal
1.3.3.1 Gene Transcription
The regulation of gene expression is complex and not only involves the regulation of a
gene at the promoter level but also involves chromatin modification, RNA polymerases,
initiation cofactors, elongation cofactors and mRNA processing (reviewed by (Lee and
Young, 2000)). However this thesis examines the regulation of transcription at the
promoter level, hence the DNA sequences that are involved in transcriptional regulation
and that are components of the transcriptional apparatus will be briefly discussed. There
are at least three features common to most promoters that are involved in gene
transcription: the transcription start site, the TATA box, and other regions involved in
binding transcriptional regulators.
The transcription start site and the TATA box are part of the core promoter element.
The average core promoter element spans from about -40 to +40 nucleotides relative to
the transcription start site. This region may contain the numerous DNA sequence
motifs, which in the appropriate combinations, are sufficient to promote transcription
initiation by the RNA polymerase II transcriptional apparatus (Burke and Kadonaga,
1996; Emami et al., 1997; Smale et ah, 1990). DNA sequence motifs within the core
promoter include the TATA box, transcription factor IID (TFIID) recognition element,
initiator (Inr), and the down stream promoter element (DPE) (reviewed in (Orphanides et
ah, 1996; Roeder, 1996; Smale, 1997; Smale, 2001)). Immediately upstream of the core
promoter is a region of DNA called the proximal promoter (from about -50 to -200 bp
relative to the transcription start site). The proximal promoter may contain multiple
DNA binding motifs that are involved in transcription. The two most commonly found
DNA binding motifs in the proximal promoter are the GC box and the CCAAT box
(Jones et ah, 1988; Maniatis et ah, 1987). The GC box contains a region of sequence
with a high GC content that is a binding site for Spl-like transcription factor proteins
(Briggs et ah, 1986; Bucher, 1990; Kadonaga et ah, 1987; Kriwacki et ah, 1992).
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Transcription factors are proteins that interacted with gene promoters and can alter
transcriptional activity. Spl is found in all cell types of the body, and is involved in the
transcription of numerous genes (Kadonaga and Tjian, 1986). Spl not only requires the
TFIID complex for efficient stimulation of transcription in vitro (Pugh and Tjian, 1990;
Smale et al., 1990; Tanese et al., 1991), but Spl can directly stabilize binding of this
factor to core promoter elements (Kaufmann and Smale, 1994). Spl may also interact
with other components of the preinitiation complex (Choy and Green, 1993). These
results demonstrate that Spl can play an important role in gene transcription. In contrast
to the GC box that mainly binds Spl-like transcription factors, the CCAAT box binds a
number of different proteins (reviewed in (Mantovani, 1998)). The activation of
transcription occurs through the combined activities of numerous transcription factors
acting on the core promoter. However the majority of genes are also regulated through
the presence of distal binding sites (activating sequences (UAS), enhancers, and
repressor sequences) to which transcriptional regulators may bind.
UAS and enhancers Transcription factors activate transcription through binding to
sequences on gene promoters called UAS or enhancers (reviewed in (Blackwood and
Kadonaga, 1998; Khoury and Gruss, 1983)). UAS influence transcription near to the
transcription start sites while enhancers are DNA sequences that increase transcription
from up to 85 kb from the transcription start site. Also enhancers work independent of
their orientation.
Repressors Transcription factors repress transcription through binding DNA
sequences-specific sites through various mechanisms. These include interfering with
activator binding, preventing recruitment of transcriptional apparatus and modifying




Factors that associate with SMADs may be involved in TGFbeta-mediated transcription
and therefore it is important to identify such factors. An example of a protein that binds
SMADs and which is a component of the first identified SMAD transcriptional complex
(Huang et ah, 1995) is Fast-1. Fast-1 is a member of the winged-helix family of putative
transcription factors (Lai et ah, 1993) and was the first component of the activin
response factor (ARF) to be identified based on its ability to bind to activin response
element (ARE) (Chen et ah, 1996a). ARF is a DNA-binding complex that forms in
response to activin or an endogenous factor, in Xenopus embryo explants, that binds to a
50 base pair ARE. Fast-1 resides in the nucleus (Chen et ah, 1996a) and here it
associates with SMAD2 and SMAD4, forming a complex that binds to ARE (Chen et
ah, 1997; Liu et ah, 1997). Other members of the winged helix family might be DNA
binding partners of SMADs.
Another factor shown to cooperate with SMADs and that may be important in context
with this thesis is Spl (Botella et ah, 2001; Brodin et ah, 2000; Feng et ah, 2000b;
Moustakas and Kardassis, 1998). SMAD proteins have been shown to cooperate with
Spl in the up-regulation by TGFbeta of endoglin (Botella et ah, 2001), p21 (Moustakas
and Kardassis, 1998), p 15 (Feng et ah, 2000b), SMAD7 (Brodin et ah, 2000),
plasminogen activator inhibitor 1 (Datta et ah, 2000), and beta5 integrin (Feng et ah,
2000a) gene promoters. All these genes are Spl-dependent because the Spl site
involved participates in transcription initiation.
An important process in TGFbeta mediated gene transcription is the binding of SMAD
DNA-binding complexes with response elements within the promoter of the target
genes. TGFbetal has been shown to cause numerous gene responses including inducing
cell cycle arrest (Datto et ah, 1995; Feng et ah, 2000b; Hannon and Beach, 1994;
Reynisdottir and Massague, 1997; Reynisdottir et ah, 1995) and stimulating expression
of collagen and ECM proteins (Inagaki et ah, 1994; Keeton et ah, 1991; Riccio et ah,
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1992; Ritzenthaler et al., 1993). TGFbeta has been shown to mediate these responses
possibly through the interaction of SMAD DNA-binding complexes with putative Spl
sites located in the genes promoter. This also correlates with the fact that SMAD
transcriptional complexes can contain the Spl transcription factor (Botella et al., 2001;
Brodin et al., 2000; Feng et al., 2000b; Moustakas and Kardassis, 1998). In fact studies
conducted on several different promoters have identified Spl sites as major TGFbeta-
responsive promoter elements (Bloom et al., 1996; Botella et al., 2001; Datto et al.,
1995; Greenwel et al., 1997; Li et al., 1998; Li et al., 1995; Moustakas and Kardassis,
1998). The effects observed on some of these genes also appear to require AP-1 activity
(Chang and Goldberg, 1995; Chen et al., 1996b).
Interestingly, TGFbeta does not always promote gene transcription but can rapidly
inhibit this process (Alexandrow and Moses, 1995; Iavarone and Massague, 1997). The
rapid inhibition of gene transcription may be due to the stimulation of the TGFbeta-
inducible early genes (TIEG). There are two TIEGs identified to date: TIEG1 and
TIEG2. TIEG1 was identified as the product of a TGFbeta-inducible gene from
osteoblastic cell population (Subramaniam et al., 1995). It is a member of the Spl-like
zinc finger transcription factor family that inhibits the growth of epithelial (Tachibana et
al., 1997) and mesenchymal (Tau et al., 1998) cells. TIEG2 protein is very similar to
TIEG1 and is also inducible by TGFbeta signalling and inhibits epithelial cell
proliferation (Cook et al., 1998). Thus TIEGs may play an important role in the
molecular machinery that regulates the growth of cells from various lineages. An
important feature of TIEG1 and TIEG2 are their ability to bind to GC-rich Spl-like cis-
regulatory sequences (Cook et al., 1999; Cook et al., 1998; Yajima et al., 1997). This
may be important owing to the fact that Spl is involved in promoting transcription in
numerous genes (briefly described above). The amount of Spl protein is not affected by
TGFbeta treatment (Botella et al., 2001) but TIEG transcription increases rapidly after
TGFbeta treatment reaching a maximum level after about four hours (Cook et al., 1998;
Subramaniam et al., 1995). The expression of TIEG transcripts decreases rapidly after
reaching maximum levels. As TGFbeta inhibits gene transcription of numerous genes,
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and this has been proposed to be mediated through the Spl site, TIEG proteins may be
acting as mediators of this effect. For example, a rapid increase in TIEG may result in a
rapid decrease in gene transcription of Spl regulated genes as TIEG may be competing
for binding to the GC-rich regions normally bound by Spl. The result of antagonizing
Spl binding may result in a decrease in gene transcription.
Overall this data suggests that the Spl protein may form an active complex with
TGFbeta activated proteins. The DNA-binding complexes may mediate TGFbeta-
induced transcriptional changes via the Spl binding sites located in numerous TGFbeta
regulated promoters. However TGFbeta may inhibit gene transcription through the
induction of TIEG. TIEG may compete for binding of Spl sites thus repressing gene
transcription in genes regulated by Spl. So the overall consensus is that the TGFbeta
has differing effects on different genes depending on how it influences transcription.
1.3.4 TGFbetal in the Prostate
TGFbetal was proposed as a factor involved in mesenchymal-epithelial interactions
during development of the prostate (Timme et al., 1994). Numerous studies have
investigated the distribution of Tgfbeta transcripts and TGFbeta proteins in adult tissue
and during prostate organogenesis. In the adult human prostate TGFbetal has been
localised both to the epithelial and stromal cells (Gerdes et al., 1998; Muir et al., 1994;
Perry et al., 1997; Raghow et al., 1999; Wikstrom et al., 1998), and the receptor has been
localised in the epithelium, although some staining in the stroma was detected (Cardillo
et al., 2000; Kim et al., 1996b; Royuela et al., 1998). This suggests that in the human
adult TGFbetal could act as both a paracrine and an autocrine cytokine, as it may
regulate processes in both stromal and epithelial cells.
In the adult rodent the expression of TGFbetal protein was tightly associated with the
prostatic smooth muscle and RT-PCR showed that Tgfbetal transcripts were also
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expressed in the stroma (Nemeth et al., 1997). A preferential staining for TGFbetaR was
demonstrated in epithelial cells (Kim et al., 1996a). Also during development of the
rodent prostate Tgfbeta 1 transcript expression was more highly expressed in the UGM
than UGE, and was predominantly immuno-localised to the UGM surrounding the
developing buds throughout the perinatal period (Timme et al., 1994).
1.3.5 TGFbetal in Prostate Cancer
Both rat and human prostate tumours have been found to express high levels of
TGFbetal (Thompson et al., 1992; Truong et al., 1993). It has been shown that the
increase in TGFbetal expression is not only an early event of prostate cancer but is also
associated with prostate cancer progression (Wikstrom et al., 1998). As TGFbetal has
been shown to inhibit the proliferation rate of epithelial cells the over-expression of
TGFbetal must be causing other effects. Hence TGFbetal has been implicated in cancer
progression owing to its multiple effects on biological processes. TGFbetal has been
suggested to promote tumour growth by stimulating angiogenesis, ECM modulation and
by inhibiting immune responses (Arteaga et al., 1993; Chang et al., 1993; Steiner and
Barrack, 1992). Hence, in vivo, direct effects of TGFbeta on the tumor environment,
such as increased ECM, and local suppression of the immune responses may provide a
growth advantage, which overrules any direct antiproliferative effects of TGFbetal, as
suggested by the effects in culture.
Research performed by Steiner and Barrack tested the direct effect of TGFbetal on
prostate tumour cells by stably transfecting MATLyLu cells with an expression vector
that codes for latent TGFbetal, and growing them in vitro and in vivo (Steiner and
Barrack, 1992). When the cells were inoculated into a host the resulting tumours were
larger, less necrotic and more metastatic than inoculated MATFyFu cells that were not
stably transfected with TGFbetal. In vitro cell proliferation was initially inhibited by
TGFbetal but the cells later resumed proliferation. These experiments showed that
TGFbetal produced in vivo is biologically active and can promote prostate cancer
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growth, viability, and aggressiveness, and that the enhanced tumor growth in vivo was at
least in part via an effect of TGFbetal on the tumor cells themselves.
Also the proliferation of cancerous cells have been shown to increase in the presence of
TGFbetal. Colon carcinoma cells switch their response to TGFbetal with tumour
progression (Hsu et al., 1994; Schroy et al., 1990). As the tumour becomes more
aggressive and less differentiated the growth rate of cells is stimulated and not repressed
by TGFbetal (Hsu et al., 1994; Schroy et al., 1990). More recently insulin-like growth
factor binding protein 3 was shown to mediate the TGFbetal-induced proliferation of
highly metastatic or highly aggressive colon carcinoma cell lines (Kansra et al., 2000).
TSU-Prl cells were originally thought to be of prostate cancer origin (Iizumi et al.,
1987) and represent a cell type whose proliferation is increased in the presence of
TGFbetal (Lamm et al., 1998). More recently TSU-Prl cells were shown to have
probably originated from a bladder cancer cell type and not prostate cancer (van
Bokhoven et al., 2001). However TSU-Prl cells represent a highly aggressive and
relatively undifferentiated cancer cell type that is growth responsive in the presence of
TGFbetal. The fact that aggressive cancer cells are stimulated by TGFbetal and
TGFbetal protein is expressed in cancer suggests that TGFbeta's not only promote
cancer progressive by modulation of ECM and immunosuppressive actions but may also
directly promote the growth of cancer cells.
However Tgfbetai heterozygote mice, when treated with carcinogens, have an enhanced
development of lung and liver cancer (Tang et al., 1998), and Tgfbetal null mice also
develop cancer if rescued from autoimmune disease (Engle et al., 1999). These results
demonstrate that TGFbetal is involved in preventing cancer initiation as well as
TGFbetal's ability to promote cancer progression, described above.
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1.3.6 Function of TGFbetal in the Prostate
The function of TGFbetal in the lung was described above and TGFbetal may play
similar roles in the prostate. In vitro, TGFbetal inhibits the proliferation and induces
cell death of both normal prostatic epithelial and stromal cells derived from rodents and
humans (Ilio et al., 1995; Kassen et al., 1996; Story et al., 1993; Sutkowski et al., 1992).
TGFbetal has been shown to inhibit prostate epithelial cells in G1 by stimulating the
production of cyclin-dependent inhibitors (Robson et al., 1999), but at low
concentrations TGFbetal causes small increases in cell proliferation in prostate cells
(Collins et al., 1996; Robson et al., 1999). TGFbetal has numerous other effects on
prostate stromal cells; it induces the expression of SM (Peehl and Sellers, 1997) and has
been shown to inhibit AR action in a prostate smooth muscle cell line (PS-1) by
inducing a nuclear to cytoplasmic distribution of AR (Gerdes et al., 1998). Also
TGFbeta downstream signalling molecule, SMAD3, has been shown to directly bind to
AR and may either promote (Kang et al., 2001) or inhibit (Hayes et al., 2001) AR
signalling in prostate cell lines. Also the binding of SMAD3 to AR may inhibit
TGFbeta signalling (Chipuk et al., 2002). Hence several possible roles for TGFbetal in
affecting prostate development and homeostasis in adulthood have been demonstrated in
cells cultured in vitro.
Early studies of rodent VPs in castration-induced androgen withdrawal demonstrated a
role for TGFbetal during prostate regression (Bacher et al., 1993; Itoh et al., 1998a;
Kyprianou and Isaacs, 1989). It was shown that there was a temporal correlation
between the expression of TGFbeta transcripts and the activation of programmed cell
death in the rat ventral prostate after castration (Kyprianou and Isaacs, 1989). TGFbeta
transcript levels were elevated after castration and androgen replacement suppressed
these levels back to the low level observed in the intact control (Kyprianou and Isaacs,
1989). To test if TGFbeta activates programmed cell death observed in the rat prostate
after castration TGFbeta protein was administered directly to the VP. In vivo treatment
with TGFbeta lead to a significant decrease in DNA content suggesting it was able to
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induce cell death of at least a portion of epithelial cells. However the same effect is not
observed in isolated prostatic epithelial or stromal cells (Itoh et al., 1998a) suggesting
stromal-epithelial interactions were required for the effect observed in the prostate. This,
along with evidence in prostate developmental models, provides a hypothesis that a
network of locally produced growth factors that are potentially regulated by androgens is
required for prostate growth and differentiation.
TGFbetal has also been shown to repress growth and branching morphogenesis of
numerous organs including the prostate and seminal vesicles (Itoh et al., 1998a; Tanji et
al., 1994). TGFbetal had no or little effect on branching morphogenesis in the absence
of testosterone but it inhibited testosterone-induced branching morphogenesis in both the
seminal vesicle and VP. These data suggests that TGFbetal has an integral role in
regulating growth and development of the VP. As a result TGFbetal will be examined
not only in the regulation of FgflO transcript levels but also as a factor that regulates
growth and development of the VP.
1.4 Summary
The development of the prostate is controlled by mesenchymal-epithelial signaling and
is dependent on the presence of androgens (Chung et al., 1991; Cunha et al., 1983;
Tenniswood, 1986). Numerous molecules are involved in mesenchymal-epithelial
signaling and have been shown to regulate prostatic organogenesis (Itoh et al., 1998a;
Lamm et al., 2001; Podlasek et al., 1999a; Thomson and Cunha, 1999). Two factors
shown to have opposing roles in regulation of prostate growth are FGF10 and TGFbetal
and both have been postulated as being regulated by androgens (Bacher et al., 1993; Itoh
et al., 1998a; Kyprianou and Isaacs, 1989; Lu et al., 1999).
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FGF10 is a mesenchymal-derived paracrine factor that may regulate the pattern of
epithelial growth during development of the numerous organs including the prostate,
lungs and mammary glands. In the lung FGF10 acts as a chemotactic agent for epithelial
growth (Park et ah, 1998), and FgflO is expressed in mesenchymal cells surrounding
branching epithelial tips, suggesting FgflO is strictly regulated and is involved in
patterning of the epithelium architecture (Thomson and Cunha, 1999; Bellusci et ah,
1997b). In fact, FgflO is regulated by factors produced in the epithelium and in cells
surrounding the epithelium (Bellusci et ah, 1997b). A small number of studies have
investigated the regulation of FgflO in the prostate. In prostate cells FgflO transcript
levels have been shown to be up-regulated by testosterone (Lu et ah, 1999), however no
direct testosterone-mediated regulation of FgflO transcript levels in organ rudiments
grown in vitro was demonstrated (Thomson and Cunha, 1999). Factors shown to
regulate FgflO in the lung need to be investigated in the prostate to understand prostate
organogenesis and to establish whether mechanisms of branching morphogenesis are
maintained throughout branched organs. One such factor is TGFbetal.
TGFbetal is expressed in prostatic mesenchymal cells directly surrounding the tips of
prostatic epithelial buds (Timme et ah, 1995). TGFbetal is expressed during
development of the prostate (Itoh et ah, 1998a; Timme et ah, 1994) and during prostate
cancer (Thompson et ah, 1992; Truong et ah, 1993). TGFbetal has been postulated as
regulating prostatic growth by inducing cell death (Martikainen et ah, 1990) and/or
inhibiting cell proliferation (McKeehan and Adams, 1988). More recently TGFbetal
has been shown to repress in vitro VP growth by inhibiting branching morphogenesis
(Itoh et ah, 1998a). Furthermore, evidence has suggested that TGFbetal represses FgflO
transcript levels in numerous cell types and in lung explants (Beer et ah, 1997; Lebeche
et ah, 1999). Hence TGFbetal may in part inhibit growth of VPs by repressing FgflO
gene expression. Therefore TGFbetal may play an opposing role to FGF10 during the
development of the prostate, and the regulation of FgflO by TGFbetal may be one
mechanism of branching morphogenesis.
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Hence, the objective of this thesis is to provide further insight into the molecular
mechanisms underlying prostate development. More specifically, this thesis aims to 1)
investigate whether FgflO is regulated by TGFbetal in prostate cells and organs, 2)
characterise the FgflO promoter to identify regions that regulate FgflO gene expression,
and to determine whether any regions of the promoter mediate the effects of TGFbetal
and 3) determine the role of TGFbetal in prostatic growth during development. Overall,
we aim to have provided an insight into the regulation of FgflO and hence to have
identified a possible mechanism of branching morphogenesis in the prostate.
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2 Materials and Methods
2.1 Materials
2.1.1 Equipment
Agarose gel electrophoresis was performed using Bio-Rad equipment.
Automated sequencing gels were run using an ABI 310 Genetic Analyser by the Human
Reproductive Sciences Sequencing Service, MRC, UK.
Autoradiography was performed using Kodak Biomax MS X-ray film, with Amersham
Biosciences Hypercassette intensifying screens.
Colourmetric assays were read on Labsystems original Multiscan EX.
Confocal microscopy was performed on a Zeiss LSM 510 Laser scanning microscope
and lower power (10X) fluorescent microscopy was performed using the Provis
Olympus AX70 with a Kodak DS330 digital camera.
Glass bottom microwell dishes (Cat No. P35G-0-10-C) were purchased from Plastek®
Cultureware, MatTek Corporation, USA.
Luciferase assays were performed on a EG& G Berthold microplate luminometer.
Nucleic acid concentrations were determined using a WPA lightwave
spectrophotometer.
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Paraffin embedding was performed on a Leica TP 1050, the tissue embedding center
was purchase from Reichert-Jung and tissue sections were cut using the Leica
Microtome RM 2135.
PCR was performed using a Peltier Thermal Cycler PTC 200 from MJ Research.
Phospho Screen and Phosphoimager Storm 860 were purchased from Molecular
Dynamics.
Platform Shaker STR6 was purchased from Stuart Scientific.
RNase protection sequencing gels (CastAway® Precast Sequencing Gel, 6 %
polyacrylamide 1 X TBE 7 M Urea (Cat NO. 401090)) were run and dried using
Stratagene CastAway® Sequencing Device and CastAway® Gel Dryer.
Western analysis was performed using the Invitrogen™, NuPAGE™ Electrophoresis
System.
2.1.2 Computer Software
Sequence analysis and alignments were performed using GeneJockey II Sequence
Processor (P. Taylor, BIOSOFT) and VISTA analysis (http://www-gsd.lbl.gov/vista/).
Sequence similarity searches were performed using NIX from the UK Human Genome
Mapping Project Resource Centre (http://www.hgmp.mrc.ac.uk/). and BLAST from
NCBI (http://www.ncbi.nlm.nih.gOv/BLAST/l. Phospho-images were quantitated using
image Quant Version 1.2 (Molecular Dynamics). Images were captured on a Macintosh




T7 and T3 RNA polymerases, T4 polynucleotide kinase, bovine alkaline phosphatase,
T4 DNA ligase, Taq DNA polymerase, RNase-free DNase I and restriction
endonucleases were purchased from Promega and used with the supplied buffers.
SUPERSCRIPT™ II RNase H" Reverse Transcriptase was purchased from Invitrogen™,
Life Technologies and used with the supplied buffers.
DNase-free RNase cocktail was purchased from Ambion, Inc.
Proteinase K was purchased from Sigma-Aldrich, Inc.
2.1.4 Nucleic Acids
Generuler™ lkb DNA ladder and O X174 DNA/BsuRI (Haelll) marker were purchased
from MBI Fermentas.
Ultrapure NTP Set, Nucleoside 5'-Triphosphate (NTPs), was purchased from Amersham
Biosciences, Inc.
2'-deoxynucleoside-5'-triphosphates (dNTPs) were purchased from Promega Inc.
Radioisotope redivue uridine 5'-[a-32P]-triphosphate, triethylammonium salt was
purchased from Amersham Biosciences, Inc.




5'-bromo-4'-chloro-3'-indolyl-P-D-galactopyranoside (X-gal) was purchased from
CALBIOCHEM®.
Recombinant RNase Inhibitor (Cat. No. N251A) was purchased from Promega.
All other chemicals for standard solutions were obtained from BDH, Sigma-Aldrich or
Invitrogen™, life technologies and were of analytical grade.
2.1.6 Bacterial Strain Genotypes
DH5oc: endAl, hsdR17, (rk'rnk), supE44, thi-1, recAl, gyr A, (NaP),
relAl, A(lacIZY A-argF)U169, deoR, (4>80dlacA(lacZ)M15),
competent cells purchased from Invitrogen™, Life Technologies
(Cat No. 18258-012)
XL-1 blue recAl, endAl, gyrA96,thi-1, hsdR17, supE44, reiAl,
lac[F'proABIlacl9ZAM15Tnl0(Tetr)], competent cells purchased
from Stratagene (Cat No. 200130)
2.1.7 Bacterial Culture Media
Luria Agar (LA) Luria broth plus 1.5 % (w/v) agar
Luria Broth (LB) 10 g f1 bacto-tryptone, 5 g l"1 bacto-yeast extract,
5 g l"1 NaCl, adjusted to pH 7.0 with 5 N NaOH
SOC media 2 % bacto-tryptone, 0.5 % bacto-yeast extract,
20 mM glucose, 2.5 mM KC1, 10 mM MgCl2,
10 mM MgS04, 10 mM NaCl
2.1.8 Mammalian Cell Lines
NIH-3T3 Clonally derived cell line from mouse embryo fibroblasts (Muller et al.,
1984)
PS-1 Clonally derived from prostate stromal cells in the VP (Gerdes et al.,
1996)
2.1.9 Organ and Cell Culture Media and Equipment
All flasks, cryotubes and pipettes were purchased from Falcon®, NUNC™, or Corning
Inc. (COSTAR®).
Controlled Process Serum Replacement - type 1 (CPSR, Cat No. C8905) was purchased
from Sigma-Aldrich, Ltd.
Dulbecco's Modern Eagle media (DMEM) with glutamax I (Cat No. 31966-021),
DMEM/NUT.MIX F-12 with glutamax II (Cat No. 4133-026), Penicillin-Streptomycin
(Cat No. 15240-062), Trypsin-EDTA (Cat No. 25300-062), Foetal Bovine Serum (Cat
No. 10106-169), Bovine Transferrin (Cat No. 11107-018), and Crystalline Bovine
Insulin (Cat No. 13007-018) were purchased from Invitrogen™, Life Technologies.
GenePORTER™ Transfection Reagent (Cat No. T201075) was purchased from Gene
Therapy Systems.
Manipulations were carried out in statutory Class II tissue culture hoods.
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Millicell® CM Culture plate inserts (Cat No. PICM03050) were purchased from
Millipore.
2.1.10 Immunohistochemical and Western Reagents
Hybond-P Protein Transfer Membrane (Cat No. RPN303F) and ECF™ substrate (Cat
No. 1067873) were supplied by Amersham Biosciences.
Normal Goat and Rabbit serum were supplied by Diagnostic Scotland.
NuPAGE™ 10 % Bis-Tris Gel 1.0 mm X 15 well (Cat No. 1091713), Loading Dye (Cat
No. 46-5030), Sample Antioxidant (Cat No. 46-5027), 20 X MOPS SDS Running Buffer
(Cat No. 46-5025) and 20 X Transfer buffer (Cat No. 46-5033) were supplied by
Invitrogen™, Life Technologies.
Pre-stained SDS Page standards (broad-range) (Cat No. 161-0318) were purchased from
Bio-Rad.
Table 2.1 Antibodies used and their dilutions in Westerns and Immunohistochemistry

































































ECF substrate kits were purchased from Ambion, Inc.
GeneClean® II Kits (Cat No. 1001-400) were purchased from Anachem, Ltd.
Luciferase Assay System Kits (Cat No. El801) were purchased from Promega.
Mini Quick Spin RNA Columns (Cat No. 814 427) were purchased from Roche
Diagnostic Corp.
pGEM®-T Easy Vector System I Kit (Cat No. A1360) was purchased from Promega.
Qiaprep® Spin Miniprep Kits (Cat No. 27140) were purchased from Qiagen®.
Qiagen Maxiprep Kits (Cat No. 12162) were purchased from Qiagen®.
Advantage™ 2 PCR Kits (Cat No. K1910-y) were purchased from BD Biosciences
Clontech.
2.1.12 Standard Solutions (A to Z)
2X Buffer
6-Galactosidase Enzyme Assay 200 mM sodium phosphate buffer, pH 7.3,
2 mM magnesium chloride,
100 mM B-mercaptoethanol,
1.33 mg ml"1 o-nitrophenyl B-D-galactopyranoside
(ONPG)
Boiuns fixative 75 ml saturated picric acid,
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25 ml 40 % (v/v) Formaldehyde,
5 ml glacial acetic acid
Hybridisation Buffer (5X)
(for RNase protection assay)
200 mM PIPES pH6.4,
2 M sodium chloride,
5 mM EDTA
Paraformaldehyde fixative 4 % (w/v) paraformldehyde in PBS
PBS
Sigma®
phosphate buffered saline tablet supplied by
Protein Extraction Solution
for cells
20 mM HEPES pH 7.9,
150 mM sodium chloride,
1 mM EDTA,
1 % (v/v) NP40,
0.5 mM DTT,
1 mM PMSF,
20 /xg ml"1 aprotinin,
10 /xg ml"1 leupeptin,
20 jUg ml"1 pepstatin
Protein Extraction Solution
for tissue






20 /ig ml"1 aprotinin,
10 /xg ml"1 leupeptin,
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20 /rg ml"1 pepstatin
RNase Protection Digestion Buffer 300 mM sodium chloride,
10 mM Tris pH 7.5,
5 mM EDTA
RNase Protection Loading Buffer 80 % (v/v) formamide,
10 mM Tris pH 7.5,
5 mM EDTA.
Xylene Cyanole FF (few grains)
Sequencing Gel Fixative 5 % (v/v) methanol,
5 % (v/v) glacial acetic acid,
in dH20
Solution D (50 ml)
(Chomczynski and Sacchi, 1987)
25 g guanidinium thiocyanate,
29.3 ml dH20,
1.76 ml 0.75 M sodium citrate pH 7.0,




3 M NaCl, 0.3 M sodium citrate pH 7.0
2 M Tris acetate, 50 mM EDTA pH 8.0
TBST 0.15 M sodium chloride,
0.1% Polyoxyethylenesorbitan Monolaurate
(Tween20),
in Tris pH 7.4
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TE 10 mM Tris HC1 pH 8.0, 1 mM EDTA
2.2 Methods
2.2.1 Mammalian Cell Culture
2.2.1.1 Isolation and Culture of Primary Mesenchyme Cells from the Female
Urogenital Sinus
Cells used for primary culture were derived from micro-dissected urethral and VMP
stroma from P0 Wistar rat female urogentital sinus (UGS). Between 13 and 18 UGSs
were micro-dissected into VMP and urethral stromal tissue. VMPs and urethral stroma
tissue were put into seperate 1.5 ml eppendorf with 1 ml serum free DMEM with
glutamax I supplemented with 1 X penicillin/streptomycin (penicillin G sodium (100 U
ml"1), streptomycin sulphate (100 jUg ml"1), and amphotericin B (0.25 jug ml"1)) and 1 mg
ml"1 collagenase. Incubating and shaking vigorously, at 37 °C for 45 minutes
dissociated the stromal cells. Dissociated VMP (VMPC) and urethral stromal (URSC)
cells were cultured in T75 flasks in the presence of 10 ml DMEM with glutamax I
supplemented with 10 % FBS (foetal bovine serum) and 1 X penicillin/streptomycin.
The cell media was replaced with fresh DMEM (10 % FBS) every two days until they
were passaged at 95 % confluence. VMPC were passaged a maximum of three times
and URSC were passaged a maximum of 4 times.
At approximately 95 % confluence, cells were washed twice in PBS and detached from
the flask by incubation with 2.5 ml of 1 X trypsin-EDTA for 5 minutes at 37 °C.
Trypsin-EDTA was neutralised by the addition of fresh media containing 10 % FBS and
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cells were collected by centrifugation at 1000 rpm. Cells were re-suspended in 10 ml of
fresh media and were seeded at a ratio of 1:10 into new flasks (grown at 37 °C in a 5 %
C02 incubator).
Cells were treated with 10"8M testosterone and/or TGFbetal (5 ng ml"1) for varying times
to study the regulation of endogenous FgflO transcript levels. They were also used in
transfection studies to identify elements that regulate the FgflO promoter and to test the
response of the promoter constructs to TGFbetal.
2.2.1.2 Culture of Cell Lines
Cell lines were grown in DMEM with glutamax I supplemented with 10 % FBS (foetal
bovine serum) and 1 X penicillin/streptomycin. Cells were passaged in the same way as
for primary cells a maximum of 15 times. NIH-3T3 and PS-1 cells were treated with
10"8 testosterone and/or TGFbetal (5 ng ml"1) for varying times to study the regulation of
endogenous FgflO transcript levels. NIH-3T3 cells were also used in transfection
studies to identify elements that regulate the FgflO promoter.
2.2.1.3 Transfection Studies
Transfection
Cells were passaged, as above, and cultured overnight in 6 well dishes, at a
concentration of 1 X 105 cells per well at 37 °C in a 5 % C02 incubator. 0.1 /rg of
plasmid DNA (luciferase expressing vector with promoter element) mixed with 0.02 yttg
of a pSV-B-galactosidase control vector (Promega) in 10 /d of deionised H20, was
incubated with 8 /d GenePORTER™ and 10 /d PBS, for 15 minutes at room
temperature. Cells were rinsed twice in serum free cell culture media (DMEM with
glutamax I and 1 X penicillin/streptomycin) and finally covered with 800 /d of serum
59
free media. After 15 minutes 200 /xl of serum free media was mixed with the
plasmid/GenePORTER mixture and pipetted into each well. The cells were incubated
for 6 hrs at 37 °C in 5 % C02, then washed twice with serum-containing media (DMEM
with glutamax I, 10 % CPSR, and 1 X penicillin/streptomycin). Cells were incubated
for 36 hrs in 2 ml of serum containing media, then rinsed twice in PBS and harvested by
scraping in the presence of 1 X Reporter Lysis Buffer. Luciferase activity was measured
and normalised to 8-galactosidase activity.
Luciferase Assay
20 /x 1 of cell extract in 1 X Reporter Lysis Buffer was used per reaction. As a negative
control, the same dilution of the cell extract was made from cells that have been
transfected with a luciferase-expressing vector with no promoter elements. Luciferase
activity was measured on the EG&G Berthold Microplate Luminometer, as per
manufacturers' instructions, and repeated twice per cell extract.
B-galactosidase Assay
50 /xl of cell extract in 1 X Reporter Lysis Buffer was used per reaction. As a negative
control, the same dilution of the cell extract was made from cells that have not been
transfected with 8-galactosidase gene. 50 /xl of the cell extract was mixed with 50 /x 1 of
8-galactisadase enzyme assay buffer (2 X) in 96 well plates. The plate was incubated at
37 °C until a faint yellow colour had developed. The reaction was stopped by adding
150 /xl of 1 M sodium carbonate. The absorbance was read using the Labsystems
Original Multiscan EX at 402 nm. Each reaction was performed in duplicate.
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2.2.2 In Vitro Organ Culture
Female UGTs and male VPs were micro-dissected from PO Wistar rats and grown in
serum-free organ culture (DMEM/NUT.MIX F-12 supplemented with transferrin (20 /rg
ml"1), insulin (20 fxg ml"1), and 1 X penicillin/streptomycin). Female UGTs and VPs
were positioned in a drop of media on Millicell® CM filters that were floated on 1ml of
culture media in 4 Well NUNCLON™ plates. Organ rudiments were cultured at 37 °C
in 5 % C02 for up to six days. Regulation of growth and proliferation of epithelial and
stromal cells in VPs were examined by incorporation of BrdU (O.Olmg ml"')(incubated
for 2 hours at 37 °C) on day three or six of culture. VPs were imaged under light-field
illumination prior to fixation, and immunohistochemistry was used to visualise BrdU
incorporation. To study regulation of endogenous FgflO transcript levels, organ
rudiments were cultured in the absence and presence of testosterone (108 M) and/or
TGFbetal (10 ng ml"1) for either seven hours, three days or six days. Organs rudiments
were imaged under light-field illumination at the end of culture prior RNA extraction.
2.2.3 Total RNA Extraction
Total RNA was extracted from mammalian cell types or tissue using a modified AGPC
(acid guanidinium thiocyanate-phenol-chloroform) method (Chomczynski and Sacchi,
1987). The protocol was scaled up so that 500 fi\ of solution D was used per 75 cm2
flask, or approximately 20 cultured VPs. The following protocol was used for harvesting
one 75 cm2 flask of cultured primary VMP cells.
The cells were washed three times in PBS then lysed with 500 (id of solution D. The
flask was incubated at RT for 10 minutes and scraped using a cell scraper. The cell
lysate was removed and put into a 2.0 ml eppendorf. To this was added 50 /d 2 M
sodium acetate pH 4.0, 500 /rl of unbuffered phenol, and 100 fi\ chloroform: iso-amyl
alcohol (49:1). The sample was mixed after each chemical was added, then chilled on
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ice for 15 minutes, and centrifuged at 15 000 rpm for 15 minutes at 4 °C. The aqueous
top phase was pipetted into a clean tube, and 1.2 ml of 100 % ethanol was added. The
sample was incubated at -70 °C for approximately 30 minutes, and spun at 15 000 rpm
for 15 minutes at 4 °C. The RNA pellet was washed in 70 % ethanol, spun at 15 000
rpm for 5 minutes, air-dried for 15 minutes, and resuspended in 200 /xl of ddH20. The
concentration of RNA was determined by UV spectrophotometry at 260nm. Integrity of
the RNA was checked by gel electrophoresis; 1 /xg RNA (in 20 /x 1 of ddHUO) was heated
to 70 °C for 10 minutes, cooled on ice, spun down, and loaded onto a 0.6 % (w/v)
agarose gel. The gel was stained with ethidium bromide and photographed. The
presence of 28S and 18S ribosomal RNA bands confirmed RNA integrity
2.2.4 cDNA Synthesis
1 /xg of total RNA was reverse transcribed in the presence or absence of reverse
transcriptase (SUPERSCRIPT™ II RNase H" Reverse Transcriptase; Invitrogen™, life
technologies), as per manufacturers' instructions. The completed reactions were diluted
with 80 /xl of ddH20. The quality of cDNA was always checked using PCR for HPRT
(HPRT-L-CCTGCTGGATTACATTAAAGCACTG, HPRT-R-CTGAAGTACTCAT
TATAGTCAAGGG).
2.2.5 Polymerase Chain Reaction
In a 20 /xl reaction volume, 5 ng of plasmid DNA or 7.5 /xl of cDNA was mixed with 1
X PCR buffer, 15 mM MgCl2, 0.2 mM dNTPs, 10 pmoles of each primer, and 0.5 U Taq
DNA polymerase. Typically 35 cycles of PCR were performed using the following
conditions: samples preheated to 94 °C for 1 minute, then a standard 35 cycles of 94°C
for 30 seconds, Tm for 30 seconds and 72 °C for 1 minute per kb to be amplified. A final
extension at 72 °C for 15 minutes was performed and samples were incubated at 15 °C.
Tm refers to the annealing temperature in °C used for the oligonucleotides based upon
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the formula Tm = 4 (No. of G/C bases in the oligonucleotide) + 2 (No. of A/T bases in
the oligonucleotide). PCR products were visualised by agarose gel electrophoresis and
ethidium bromide staining.
Table 2.2 Primers for RT-PCR and cloning riboprobes












2.2.6 Cloning of DNA
2.2.6.1 Subcloning of Restriction Fragments
Preparation of Insert DNA.
DNA was digested with the required restriction enzymes and subjected to agarose gel
electrophoresis to resolve the correct restriction fragment. The desired DNA fragment
was extracted from the gel using the GeneClean II kit, as per the manufacturers'
instructions. The extracted DNA was resuspended in 10 /xl of ddH20 and its'
concentration estimated by running a 1 /xl aliquot on an agarose gel against a known
amount of DNA ladder.
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Preparation of Plasmid DNA
Plasmid DNA was digested with the required restriction enzymes and subjected to
agarose gel electrophoresis to check for complete digestion.
If the restriction digestion produced self-cohesive ends the following procedure was
used. The restriction enzyme was heat inactivated at 65 °C for 10 minutes, the vector
DNA was purified by extraction with phenol:chloroform:IAA (25:24:1) and precipitated
with 1/10 volume sodium acetate pH 5.2 and 2.5 volumes of ethanol. The vector DNA
was resuspended in an appropriate volume of ddH20 and then de-phosphorylated using
bovine alkaline phosphatase, as per the manufacturers' instructions. The vector was
then purified by agarose gel electrophoresis and gel extracted using the GeneClean II kit.
The digested vector was resuspended in ddH20 to a concentration of approximately 50
ng pi"1.
Vectors prepared without self-cohesive ends were purified by agarose gel
electrophoresis and gel extracted using the GeneClean II kit. The volume of the vector
DNA solution was adjusted to a concentration of approximately 50 ng pi"1.
Ligation
Ligation of the restriction fragments into the prepared vectors was performed using
appropriate insert: vector ratios (as suggested by manufacturers' instructions), 1 X T4
DNA ligase buffer, and 0.05 U pi"1 T4 DNA ligase in a 10 pi volume. Blunt-end
ligation was performed at 4 °C overnight and sticky-end ligation was performed at room
temperature for four hours or at 16 °C overnight. 2 pi of the ligation mix were
transformed into 50 pi of DH5a (Gibco, UK) or XL-1 blue (Statagene, UK) E.coli, as
per the manufacturer's instructions.
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Cloning of PCR Products
PCR products were purified from agarose gels using the GeneClean II kit, and cloned
into a T-tailed vector using the Promega pGEM®-T Easy Vector, as per manufactures
instructions, before transformation into DH5a or XL-1 blue E. coli.
2.2.6.2 Cloning of FgflO Promoter Constructs
Preparation of pA3Lucm
pA3Lucm was derived from pA3Luc, a vector designed to prevent cryptic plasmid
transcription (Wood, 1989). The Bglll restriction site of pA3Luc was cut by restriction
digestion, the protruding ends were filled in and blunt ended with T4 DNA polymerase
(as per manufacturers instructions, Promega), and ligated (section 2.2.6.1). The vector
was restricted digested with Kpnl and Hindlll and ligated with a polylinker, containing
Kpnl, SacI, Mini, Nhel, Smal, Xhol, Bglll and Hindlll, digested from Full pGL3
(supplied by Justin Grindley). 2 p\ of ligation reaction mix was transformed into XL-1
blue cells, as per manufacturers' instructions, sequencing checked the insert was correct,
then the plasmid was grown and and extracted using a Qiagen® plasmid maxi kit
(section 2.2.7.2). pA3Lucm was used to make all the constructs described below.
Preparation of 5' Deletion Constructs
Full length and 5' deleted sequences from the FgflO promoter were amplified by PCR
using the sequence specific primers detailed in table 2.3. Details of the constructs can be
found in table 2.4. Using the Advantage™ 2 PCR kit, samples were preheated to 94 °C
for 1 minute, then 5 cycles of 94 °C for 30 seconds, 53 °C for 30 seconds and 69 °C for
1 minute. A final extension at 72 °C for 15 minutes was performed and samples were
incubated at 15 °C. PCR products were ligated into pGEM T-easy vector system I, as
per manufactures instructions. Inserts were released by restriction digestion using Spel
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and BamHl and ligated, as described in section 2.2.6.1.4., into pA3Lucm which had
been digested with Nhel and BgUI. 2 pil of ligation reaction mix was transformed into
XL-1 blue cells, as per manufacturers' instructions, sequencing checked the insert was
correct, then the plasmid was grown and extracted using a Qiagen® plasmid maxi kit
(section 2.2.7.2.).
Table 2.3 FgflO sequence specific primers











SS R +482.+502 CCCAAGCTTCGCTCCGTCCTCGGATC
FULLSPE F -5853,-5834 CACTAGTATTCCCATCCCTAAT GTCA
AFR -2103,-2123 CGGATCCAATTCAAATGTTTGAATTGACAACC
AF-CR -3573,-3593 CGGATCCATAGATACAATCAACCACGTTG
AF-B R -4712,-4732 CGGATCCAAGCAGATTCTTTCAAATGATATGAA
AF-AR -5473,-5493 CGGATCCGTGATATTTGTAATATTTTGTTAGA
+SP1 F -214,-197 CACTAGTAAGGCATCGCGCACTCC
-SP1 F -171,-158 CACTAGTTCCCCGGTTCCTTC
AA-DASPlbglllF -171,-152 GAAGATCTTCTCCCCGGTGCCTTCCCCCTC
AA-DASPlhindHIR +482,+502 TTCAAGCTTACTCTCAGGGTGAACAGTGGACG
AA-DASPlspeF -2447,-2425 GGACTAGTACCTCACTATAG GTAGAAC
AA-DASPlbglR -203,-183 GGAAGATCTTCCGATATTTGGGCGAGAGGAGTG
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Forward Primer (F) Reverse Primer (R) SP1
site
Full -5853,+502 Full F Full R YES
AA -5221,+502 AA F Full R YES
AA-C -3136,+502 AA-CF Full R YES
AA-D -2447,+502 AA-DF Full R YES
AA-F -307,+502 AA-FF Full R YES
AA-G -63,+502 AA-GF Full R NO
AA-GA5'UTR -63,+72 AA-GA5'UTRF Full R NO
SS-pA3Lucm -307+502 SSF SS R YES
AF -5853,-2123
-307+502
FULLSPE F AFR YES
AF-C -5853,-3593
-307+502
FULLSPE F AF-CR YES
AF-B -5853,-4732
-307+502
FULLSPEF AF-B R YES
AF-A -5853,-5493
-307+502
FULLSPE F AF-AR YES
+SP1 -214+502 +SP1 F SS R YES
-SP1 -171+502 -SP1 F SS R NO




Preparation of 3' Deletion Constructs
The region containing the transcription start site (from -307,+502) was amplified by
PCR using primers SSF and SSR (Table 2.4). The forward primer incorporated a Bglll
restriction site and the reverse primer incorporated a Hindlll restriction site (Table 2.3).
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Using the Advantage™ 2 PCR kit, samples were preheated to 94 °C for 1 minute, then 5
cycles of 94 °C for 30 seconds, 52 °C for 30 seconds and 69 °C for 1 minute, followed
by 30 cycles of 94 °C for 30 seconds, and 69 °C for 1 minute. A final extension at 72 °C
for 15 minutes was performed and samples were incubated at 15 °C. PCR products were
ligated into pGEM T-easy vector system I, as per manufactures instructions. Inserts were
released by restriction digestion using Bglll and Hindlll and ligated, as described in
section 2.2.6.1.4, into pA3Lucm that had been digested with the same enzymes. The
FgflO transcription start site in pA3Lucm (SS-pA3Lucm) was used to make the 3'
deletion constructs. 3' deleted sequences from the FgflO promoter were amplified by
PCR using primers Full-Spe F and sequence specific primers detailed in table 2.3. Using
the Advantage™ 2 PCR kit, samples were preheated to 94 °C for 1 minute, then 5 cycles
of 94 °C for 30 seconds, 51 °C for 30 seconds and 69 °C for 1 minute, followed by 30
cycles of 94 °C for 30 seconds, 60 °C for 30 seconds and 69 °C for 1 minute. PCR
products were ligated into pGEM T-easy vector system I, as per manufactures
instructions. Inserts were released by restriction digestion using Spel and BamHl and
ligated, as described in section 2.2.6.1.4., into SS-pA3Fucm which had been digested
with Nhel and Bglll. 2 p\ of each ligation reaction mix was transformed into XF-1 blue
cells, as per manufacturers' instructions, sequencing checked the insert was correct, then
the plasmid was grown and extracted using a Qiagen® plasmid maxi kit (section
2.2.7.2.).
Preparation of SP1 Deleted Constructs
The SP1 site was 5' deleted and deleted out of AA-D by PCR.
5' Deletion of the SP1 Site
The region containing the SP1 site (-214,-1-502) was amplified by PCR using primers
+SP1F and SSR. The region commencing 3' of the SP1 site (-171,+502) was amplified
using primers -SPF and SSR. The forward primer incorporated a Spel restriction site
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and the reverse primer incorporated a Hindlll restriction site. Using the Advantage™ 2
PCR kit, samples were preheated to 94 °C for 1 minute, then 5 cycles of 94 °C for 30
seconds, 52 °C for 30 seconds and 69 °C for 1 minute, followed by 30 cycles of 94 °C
for 30 seconds, 59 °C for 30 seconds and 69 °C for 1 minute. A final extension at 72 °C
for 15 minutes was performed and samples were incubated at 15 °C. PCR products were
ligated into pGEM T-easy vector system I, as per manufactures instructions. Inserts
were released by restriction digestion using Spel and Hindlll and ligated, as described in
section 2.2.6.1.4., into pA3Lucm which had been digested with Nhel and Hindlll. 2 /d
of each ligation reaction mix was transformed into XL-1 blue cells, as per
manufacturers' instructions, sequencing confirmed the insert was correct, then the
plasmid was grown and and extracted using a Qiagen® plasmid maxi kit (section
2.2.7.2.).
Preparation of AA-DASP1
The region 3' of the SP1 site (-171,+502) was amplified by PCR using primers AA-
DASPlbglllF and AA-DASPlhindlllR. The forward primer incorporated a Bglll
restriction site and the reverse primer incorporated a Hindlll restriction site. Using the
Advantage™ 2 PCR kit, samples were preheated to 94 °C for 1 minute, then 5 cycles of
94 °C for 30 seconds, 52 °C for 30 seconds and 69 °C for 1 minute, followed by 30
cycles of 94 °C for 30 seconds, 62 °C for 30 seconds and 69 °C for 1 minute. A final
extension at 72 °C for 15 minutes was performed and samples were incubated at 15 °C.
PCR products were ligated into pGEM T-easy vector system I, as per manufactures
instructions. Inserts were released by restriction digestion using Bglll and Hindlll and
ligated, as described in section 2.2.6.1., into pA3Lucm which had been digested with
Bglll and Hindlll. 2 /xl of each ligation reaction mix was transformed into XL-1 blue
cells, as per manufacturers' instructions, sequencing confirmed the insert was correct,
then the plasmid was grown and and extracted using a Qiagen® plasmid mini kit
(section 2.2.7.2.), and named ASPl-pA31ucm. The region 5' of the SP1 site (-2447,-
183) was amplified by PCR using primers AA-DASPlspeF and AA-DASPlbglR. The
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Bglll site, plus additional nucleotides, replaced the Spl site with non-Spl sequence. The
forward primer incorporated a Spel restriction site and the reverse primer incorporated a
Bglll restriction site. Using the Advantage™ 2 PCR kit, samples were preheated to 94
°C for 1 minute, then 5 cycles of 94 °C for 30 seconds, 50 °C for 30 seconds and 69 °C
for 3 minutes, followed by 30 cycles of 94 °C for 30 seconds, 59 °C for 30 seconds and
69 °C for 3 minutes. A final extension at 72 °C for 15 minutes was performed and
samples were incubated at 15 °C. PCR products were ligated into pGEM T-easy vector
system I, as per manufactures instructions. Inserts were released by restriction digestion
using Spel and Bglll and ligated, as described in section 2.2.6.1.4., into ASPl-pA31ucm
which had been digested with Bglll and Nhel. 2 p\ of each ligation reaction mix was
transformed into XL-1 blue cells, as per manufacturers' instructions, sequencing
confirmed the insert was correct, then the plasmid was grown and and extracted using a
Qiagen® plasmid maxi kit (section 2.2.7.2.)
2.2.7 Plasmid DNA Preparation
2.2.7.1 Plasmid Mini-Preparation
A 5 ml culture of bacteria was grown in LB, with the appropriate antibiotic, at 37 °C in a
shaking incubator overnight. 1.5 ml of culture was pelleted in a 1.5 ml eppendorf tube
and plasmid DNA was prepared as described in the Qiaprep® mini kit protocol.
2.2.7.2 Plasmid Maxi-Preparation
A 200 ml culture of bacteria was grown in LB using the appropriate antibiotic, overnight
at 37 °C in a shaking incubator. The culture was spun down and the remainder LB
poured off. The procedure as described in the Qiagen® maxi kit protocol was followed.
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2.2.8 Restriction Endonuclease Digestion
Plasmid DNA was digested using the recommended buffer and approximately 2 U
enzyme per 1 /rg DNA for 90 minutes. Restriction endonuclease digestion was
performed in a water bath at 37 °C.
2.2.9 Agarose Gel Electrophoresis
2.2.9.1 DNA
Plasmid DNA was run on agarose gels of varying percentage and voltage, determined by
the best possible resolution of fragments. DNA was loaded into the gels using MBI
Fermentas DNA loading dye. UV light was used to visualised ethidium bromide stained
DNA and photography was used to record the image.
2.2.9.2. RNA
RNA was run on horizontal 0.6 % (w/v) agarose gels using IX TAE. MBI Fermentas
RNA loading dye was used. RNA was visualised by ethidium bromide staining and
photography.
2.2.10 RNase Protection Assay
2.2.10.1 In Vitro Transcription of 32P-Labelled Riboprobes
The plasmid DNA template was linearised with the appropriate restriction endonuclease,
to create a 5' overhang. Complete digestion was confirmed by agarose gel
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electrophoresis. The linearised template was extracted with an equal volume of
phenol:choloform:iso-amyl alcohol (IAA) (25;24;1) and precipitated by the addition of
0.1 volume 3 M sodium acetate pH 5.2 and 2.5 volume ethanol. The template was
incubated at -70 °C for 30 minutes then centrifuged at 13 000 rpm for 15 minutes. The
pellet was washed in 70 % ethanol, centrifuged at 13 000 rpm for 5 minutes and air-
dried for 15 minutes. The linearised plasmid DNA template was re-suspended to a final
concentration of 100 ng /xT1 in deionised water.
In a reaction volume of 20 /zl, 100 ng of linearised plasmid DNA template was mixed
with transcription reagents to final concentrations of IX transcription buffer (Promega),
10 mM DTT, 40 U recombinant RNase inhibitor, 500 /xM each of ATP, CTP, GTP and
10 /xM UTP, 40 /xCi 32-P UTP and 15 U of either T3 or T7 DNA polymerase. The
reaction mixture was incubated at 37 °C for lhour. The DNA template was digested by
incubation for 20 minutes at 37 °C after the addition of 2 U DNase I in DNase buffer to
1 X in a final volume of 50 /zl. Labelled riboprobe was recovered by column
purification (mini Quick Spin RNA Columns). The riboprobe was precipitated with an
equal volume of 5 M ammonium acetate and 2.5 volume ethanol at -70 °C for 30
minutes. Samples were centrifuged at 13 000 rpm for 20 minutes. The pellet was
washed in 70 % ethanol, spun at 13 000 rpm for 5 minutes, air-dried for 15 minutes, and
re-suspended in 100 /zl of 1 X hybridisation buffer (1 part 5 x hybridisation buffer and 4
parts formamide). The labelled probe could be stored at -20 °C for up to 4 weeks.
2.2.10.2 Hybridisation of Labelled Riboprobes
Typically 10 /xg of each RNA sample, including one sample of tRNA (10 /zg), were
precipitated with an equal volume of 5 M ammonium acetate and 2.5 volume ethanol at
-70 °C for 30 minutes. Samples were centrifuged at 13 000 rpm for 20 minutes. The
pellet was washed in 70 % ethanol, spun at 15 000 rpm for 5 minutes, air-dried for 15
minutes, and re-suspended in 10 /zl of 1 X hybridisation buffer.
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A cocktail mix of probes, including test and internal control probes, was prepared as
follows: in a total volume of 10 /d of hybridisation buffer, 1 /d of internal control probe
and 0.5 /d of test probe were added per sample. 10 /d of cocktail was mixed with each
RNA and tRNA samples, heated to 95 °C for 3 minutes, and incubated overnight at 45
°C.
2.2.10.3 RNase Protection Assay
Tubes were briefly centrifuged and placed on ice for 5 minutes. 350 /d of RNase
mixture (IX RNase digestion buffer containing 10 /d of RNase Cocktail™(Ambion);
RnaseA (500 U/ml) and RNase T1 (20000 U/ml) per sample) was mixed into each
sample and incubated at 30 °C for 45 minutes. Tubes were briefly centrifuged, and 20 /d
10 % SDS and 5 /d Proteinase K (lOmg ml"1) were added. Tubes were incubated at 37
°C for 15 minutes. The protected fragment was extracted with an equal volume of
phenol:choloform: IAA (25;24;1) and precipitated by the addition of 1ml 100 % ethanol
at -70 °C for 30 minutes. Samples were centrifuged at 13 000 rpm for 20 minutes. The
pellet was washed in 70 % ethanol, spun at 15 000 rpm for 5 minutes, air-dried for 15
minutes, and re-suspended in 3 /d of RNase protection loading dye.
As internal controls, in vitro transcribed 32P-labelled riboprobes and riboprobe size
markers were diluted between 1 in 200 and 400 in water and 1 /d was mixed with 3 /d of
RNase protection loading dye. The cocktail mix of probes was diluted 1 in 40 and 1 /d
mixed with 3 fx 1 of RNase protection loading dye. All samples were heated to 95 °C for
4 minutes and loaded onto pre-run CastAway® Precast Sequencing Gel. Gels were
subjected to 70 Watts on a vertical CastAway® Sequencing device for one hour. Gels
were fixed in sequencing gel fixative for 10 minutes, washed in dHT) for 10 minutes,
and dried in a Castaway® Gel Dryer. The RNase protection was visualised using Kodak
Biomax MS X-ray film, with Amersham Biosciences Hypercassette Intensifying
Screens. Hybridised riboprobes were quantified using a phosphoimager and normalised
to the internal control.
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2.2.11 Western Blot Analysis
2.2.11.1 Protein Extraction
Tissue
Micro-dissected tissue was stored at -70 °C until enough was collected to prepare
protein. Tissue was thawed in an appropriate volume of tissue protein extraction buffer.
Tissue was dissociated by douncing and drawing it through a needle and syringe.
Remaining tissue debris was centrifuged and the supernatant containing the protein
extract was pipetted off into a new tube.
Cells
Cells were allowed to reach 95 % confluence before being harvested for protein. Cells
were rinsed twice in PBS and excess solution was removed. 200 /d of cell protein
extraction buffer (per T75 flask) was pipetted on to the cells and incubated on ice for 10
minutes. After 10 minutes the cells were scraped and incubated on ice for a further 10
minutes. Cell lysate was pipetted up and down to further lyse cells and harvested into a
1.5 ml eppendorf. Remaining cell debris was centrifuged and the supernatant containing
the protein extract was pipetted off into a new tube.
Protein Quantification
Protein quantification was performed using the Bio-Rad Bradford Assay, as per
manufacturers' instructions.
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2.2.11.2 Western Electrophoresis, Transfer and Blotting
Appropriate amounts of protein were mixed with final concentrations of 1 X
Invitrogen™ NuPAGE™ LDS Sample Buffer and 1 X NuPAGE™ Reducing Agent in a
20 jul volume. Samples were heated for 10 minutes at 70 °C, mixed and loaded on to a
10 % NuPAGE™ Bis-Tris gel with appropriate protein size markers. Western gels were
run and blotted following the manufacturers' instructions and using NuPAGE™ Loading
Dye, Sample Antioxidant, 1 X MOPS SDS Running Buffer, and 1 X Transfer buffer,
and Biosciences Hybond-P Protein Transfer Membrane, all supplied by Invitrogen™.
2.2.11.3 Western Analysis
Transfer membranes were removed from the NuPAGE™ Electrophoresis Apparatus and
incubated, at room temperature for one hour on the Platform Shaker STR6, in 2 % (w/v)
instant dried semi-skimmed milk dissolved in TBST. The transfer membranes were
incubated, at 4 °C overnight, in 2 % (w/v) milk TBST with the appropriate dilution of
antibody (see table below). The membranes were washed 3 times for 15 minutes with
TBST and incubated for 1 hr with the appropriate secondary AP-conjugated antibody
diluted 1 in 20000 in TBST. Membranes were washed in TBST for 30 minutes and
subjected to ECF reagent, as per manufacturers' instructions. Protein-antibody
conjugates were visualised using a phosphoimager (STORM 860) with a blue
chemiluminescence filter.
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Table 2.5 Primary and secondary antibodies used in western analysis
Western Primary antibody in 2
% milk TBST
Secondary in TBST











2.2.12.1 Paraffin Embedding of Tissue
Micro-dissected tissue or cultured VPs were fixed in 4 % PFA or Bouins fixative for 2
hr on ice. Tissue was stored in 70 % ethanol until processed. Dehydration and further
processing was performed on a Leica TP 1050. Paraffin embedding was performed on
the Tissue Embedding Center and 5 /xm sections cut using a microtome (Leica
RM2135).
2.2.12.2 Tissue Immunohistochemistry
Sections were dewaxed (in xylene) for ten minutes and rehydrated through an ethanol
series of 95 %, 80 %, 60 % and 40% for thirty seconds in each. Sections were pressure
cooked for 5 minutes in citrate buffer, cooled for 20 minutes and washed twice in TBST
on a platform shaker. Sections were blocked in 20 % normal serum (serum of the host
the secondary antibody was raised in, see table below) in TBST at room temperature for
45 minutes, followed by an overnight incubation with the required primary antibodies
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(see table below) diluted in 20 % normal serum in TBST. Slides were washed three
times for 5 minutes in TBST followed by incubation for 1 hr at room temperature in the
required IgG-biotinylated secondary antibodies (diluted in 20 % normal serum in TBST,
see table). Slides were washed twice for 5 minutes in TBST and twice for 5 minutes in
PBS. Sections were then incubated for 3 hours with the required conjugated antibodies
and/or streptoavidin-fluorophore complex (diluted in 2 % normal goat serum, see table),
followed by an overnight wash in PBS. Nuclei were counterstained using 10 /ig ml"1
propidium iodide in PBS for 45 minutes, followed by four washes in PBS for 1 hr.
Sections were visualised and imaged using confocal microscopy (Zeiss LSM 500).



















Streptoavidin alexafluor 488 1:200
Anti-actin, a-smooth
muscle 1:5000









Goat anti-mouse CY5 1:60
Anti-BrdU 1:300
Streptoavidin alexafluor 488 1:200
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2.2.12.3 Cell Immunohistochemistry
Cells were cultured on glass bottom microwell dishes for 48 hrs at 37 °C in a 5 % C02
incubator. Cells were washed twice in PBS, fixed in ice-cold methanol for 5 minutes,
and washed twice in PBS. 0.2 % triton in PBS was added for 2 minutes to permeabilise
the cells, and cells were washed twice in PBS. Cells were blocked in 20 % normal goat
serum in PBS at room temperature for 45 minutes, followed by an overnight incubation
with the required primary antibodies (see table below) diluted in 20% normal goat serum
in PBS. Cells were washed three times for 5 minutes in PBS followed by incubation for
3 hr at room temperature in the required CY5/FITC-conjugated secondary antibodies
(diluted in 2 % normal goat serum in PBS, see table below). Nuclei were counterstained
using 10 fig ml"1 propidium iodide in PBS for 30 minutes, followed by four washes in
PBS for 1 hr. Cells were visualised and imaged using confocal microscopy (Zeiss LSM
500).












Goat anti-rabbit FITC 1:200
Anti-actin, a-smooth muscle
1:5000






Goat anti-rabbit FITC 1:200
Anti-P-tubulin 1:300
Goat anti-mouse CY5 1:60
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3 The Isolation and Characterisation of VMP-
Derived Primary Cells
3.1 Introduction
The aim of this thesis was to examine the regulation of FgflO transcript levels during
prostate organogenesis. A primary cell system from the VMP was established and
characterised to study the regulation of FgflO transcripts during prostate organogenesis
(Fig. 3.1). Although numerous prostate cell lines exist, the vast majority were derived
from diseased prostate epithelium (e.g. BPH, PC-3, LnCaP, TRAMP) and some from
adult prostate stromal tissue (e.g. PS-1). FgflO transcripts are expressed in prostatic
mesenchyme cells, so a cell type that was derived from mesenchyme capable of
inducing prostate development was required. The VMP is a condensed pad of
mesenchyme that has been shown to be required for induction of prostate development
in males. A female VMP has been identified and prostatic budding can be induced in
the female rat VMP in the presence of testosterone (Timms et al., 1995). FgflO
transcripts have been localised to the female rat VMP (Thomson and Cunha, 1999).
Therefore primary cultures of VMP cells (VMPC) derived from the PO female VMP
were thought to be a potentially good model for studying regulation of FgflO transcript
levels.
In order to validate the use of primary VMPC in studies of FgflO gene regulation, it was
decided to compare primary VMPC to primary stromal cells from non-FgflO expressing
cells to identify any differences in VMP and URS markers between cell types. Also it
was hoped to compare the activity of FgflO promoter constructs in primary cells that do
not express FgflO transcripts but were derived from a similar origin to primary VMPC.
As the VMP is part of neonatal reproductive tract primary VMPC were compared to a







(Primary VMPC compared to URSC;
growth, size and expression of SM alpha actin,
AR, Fgf10, and Tgfbeta~\, 2, and 3)
URSC and VMPC
used in;
Fgf10 mRNA expression Fgf10 promoter
studies (TGFbeta 1 treatments) analysis
Fig. 3.1 Diagramatic representation of the derivation, characterisation and analysis of
primary mesenchymal prostatic cells
Primary prostatic cells were derived from either PO rat urethra stromal (URS) or ventral
mesenchymal pad (VMP). Cells were derived by collagenase-disassociation of microdissected
URS and VMP. Primary VMP cells (VMPC) and URS cells (URSC) were plated out in T75
flasks and were passaged a maximum of 4 times during which they were characterised. Cells
were treated with androgens and/or TGFbetal to study the regulation of endogenous Fgf10
mRNA. Cells were also used in transfection studies to identify Fgf10 promoter elements.
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has been shown that non-VMP urethral stroma (URS) (shown on Fig. 3.1) does not
express FgflO transcripts, by in situ hybridisation (Thomson and Cunha, 1999), so it was
decided to compare primary VMPC to primary URS cells (URSC). Primary cultures of
VMPC and URSC were established as described (Fig. 3.1), and passaged a maximum of
four times. These primary cell types were fully characterised to establish whether they
maintained the features of the tissues from which they were derived, and hence were a
good model for the study of Fgfl0 transcript regulation. The following parameters were
examined: cell size, growth rate, responsiveness of growth to testosterone, and the
expression of markers normally expressed in the organ rudiments from which the cell
types were derived (AR, SM a actin, Tgfbetal, Tgfbetal and Tgfbeta3, and FgflO).
3.2 Results
3.2.1 Primary VMPC and URSC Size Differences
Initial observations of primary VMPC and URSC by bright field microscopy indicated
there might be a difference in cell size between passage numbers and cell types.
Numerous reports have indicated that an increase in cell size may be a result of stress or
senescence (Hayflick and Moorhead, 1961; Rubin, 1997; Schneider and Mitsui, 1976).
Enzymatic dispersion has been reported to severely stress vertebrate cells (Rubin, 1997).
It has also been suggested that there is an intrinsic fixed limit to the number of divisions
that normal vertebrate cells can undergo before they senesce or terminally differentiate
(Hayflick and Moorhead, 1961). Also late passage primary cultures have a significantly
larger volume than early passage cells (Schneider and Mitsui, 1976). Thus it was
decided to measure the size of primary VMPC and URSC at different passage numbers.
Primary VMPC and URSC were fixed at low confluence (approximately 40 %), and
their surface area measured by brightfield microscopy (Fig. 3.2). Primary VMPC were
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examined over three passages and URSC were examined over four passages, as these
were the maximum number of passages that could be performed with these cell types.
As there is an intrinsic fixed limit to the number of divisions that normal vertebrate cells
(i.e. untransformed) can undergo before they senesce or terminally differentiate, and that
cells at late passage cultures are larger (i.e. older and more senescent or terminally
differentiated), this data itself suggested that primary VMPC senesce or terminally
differentiate faster than primary URSC. The same number of primary VMPC and
URSC were passaged suggesting that the differences in senescence is not due to the
differences in number of cells in each experiment i.e. a different number of cell divisions
to confluence. However the amount of VMP tissue compared to the amount of URS
tissue used for dissociation was hard to keep the same. Hence differences in cell
senescence could have been due to different amounts of tissue being dissociated and
therefore different numbers of cells plated out. If different amounts of VMP and URS
tissue were being used then after dissociation the cells should reach confluence at
different times, however this was not observed suggesting similar number of cells were
being dissociated and plated out. This suggests that the differences in VMPC and URSC
senescence is probably due to differences obtain from the where the tissue was derived
and not differences in the number of cells dissociated and plated out.
After the first passage the average primary VMPC size was 3604 pm2 (Fig 3.2B). After
passage number two VMPC size (8210 pm2) had increased two-fold. The third and final
passage caused a further small increase in cell size to 9506 pm2. After the first passage
the average URSC size was 2323 pm2, which slightly increased after the second passage
to 2756 pm2. A third passage resulted in an approximately two-fold increase to 5293
pm2, and the fourth and final passage resulted in a 1.7-fold increase in URSC size to
8991 pm2.
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Fig. 3.2 Primary VMPC and URSC size differences
Cells were fixed and their nuclei stained with propidium iodide before being
imaged and measured using phase contrast microscopy. If the cells borders were
indistinguishable, ceil area represents the total surface area of a group of ceils
divided by the number of nuclei present. Panel A shows primary VMPC and URSC
at passage number two (scale bar = 100pm) and panel B represents cell size at
different passage times (VMPC; blue line and URSC; red line). VMPC and URSC
size increases with passage number but VMPC become larger earlier in all
experiments (n=3).Error bars are standard error to the mean (SEM).
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At passage number one the average VMPC size was 1.5 X larger than the average URSC
size (Fig 3.2B). By passage number two VMPC were visibly larger then URSC (Fig
3.2A), which was confirmed by measurement to a value of 3-fold. At passage number
three VMPC were 2 X larger than URSC but after four passages, URSC were of similar
size to VMPC at passage number three.
These data show rapid increase in primary VMPC size at passage number two,
suggesting that these cells had begun to senesce. Primary URSC increased in size
slower than VMPC, indicating that they senesce more slowly. This data demonstrated
that there was a consistent difference in cell size between primary VMPC and URSC
suggesting that primary VMPC senesce more quickly than primary URSC.
3.2.2 The Growth Rate of Primary VMPC and URSC
Another marker of cell stress and senescence is a decline in growth rate with passage
number (Rubin, 1997). It was observed that at higher passage numbers primary VMPC
took longer to become confluent than URSC. This was confirmed by comparing cell
growth rate, for both cell types at each passage (Fig 3.3). Cell growth rate was defined
as the fold change in number of cells between day two and day six of culture, and
represents the total number of cells still alive after the four days in culture.
The growth rate of primary URSC did not change between passage number one and two,
but by passage three the fold change in number of cells had decreased from 11-fold to 7-
fold. On passage number four the fold change in number of cells had further decreased
to just 3-fold. On passage number one primary VMPC had increased in number by 10-
fold. By passage number two there was only a 3-fold change in cell number, and on






Fig. 3.3 Changes in cell growth rate
Cell number was counted for primary VMPC (red bar) and URSC (blue bar) after
each passage. The number of celis in two T75 flasks of each cell type were
counted on day two and six of culture and the fold increase in cell number
determined. Cells were counted in duplicate and the graph represents the
average of three experiments. On passage number one VMPC number increased
by ten-fold, but this decreased to three-fold by passage number two, over the four-
day culture. By passage three VMPC number did not change over the four-day
culture. URSC number increased by over ten-fold on passage number one and
two, seven-fold on passage number three and three-fold on passage number four,
over the four day culture period. Error bars are SEM.
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Primary URSC and VMPC growth rate was similar on passage number one. On passage
number two URSC grew over 3.5 X quicker than VMPC, and on passage number three
URSC grew 7 X quicker than VMPC. On passage number four URSC growth rate was
similar to VMPC growth rate on passage number two.
It has been speculated that a decline in cell growth rate with passage number is a marker
of cell senescence, which implies that primary VMPC start to senesce on passage
number two and primary URSC start to senesce on passage number three. This data is
comparable to primary VMPC and URSC size differences i.e. as cell size increases, cell
growth rate decreases, which are signs of cell senescence or terminal differentiation
(Rubin, 1997).
3.2.3 Effect of Testosterone on Primary VMPC and URSC
number
Growth and development of the prostate are dependent on androgens. Data from
primary cultures of prostate stromal and epithelial cells, and organ transplantation
experiments suggest that epithelial cell proliferation is not directly regulated by
androgens, but is growth responsive to androgen-stimulated stromal cells (Chang and
Chung, 1989; Gao et al., 2001). Also, androgens have been shown to inhibit the
growth rate of primary epithelial cells cultured without stroma (Chang and Chung, 1989;
Nishi et al., 1988), and promote cell proliferation in prostatic stromal cells (Chang and
Chung, 1989; Gerdes et al., 1996). The effect of testosterone on the growth rate of
primary VMPC and URSC was investigated (n=3).
Primary VMPC and URSC were treated with testosterone and counted on day 2, 4 and 6
of culture, and the number of cells was compared to the number of cells in untreated
cultures. Cells were cultured in DMEM both in the presence (Fig 3.4A) and absence





















Day of cell harvest
after plating out
Fig. 3.4 The effect of testosterone on ceil growth rate
The effect of testosterone on the growth rate of primary VMPC (blue line) and
IIRSC (red line) after the second passage. Panel A, cells grown in the presence
of 10 % FCS. Panel B, cells grown under serum free conditions. The X-axis
represents the day after plating that cells were counted. The Y-axis shows the
percentage change in cell number for testosterone treated cells relative to vehicle-
treated cells. Cell counts were performed In duplicate and the graphs represent
an average of three experiments. Testosterone caused no significant change in
primary VMPC or URSC number. Error bars are SEM.
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not significantly alter primary VMPC or URSC number compared to untreated cells in
either the presence or absence of serum.
3.2.4 Comparison of AR and SM a Actin Expression
between Female UGTs, and Primary VMPC and
URSC
3.2.4.1 AR Expression
Early in prostate development, androgen/AR interactions that occur in stromal cells
induce growth and development of prostatic epithelial cells (Cunha and Lung, 1978;
Lasnitzki and Mizuno, 1980; Shannon and Cunha, 1983; Takeda and Mizuno, 1984;
Takeda et ah, 1985), and AR expression in the mesenchyme is required for the
development of the prostate (Cunha and Chung, 1981; Cunha and Lung, 1978). FgflO
transcript levels were postulated as being regulated by testosterone in prostate cells and
as primary VMPC were derived to examine the regulation FgflO transcript levels we
thought it necessary that primary VMPC express AR. Also we wanted to establish a cell
type that represented inductive prostatic stromal tissue and as androgen/AR is essential
for this process, again we felt it necessary that primary VMPC express AR. AR protein
expression in the female UGT was examined and compared to AR expression in primary
VMPC and URSC, by immunohistochemistry and western blotting (n=3).
AR was expressed in both epithelial and stromal cells of the P0 female rat UGT (Pig.
3.5B and 3.5D). AR appeared to be expressed at a higher level in the VMP than UR
(Pig. 3.6A-C).
AR expression was observed in all primary VMPC (Pig. 3.7A) and URSC (Fig 3.7C), by
immunohistochemistry. The amount of AR expressed was examined, in protein samples
prepared from cell lysates at each passage number and compared to protein sampled
prepared from microdissected VMP and UR, by western blotting (Fig 3.8A). Primary
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VMPC and URSC expressed AR at each passage number, and the amount of protein
expressed was similar between cell types and passage numbers. The amount of AR in
primary VMPC and URSC was comparable to the amount expressed in the UR
rudiment. However, a higher expression of AR was observed in the VMP rudiment than
either cell type.
3.2.4.2 SM a Actin Expression
The expression pattern of SM a actin was examined in PO female rat UGTs and in
primary VMPC and URSC, by immunohistochemistry (n=3) and western blotting (n=3).
Immunohistochemistry showed SM a actin was expressed in a distinct layer surrounding
the urethra along the PO female rat UGT (Fig 3.5A and D). The smooth muscle layer
formed an obvious barrier between the VMP and UR (Fig. 3.6A, B and C), and VMP
cells in vivo (Fig 3.5A) are SM a actin negative. To determine whether micro-dissection
of the VMP (for collagenase-disassociation) resulted in any SM layer being included, a
western blot was performed on protein samples prepared from micro-dissected VMP and
URs (Fig. 3.9A). The VMP rudiment protein expressed SM a actin, demonstrating
micro-dissected VMPs had some smooth muscle layer attached, and that micro¬
dissection of the VMP was not precise. Only a small layer of SM would represent a
significant proportion of the dissected VMP, and as the epithelium was not removed
from the UR the proportion of SM was under represented in UR protein compare to if it
was URS protein alone. This may explain why the amount of SM a actin was similar
between micro-dissected samples of UR and VMP.
SM a actin expression was observed in all primary VMPC (Fig. 3.7A) and URSC (Fig.
3.7C), by immunohistochemistry. The amount of SM a actin was examined, in protein
samples prepared from cell lysates at three passages by western blotting (Fig. 3.9A).
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Fig. 3.5 AR and smooth muscle alpha actin expression in the female UGT
Immunohistochemistryfor androgen receptor (AR) and smooth muscle alpha actin
(SM alpha actin) on the female urogenital sinus (UGS). SM alpha actin is shown
in blue (panel A), AR in green (panel B), nuclear staining in red (propidium iodide)
(panel C) and the three colours merged is shown in panel D. Primary antibodies
were not added to panel E. In the UGS AR expression is higher in the VMP than
urethra (UR), and SM alpha actin is expressed in UR stromal cells but not the VMP
(n=3). The scale bar shown in panel E represents 200/jm.
A B
Fig. 3.6 AR and smooth muscle expression in the VMP and UR
Immunohistochemistry showing AR and SM alpha actin expression in the VMP (panels
A and B) and urethra (UR, panels B and C) at x40 magnification (scale bar 100um).
AR is green (yellow staining represents AR localised to the nucleus), SM alpha actin
blue, and nuclear staining is red. Primary antibodies were not added to panel D. The
figure compares UR and VMP AR stromal expression and demonstrates that stromal
SM alpha actin expressing cells separate the VMP from UR. Panel B shows a clear
difference in AR expression between the UR and VMP stroma, more AR is expressed
in the VMP than UR (n=3).
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Fig. 3.7 AR and smooth muscle alpha actin expression in primary VMPC and URSC
Immunohistochemistry for AR and SM alpha actin on primary VMP (panel A) and URS
(panel C) cells. SM alpha actin is blue, AR is green (yellow when localised to the nucleus),
and nuclear staining (propidium iodide) is red. Primary antibodies were not added to VMPC
(panel B) and to URSC (panel D). AR and SM alpha actin was expressed in all cells













Fig. 3.8 AR expression in the VMP, UR, primary VMPC and primary URSC
Western blot for AR (98KDa but approximately 119KDa when glycosylated) on UR
and VMP organ rudiments and their respective primary cell protein of different
passage numbers. 15pg of protein was loaded per sample. Panel A shows a
western analysis and panel B shows the coomassie stain of the blot to show
consistent protein loading. AR expression was highest in the VMP organ rudiment,
























Fig. 3.9 SM alpha actin expression in the VMP, UR, primary VMPC and URSC
Western blot for SM alpha actin (42KDa) on UR and VMP organ rudiments and their
respective primary cell protein at different passage numbers. 1pg of protein was
loaded per sample. Panel A shows a western analysis and panel B shows the
coomassie stain of the blot to show consistent protein loading. SM alpha actin was
expressed at similar levels between cell types and between passage numbers
(n=3).
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Primary VMPC and URSC expressed SM a actin at every passage and the amount was
similar between cell types and passage numbers. The amount of SM a actin protein in
VMPC and URSC was comparable to the amount in the VMP and UR rudiments. This
result demonstrates firstly that both cell types were derived from stroma (Janssen et al.,
2000; Sensibar et al., 1999), and secondly that SM a actin protein is expressed in both
primary VMPC and URSC when cultured in vitro.
3.2.5 Analysis of Tgfbetal, Tgfbetal and Tgfbeta3
Transcript Levels
TGFbetas have been shown to be expressed in the prostate (Perry et al., 1997; Timme et
al., 1995) and may regulate growth during development and adulthood (Itoh et al.,
1998a; Kyprianou and Isaacs, 1989). Hence, next it was decided to investigate the
expression pattern of Tgfbeta transcripts in primary cells and organ rudiments.
Experiments were designed to examine the expression pattern of Tgfbeta transcripts to
determine if similar levels of Tgfbeta transcripts are expressed in primary VMPC and
URSC and their respective organ rudiment. Tgfbetal, Tgfbetal and Tgfbetal transcript
levels were analysed in female prostatic organ rudiments and primary VMPC and URSC
by RNase protection assay.
DNA templates for the synthesis of Tgfbetal, 2, and 3 riboprobes were cloned by RT
PCR using P0 VP cDNA. Primers (chapter 2.2.5.) were designed using GenBank-
pubiished cDNA sequences (Accession numbers; Tgfbetal, NM_021578; Tgfbetal,
AF135598; Tgfbeta3, NM_013174). Protected products for Tgfbetal, Tgfbetal, and
Tgfbetal were 261nts, 245 nts, and 324 nts, respectively. Female UGTs were micro-
dissected either for RNA preparation or for collagenase-disassociation for cells (Fig.
3.1). Cells were plated out and RNA harvested after passage number one. RNA from
VMP and UR rudiments and primary VMPC and URSC were hybridised with 32P-
radiolabelled riboprobes for Tgfbetal, Tgfbetal and Tgfbetal and cyclophilin.
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Transcript levels were quantified using a phosphoimager and normalised to cyclophilin.
In the VMP Tgfbeta transcript levels were approximately 1.3-fold (Tgfbeta 1), 1.8-fold
(Tgfbetal) and 5.6-fold (Tgfbeta3) higher than in the UR (Fig. 3.10A). In primary
VMPC, Tgfbeta transcript levels were approximately 1.5-fold (Tgfbetal), 2.8-fold
(Tgfbetal) and 4.8-fold (Tgfbetai) higher than in primary URSC (figure 3.10B). The
expression pattern of Tgfbeta isoforms in organ rudiments is maintained in their
respective primary cells.
3.2.6 Analysis of FgflO Transcript Levels
As FGF10 plays an important role in the growth of the prostate (Thomson and Cunha,
1999), FgflO transcript levels in VMP and UR organ rudiments were compared to
primary VMPC and URSC by RNase protection assay.
A DNA template for the rat Fgfl0 riboprobe was previously published (Thomson and
Cunha, 1999). Female UGTs were micro-dissected either for RNA preparation or for
collagenase-disassociation for cells (Fig. 3.1). Primary cells were plated out and RNA
harvested after passage number one, two and three. RNA from VMP and UR rudiments
and primary VMPC and URSC at different passage numbers were hybridised with 32P-
radiolabelled riboprobes for FgflO and cyclophilin. Transcript levels were quantified
using a phosphoimager and normalised to cyclophilin. The same PO VP sample was
included in each RNase protection assay so that different experiments could be
compared. FgflO transcript levels in the VMP were 14 times higher than those
expressed in the UR and 4 times higher than levels in VPs (Fig. 3.11A). FgflO transcript
levels in the VMP were 4 times higher than those expressed in primary VMPC and
URSC (Fig. 3.1 IB). UR organ rudiments expressed similar levels FgflO transcripts to
primary VMPC and URSC. However, primary URSC only expressed FgflO transcripts
in passage numbers one and two and expression was lost after passage three.
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Analysis of Tgfbeta'\, Tgfbeta2
and Tgfbeta3 transcript levels
primary cells
Analysis of Tgfbeta'\, Tgfbeta2
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Fig. 3.10 Tgfbetal, Tgfbeta2 and Tgfbeta3 expression in the female UGT and primary
VMPC and URSC
Analysis of Tgfbetal, 2 and 3 transcript levels in female organ rudiments and their
respective primary cells by RNase protection. Transcript levels were quantified using
a phosphoimager and normalised to cyclophilin (CYCL). The numbers below the figure
represent the average transcript abundance of Tgfbetal, 2 and 3 relative to UR rudiment
(panel A, n=2) or primary URSC (panel B, n=4). Panel A. Tgfbetal, 2 and 3
transcripts levels were highest in the VMP. Panel B. Tgfbetal, 2 and 3 transcript levels
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Fig. 3.11 Fgf10 transcript expression in the female UGT and primary VMPC and
URSC
Comparison of Fgf10transcript levels in female UR and VMP organ rudiments (panel A)
and their respective primary cells (panel B) at different passage numbers. Loading was
normalised using cyclophilin (CYCL). The numbers below panel A and B represent the
average transcript abundance of Fgf10 relative to levels in P0 VP (n=3). In-vitro Fgf10
transcripts are expressed mainly in the VMP, fourteen fold higher than the UR. At
passage numbers one and two primary VMPC and URSC both express Fgf10
transcripts but URSC Fgf10 transcript levels decline at passage three. Passage
number three represents approximately three weeks in culture.
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3.3 Summary of Results
Primary VMPC and URSC became larger and their growth-rate slower with increased
passage number. These changes were consistent with cellular senescence (Rubin, 1997),
and this data suggested that primary VMPC and URSC senesced after passage three and
four, respectively. Also primary VMPC and URSC showed no change in growth rate
when cultured with testosterone suggesting testosterone does not directly regulate
stromal cell growth.
Markers normally expressed in organ rudiments were also present in their respective cell
types, and some differences between primary VMPC and URSC were identified. In
particular SM a actin expression was detected in all primary VMPC but not in the VMP
by immunohistochemistry, suggesting that the cells differentiated and that there were
some changes in primary VMPC in culture. However, the most striking similarity
between organ rudiment and cell type was the expression pattern of Tgfbeta 1, Tgfbetal,
and Tgfbeta3 transcripts. Tgfbetal, Tgfbetal, and Tgfbetal gene expression was
maintained between organ rudiment and cell type, suggesting that primary VMPC and
URSC were of different lineage and represented the organ rudiment from which they
were derived. FgflO transcripts were expressed at low levels in the UR, by RNase
protection assay, despite previously not being detectable by in situ hybridisation
(Thomson and Cunha, 1999). FgflO transcripts were also expressed in primary URSC at
similar levels to primary VMPC. FgflO transcript levels in primary VMPC were
maintained throughout their three passages, while at passage number three FgflO
transcript levels in primary URSC were decreased. It appeared that primary VMPC
maintained similarities to the VMP rudiment and primary URSC maintained similarities
to the URS so it was decided that at low passage numbers primary VMPC were a good
system in which to study the regulation of FgflO gene expression.
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4 Regulation of FgflO Transcript Levels in
Cells
4.1 Introduction
This chapter describes experiments to examine regulation of FgflO transcript levels in
primary VMPC (characterised in chapter 3) and two cell lines, PS-1 and NIH3T3 cells.
Previous investigations into regulation of FgflO gene expression demonstrated that both
androgens (Lu et al., 1999) and TGFbetal (Beer et al., 1997; Lebeche et al., 1999) might
play a role in regulating FgflO transcript levels. To address these possible interactions
experiments were designed to determine if FgflO transcript levels were regulated in
prostate and non-prostate cells cultured in the presence of testosterone or TGFbetal, and
if testosterone could repress TGFbetal action.
Three types of cells were cultured, two of which were derived from rat prostate
rudiments (PS-1 cells (Gerdes et al., 1996) and primary VMPC) and the third (NIH3T3)
was derived from embryonic mouse fibroblasts (Muller et al., 1984). PS-1 cells and
primary VMPC were cultured because they have been characterised and shown to
express FgflO transcripts. NIH3T3 cells were cultured as TGFbetal down-regulated
FgflO transcripts in 3T3 cell types (Beer et al., 1997); therefore the NIF13T3 cell line
was a control for TGFbetal action.
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4.2 Results
4.2.1 AR and Tgfbeta Receptor Type I Expression in
NIH3T3, PS-1 and Primary VMPC Cell Types
Since these studies were designed to examine testosterone and TGFbetal regulation of
FgflO gene expression it was important to confirm the expression of AR and Tgfbeta
receptor type I.
4.2.1.1 AR expression
AR expression was examined by immunohistochemistry (Fig. 4.1 A) and western
blotting (Fig. 4. IB). Immunohistochemistry showed AR immunoreactivity in PS-1 cells
and primary VMPC (also shown in Fig. 3.6, 3.7 and 3.8). AR was localised both to the
cytoplasm and nucleus of PS-1 cells and primary VMPC. Some staining was seen in
NIH3T3 cells, but was not thought to represent AR (discussed in detail below). A 119
KDa band, previously shown to represent AR, was visualised in PS-1 and primary
VMPC protein, by western blotting. No full length AR was detectable in NIH3T3 cell
protein by western blotting.
4.2.1.2 Tgfbeta Receptor Type I
Primary VMPC, NIH3T3, and PS-1 cells were cultured in the presence and absence of
TGFbetal for 48 hrs. RNA was prepared from the cells and RT-PCR was performed
(Fig. 4.2). Rat ovary cDNA was used as a positive control for Tgfbeta receptor type I
expression. The quality of the cDNA was verified by RT-PCR for HPRT. Tgfbeta
receptor type I was expressed in cells when cultured in the presence of TGFbetal. No




Fig. 4.1 AR expression in primary VMPC, NIH3T3 and PS-1 cells
Immunohistochemistry (panel A) and western blot (panel B) for AR expression in PS-1,
NIH3T3 and primary VMPC. Images were captured by confocal microscopy at x40 (scale
bar =100/vm). Panel A - AR is green (yellow when co-localised with the nucleus), beta-
tubulin is blue and the nucleus is red (propidium iodide). AR expression was
demonstrated in PS-1 and primary VMPC but not in NIH3T3 cells. Panel B - Western
blot showing AR (98KDa but approximately 119KDa when glycosylated) expression in
PS-1 and primary VMPC but not NIH3T3 cells (left side), loading was confirmed by
coomassie staining (right side).
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Fig. 4.2 Tgfbeta receptor 1 (TgfbetaRt) expression in NIH-3T3, VMPC and
PS-1 cells.
cDNA was prepared from NIH-3T3, VMPC and PS-1 cells cultured in the presence
(+) or absence (-) of TGFbetal for 48 hrs (1 = +reverse transcriptase (RT), 2 = -RT),
and PCR for Tgfbetaffl and HPRT was performed. Panel A. NIH-3T3 and PS-1
cells express TgfbetaRt independent of TGFbetal treatment. TgfbetaFf\
expression in primary VMPC is dependent on TGFbetal treatment (n=3). Panel B.
PCR for HPRT was performed on the same cDNA samples as TgfbetaRI PCR to
demonstrate the presence of cDNA.
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absence of TGFbetal, suggesting that primary VMPC were the only cell type to show
TGFbetal regulation of the Tgfbeta receptor type I.
4.2.2 Regulation of FgflO Transcript Levels in Cells Cultured
with TGFbetal or Testosterone for 48 hrs
The long-term effect (48 hrs) of TGFbetal and testosterone on FgflO transcript levels in
cells was examined. Each cell type was cultured in the presence or absence of serum
and with or without TGFbetal or testosterone for 48 hrs. After 48 hrs cells were
harvested for RNA. RNA from cells were hybridised with 32P-radiolabelled riboprobes
for FgflO and cyclophilin.
4.2.2.1 NIH3T3 cells
There was no significant change in FgflO transcripts levels in NIPI3T3 cells cultured in
the presence of serum compared to cells cultured in the absence of serum (Fig. 4.3). A
two-fold increase of FgflO transcripts levels was observed in cells cultured in the
presence of testosterone and serum, but this was not observed in the absence of serum.
A four-fold reduction in FgflO transcripts levels was observed in cells cultured in the
presence of TGFbetal in the absence of serum, but the regulation of FgflO gene
expression was not observed in the presence of serum.
4.2.2.2 Primary VMPC
A consistent two-fold increase in FgflO transcript levels was observed in primary
VMPC grown in the absence of serum (Fig. 4.4). FgflO transcript levels were
significantly higher than transcript levels in the PO VP, when primary VMPC were
cultured in the absence of serum. Fgfl0 transcript levels in primary VMPC cultured in
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Fig. 4.3 Analysis of Fgf10 transcript levels in NIH3T3 cells by RNase protection
assay
NIH3T3 cells were cultured in the presence or absence of serum and/or testosterone
(10"8M) or TGFbetal (5ng/ml) for 48hrs. Fgf10 transcript levels were normalised to
cyclophilin (CYCL). The numbers below the figure represent the average transcript
abundance of Fgf10 relative to levels on serum free treated cells (n=3). Fgf10
transcript levels in cells cultured in the presence of serum and testosterone increased
by two fold. Cells grown in the presence of TGFbetal but absence of serum resulted
in a four fold decrease in Fgf10 transcript levels.
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Fig. 4.4 Analysis of Fgf10transcript levels in primary VMPC, by RNase protection
assay.
Primary VMPC cells were cultured in the presence or absence of serum and/or
testosterone (10"8M) or TGFbetal (5ng/ml) for 48hrs. Fgf10 transcript levels were
normalised to cyclophilin (CYCL). The numbers below the figure represent the average
transcript abundance of Fgf10 relative to levels in P0 VP (n=3). Fgf10 transcript levels in
VMP cells cultured in the presence of testosterone or TGFbetal were not significantly
changed. A consistent increase of Fgf10 transcripts levels was observed in cells grown
in the absence of serum.
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the presence of testosterone or TGFbetal were not significantly changed from untreated
cells, when examined at 48 hours.
4.2.2.3 PS-1 cells
The same PO VP sample was included in each RPA so that Fgfl0 transcript levels could
be compared between PS-1 cell and primary VMPC treatments. FgflO transcript levels
in PS-1 cells were less than half the levels expressed in the VP (Fig. 4.5). FgflO
transcript levels were not significantly affected in the presence or absence of serum
and/or testosterone, or TGFbetal in PS-1 cells.
FgflO transcript levels were significantly lower in PS-1 cells than in the VP, and by
extrapolation this suggested that FgflO transcripts are expressed at a lower level in PS-1
cells than primary VMPC. FgflO transcript levels in PS-1 cells was considered too low
to examine FgflO gene regulation by TGFbetal, as TGFbetal represses FgflO transcript
levels and RNase protection assay were not sensitive enough to detect any significant
decreases in FgflO gene expression in PS-1 cells. Hence studies with PS-1 cells were
not continued.
4.2.3 Regulation of FgflO transcripts in NIH3T3 cells and
primary VMPC cultured with TGFbetal for 1, 3, 7, and 48
hrs
Down-regulation of FgflO transcript levels by TGFbetal has been shown to be rapid and
reversible in 3T3 cells (Beer et al., 1997), so next an experiment was designed to
determine if a similar regulation of FgflO gene expression was observed in prostate
cells. NIH3T3 cells and primary VMPC were cultured in the absence of serum and
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Fig. 4.5 Analysis of Fgf10 transcript levels in PS-1 cells by RNase protection
assay.
PS-1 cells were cultured in the presence or absence of serum and/or testosterone (10"
8M) or TGFbetal (5ng/ml) for 48hrs. Fgf10 transcript levels were normalised to
cyclophilin (CYCL). The numbers below the figure represent the average transcript
abundance of Fgf10 relative to levels in P0 VP (n=3). PS-1 Fgf10 transcript levels were
not significantly affected in the presence or absence of serum and/or testosterone or
TGFbetal.
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in the absence of TGFbetal for 1 and 48 hours. RNase protection assay was used to
quantify any changes in FgflO transcript levels.
4.2.3.1 NIH3T3 cells
FgflO transcript levels, in cells cultured with TGFbetal, decreased two-fold after one
hour, four-fold after three hours and five-fold after seven hours compared to untreated
cells (Fig. 4.6). After a 48 hr TGFbetal treatment FgflO transcript levels had not
recovered to previous levels in NIH3T3 cells, which agrees with a previous experiment
performed over 48 hours (Fig. 4.3).
4.2.3.2 Primary VMPC
FgflO transcript levels, in primary VMPC cultured with TGFbetal, showed little change
after one hour, but decreased fourteen-fold after three hours, and four-fold after seven
hours compared to untreated cells (Fig. 4.7). This repression was reversible and FgflO
transcript levels returned to levels observed in untreated cells after 48 hrs. Again these
results agreed with previous results in experiments performed over 48 hrs (Fig. 4.4).
4.2.4 Testosterone represses TGFbetal inhibition of FgflO
transcript levels
Ligand-bound AR has been shown to inhibit TGFbeta transcriptional responses (Chipuk
et al., 2002) so next we wanted to determine if the down-regulation of FgflO transcript
levels by TGFbetal could be repressed by the addition of testosterone. Chipuk et al.
demonstrated the inhibition of TGFbeta transcriptional responses over 48 hours.
However there was no repression of FgflO transcripts by TGFbetal after 48 hours in
cultured primary VMPC (Fig. 4.7). The greatest repression was observed over three
hours (Fig. 4.7) but it was not known whether the effect observed by Chipuk et al. would
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Fig. 4.6 Analysis of Fgf10 transcript levels in NIH3T3 cells cultured with
TGFbetal, by RNase protection.
Cells were cultured in serum free media for 1 and 48hrs and with TGFbetal (5ng/mI) for
1, 3, 7 and 48hrs. Fgf10 transcript levels were normalised to cyclophilin (CYCL). The
numbers below the figure represents the average transcript abundance of Fgf10 relative
to levels in cells grown in the absence of serum (n=3). Cells cultured in the presence of
TGFbetal resulted in a five fold down regulation of Fgf10 transcript levels after seven
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Fig. 4.7 Analysis of Fgf10 transcript levels in primary VMPC cultured with
TGFbetal, by RNase protection.
Cells were cultured in serum free media for 1 and 48 hrs and with TGFbetal
(5ng/ml) for 1, 3, 7, and 48 hrs. Fgf10 transcript levels were normalised to
cyclophilin (CYCL). The numbers below the figure represent the average transcript
abundance of Fgf10 relative to levels in P0 VP (n=3). Fgf10 transcript levels in
primary VMPC cultured for three hours in the presence of TGFbetal decreased
by thirteen fold. Fgf10 transcript levels in cells cultured for 48 hrs in the presence
of TGFbetal were similar to those found in untreated cells.
111
occur over this short period of time. Hence it was decided that these experiments would
be performed over seven hours, as this was the longest time point examined that Fgfl 0
transcripts were repressed. Primary VMPC were cultured for 24 hrs in the absence of
serum then cells were cultured in the presence or absence of TGFbetal and/or
testosterone for 7hrs. RNA was prepared and hybridised with 32P radiolabeled FgflO
and cyclophilin riboprobes.
No change in FgflO transcript levels was observed after culture for 7 hours with
testosterone (Fig. 4.8). A three-fold reduction in FgflO transcript levels was observed
in primary VMPC after culture with TGFbetal, which agrees with a previous experiment
performed over the same period of time (Fig. 4.7). There was no change in FgflO
transcript levels in cells cultured with TGFbetal and testosterone, suggesting that
testosterone could inhibit TGFbeta-mediated repression of FgflO gene expression over
seven hours. This study was performed towards the end of my experiments and does
raise the question of whether testosterone inhibits TGFbeta-mediated repression of
FgflO transcript levels over three hours. In retrospect, the experiment should have been
performed over three hours as well as seven hours.
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Fig. 4.8 Analysis of Fgf10 transcript levels in primary VMPC cultured with TGFbetal
and/or testosterone, by RNase protection.
Cells were cultured in serum free media for 24 hrs then cultured in presence of testosterone
(10 8M) and/or TGFbetal (5ng/ml) for 7 hours. Cell RNA were hybridised with 32P-
radiolabelled Fgf10 and cyclophilin (CYCL) probes. Fgt 10 transcript levels were normalised
to CYCL. The numbers below the figure represent the average transcript abundance of
Fgf10 relative to levels in untreated cells (n=3). VMPC Fgf10 transcript levels were not
significantly affected when cultured for seven hours in the presence of testosterone.
However testosterone inhibited the TGFbetal down-regulation of FgflO transcripts over this
time period.
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Table 4.1 Changes in FgflO transcript levels culture in the presence of serum
Cell type Treatment (average percentage change in FgflO
transcript levels compared to untreated cells)
TGFbetal (48 hrs)+/-SEM Testosterone (48 hrs) +/-SEM
PS-1 194 +/-6.7 166 +/-8.7
NIH3T3 133+7-9.6 229+/-34.5
Primary VMPC 82+/-9.6 107+/-31.5
Table 4.2 Changes in FgflO transcript levels cultured in the absence of serum
Cell type Treatment (average percentage change in FgflO transcript levels
compared to untreated cells)





lhr 31ir 7hr 481ir 7hr 48hr 71ir
PS-1 125+/-15.8 88+/-20.4
NIH3T3 48+/-14.9 25+/-8.0 21+/-6.8 29+/-10.3 123+/-31.4
Primary VMPC 77+/-24.1 8+/-11.0 22+/-17.7 94+/-29.2 88+/-10.1 133+/-31.5 81+/-12.4
4.3 Summary of Results
Experiments were performed to determine whether TGFbetal and/or testosterone
regulated FgflO transcript levels in cells. Primary VMPC, NIH3T3, and PS-1 cells were
cultured in the presence and absence of TGFbetal and/or testosterone for varying
periods of time, and levels of FgflO transcripts were quantified by RNase protection
assay (shown in Tables 4.1 and 4.2).
Data presented here suggests that there is no direct regulation of FgflO transcript levels
by androgens over 48 hrs in PS-1 cells and primary VMPC. However, androgens did
increase FgflO transcript levels in NIH3T3 cells. AR expression was observed in
primary VMPC and PS-1 cells but not in NIH3T3 cells. The data presented here is
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highly suggestive that NIH3T3 cells do not express AR even though some
immunohistochemical staining was observed. AR expression was restricted to small
areas within the nucleus in NIH3T3 cells while AR is usually located diffusely around
the cytoplasm and in the nucleus suggesting the staining observed in NIH3T3 cells was
not AR. To confirm this western blotting was performed, and no full length AR was
observed, indicative of a lack of AR. Bands were observed that were smaller than the
typical AR and may represent a truncated form of AR. Overall this data suggested that
ligand-bound AR did not directly affect FgflO transcript levels in NIH3T3 cells. Also,
as NIH3T3 cells were derived from embryonic mouse fibroblasts, the observed changes
in FgflO transcript levels were probably not representative of a prostate-like response.
Our data in PS-1 cells and primary VMPC agrees with data published by Thomson and
Cunha, 1999, suggesting that FgflO gene expression is not regulated by androgens, but
does not agree with data published by Lu et al., 1999. As our data mainly focused on
primary VMPC, which are a developmental cell type and Lu et al. examined normal
adult and tumour primary cell cultures, the difference in results might reflect the
different stages of differentiation between developmental and adult normal and cancer
cell types. Androgens may regulate FgflO gene expression in adult and tumour cultured
cells, but do not affect FgflO transcripts expressed during development. FgflO
transcripts are also expressed in the female VMP (i.e. in the absence of testosterone), as
well as in the lung, limb buds, pancreas, kidneys, breast and skin (Bellusci et al., 1997b;
Bhushan et al., 2001; Mailleux et al., 2002; Ohuchi et al., 2000; Ohuchi et al., 1997; Tao
et al., 2002; Thomson and Cunha, 1999). Taken together it is evident that FgflO is not
directly androgen-regulated during prostate development even though prostate
development is androgen-dependent.
TGFbeta has been shown to influence prostate development (Itoh et al., 1998a), and
probably mediates stromal-epithelial interactions (Blanchere et al., 2001; Timme et al.,
1994). Previously the three isoforms of TGFbeta were shown to be present in normal
prostate, BPH and prostate cancer (Danielpour, 1996; Knabbe et al., 1993; Timme et al.,
1995). Beer et al., 1997, observed a strong repression of FgflO transcript levels in 3T3
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FgflO transcript levels increased after 8 hrs of TGFbetal treatment. Hence it was
decided to investigate if TGFbetal regulates FgflO transcript levels in primary VMPC.
Here, TGFbetal repressed FgflO transcripts levels in both NIH3T3 cells and primary
VMPC. It was demonstrated that all three cell-types expressed Tgfbeta receptor type I
cultured in the presence of TGFbetal for 48 hrs. However only primary VMPC did not
express Tgfbeta receptor type I in the absence of TGFbetal. Firstly this suggests that
TGFbetal regulates its' receptor expression and this has been previously observed
(Kyprianou and Isaacs, 1988; Wikstrom et al., 1999). Also this raises the question of
whether TGFbetal induces receptor expression rapidly enough to mediate TGFbetal
action. Repression of FgflO transcript levels was observed after three hours suggesting
that the receptor must have been expressed. In retrospect, Tgfbeta receptor type I
expression should have been examined at all time points. NIH3T3 FgflO transcript
levels were repressed after 1 hr and remained at low levels throughout culture. FgflO
transcript levels were also repressed in primary VMPC cultured with TGFbetal, but
transcript levels recovered after 48 hrs. FgflO transcript levels were not decreased in
PS-1 cells cultured for 48 hrs with TGFbetal. As these cells expressed relatively low
levels of FgflO transcripts and TGFbetal represses FgflO transcript levels, PS-1 cells
were not used in any more TGFbetal treatments. Hence the rapid effects of TGFbetal
on FgflO transcript levels were not followed up in PS-1 cells. Overall these
observations suggest that TGFbetal negatively regulates FgflO transcript levels in
primary prostate cells.
In the prostate, androgens negatively regulate the expression of TGFbeta ligands (Itoh et
al., 1998a; Kyprianou and Isaacs, 1988; Wikstrom et al., 1999). After reduction of
androgens by castration, the expression of TGFbetal in the prostate increases and can be
suppressed by in vivo treatment with androgens (Bacher et al., 1993; Itoh et al., 1998a;
Kyprianou and Isaacs, 1989). More recently it has been shown that ligand-bound AR
inhibits TGFbeta transcriptional responses through selectively repressing the binding of
Smad3 to the Smad binding element (Chipuk et al., 2002). In primary VMPC a
TGFbetal-mediated transcriptional response of FgflO transcription has been identified,
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and an experiment was designed to determine if testosterone inhibits this response.
FgflO transcript levels in primary VMPC grown in the presence of testosterone and
TGFbetal were not repressed. This demonstrated that in our system testosterone was
able to inhibit TGFbetal action over seven hours.
In conclusion, in primary VMPC testosterone did not regulate FgflO transcript levels.
TGFbetal repressed FgflO transcript levels, and this transcriptional response to
TGFbetal was inhibited with testosterone. This has identified a complex network of
interactions in regulating FgflO transcript levels in isolated prostate cells.
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5 Regulation of FgflO Transcript Levels in
Organ Rudiments
5.1 Introduction
This chapter focuses on the regulation of FgflO gene expression in prostatic organ
rudiments by testosterone and TGFbetal. Previous studies have shown that Tgfbeta
isoforms are expressed in the prostate (Timme et al., 1995) but none have thoroughly
addressed their transcript ontogeny during development. Tgfbeta 1, Tgfbeta2, and
Tgfbeta3 transcript levels in the male UGT and VP during development were analysed
by RNase protection assay. In chapter 4, it was shown that FgflO gene expression in
primary VMPC was not regulated by testosterone but was regulated by TGFbetal, so the
objective of this chapter was to see if regulation of FgflO by TGFbetal in primary cells
could be replicated in organ rudiments such as the VMP and VP. Male and female
reproductive tracts were cultured under serum-free conditions in the presence or absence
of testosterone and/or TGFbetal to address if these factors regulated FgflO gene
expression in prostatic rudiments.
5.2 Results
5.2.1 Tgfbetal, -2 and -3 Transcript Levels in Male UGT and VP
The temporal expression pattern of Tgfbetal, Tgfbetal and Tgfbetal transcripts was
examined in the male UGT and VP during development, by RNase protection assay
(Fig. 5.1). In the male UGT, Tgfbetal and Tgfbetal transcript levels were low at el7.5,
increased to maximum levels at P2, and were expressed at low levels at P6 (Fig. 5.1A).
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Fig. 5.1 Analysis of Tgfbeta^, Tgfbeta2 and Tgfbeta3 transcripts in the male
rat UGT and VP, by RNase protection assay.
RNA was hybridised with 32P-labelled antisense riboprobes for Tg/beta1, Tg/beta2
and 7gf/beta3 and 28S as an internal standard. Transcript levels were quantified
using a phosphorimager and normalised to 28S. Changes in transcript levels were
calculated as percentages of PO UGT for panel A and PO VP for panel B. Tgfbeta'\,
Tg/beta2 and 7g/beta3 transcript levels were highest in P2 UGT and were almost
absent by P6 UGT (panel A). Tgfbetal and 3 transcripts were highest in P2 VP and
Tgfbeta2 transcripts highest at PO VP (panel B). In P6 UGT and P6 VP TgfbetaA,
7g/beta2 and Tgr/beta3 transcripts were expressed at low levels.
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levels at P2, and decreased again to low levels at P6. Analysis of transcript levels in
embryonic VPs was not practical before PO owing to difficulties in precise
microdissection of VPs. Also embryonic VPs are small and as relatively large numbers
of VPs would have to be collected to get enough RNA for an RNase protection assay,
harvesting embryonic VPs was decided to be impractical. In the postnatal VP, Tgfbeta
transcripts decreased with increasing age (Fig. 5. IB). Maximum transcript levels were
observed at PO for Tgfbetal and P2 for Tgfbeta 1 and Tgfbeta3. All transcript levels had
decreased between 4- and 10-fold by P6.
5.2.2 Regulation of FgflO Transcript Levels in the VMP and UR
As TGFbetal repressed FgflO transcript levels in primary VMPC, experiments were
designed to determine if the same effect would be observed in female organ rudiments.
Serum-free in vitro organ cultures were performed to investigate if TGFbetal and/or
testosterone regulated FgflO transcript levels in the VMP or UR. Female UGSs were
cultured for either three-days or seven-hours.
5.2.2.1 3-Day Testosterone and/or TGFbetal Culture
Female PO rat UGSs were initially cultured for three days to address the long-term
regulation of Fgfl0 transcript levels in female organ rudiments by testosterone and/or
TGFbetal (Fig. 5.2). These experiments were performed as a comparison to the long-
term treatments carried out on primary VMPC. VMP+URs and URs were micro-
dissected after culture, using the microdissection method shown in Fig. 5.2A, and their
FgflO transcript levels were analysed by RNase protection assay (Fig 5.2B.). All FgflO
transcript levels were standardised to untreated VMP+UR FgflO transcript levels. FgflO
transcript levels were approximately 4-fold less in the UR than VMP+UR. FgflO
transcript levels were not affected in VMP+UR or UR by a 3-day TGFbetal treatment.
This correlates with the regulation of FgflO gene expression observed in primary












Fig. 5.2 Regulation of FgflO transcript levels by TGFbetal and testosterone in
the female UGS.
P0 female rat UGSs were cultured for three days in the presence or absence
of testosterone (lO^M) and/or TGFbetal (10ng/ml). VMP+UR and UR were
microdissected after treatment (panel A) and RNA prepared. VMP+UR and UR
FgflO transcript levels were assayed by RNase protection (panel B). quantified
using a phosphoimager and normalised to cyclophilin (CYCL). The numbers below
panel B represent the average transcript abundance of FgflO relative to levels in
the VMP+UR cultured in the absence of TGFbetal (n=2). FgflO transcript levels in
VMP+UR and UR cultured with testosterone increased by two fold. Organ rudiments
grown in the presence of TGFbetal resulted in no change in FgflO transcript levels.
121
primary VMPC. However FgflO transcript levels increased by two-fold in VMP+UR
and UR when cultured for 3-days in the presence of testosterone, which did not correlate
with regulation of FgflO transcript levels in primary VMPC. However the effect
observed in the female UGS was most likely not a direct regulation of FgflO gene
expression but was more likely to be due to an increase in the number of cells that
express FgflO transcripts; the VMP (the region of the female UGS that expresses the
majority of FgflO transcripts) appeared to be larger in UGSs cultured for three days with
testosterone than those cultured with vehicle. Also UR stroma that expressed FgflO
transcripts may have also increased in size resulting in the two-fold increase of transcript
levels, although this change was not as obvious as the change in the VMPs size.
5.2.2.2 7-Hour TGFbetal Culture
Next it was decided to address the short-term regulation of FgflO transcript levels in
female UGSs. Female PO rat UGSs were cultured over-night in serum-free conditions,
then cultured in the presence or absence of TGFbetal for seven hours (Fig. 5.3 and 5.4).
Culturing organ rudiments with testosterone over seven hours was not performed, as
testosterone had no effect on FgflO transcript levels in primary VMPC and had no direct
effect on FgflO transcript expression in the female UGS. VMPs and URs were micro-
dissected after culture in two different ways. Initially VMPs were micro-dissected as
shown on Fig. 5.3A and 5.2A. As the micro-dissected VMP had UR attached
(VMP+UR), VMP's were also micro-dissected as shown on Fig. 5.4A (VMP). FgflO
transcript levels in micro-dissected VMP+UR, VMP and UR were analysed using RNase
protection assay (Fig. 5.3B and 5.4B).
A 1.7-fold decrease and a three-fold decrease in FgflO transcript levels were observed in
the VMP+UR (Fig. 5.3B.) and the VMP (Fig. 5.4B.), respectively, after treatment with
TGFbetal. No change was observed in FgflO transcript levels in the UR. These results
demonstrate that TGFbetal regulated FgflO gene expression in the VMP but did not
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Fig. 5.3 Regulation of Fgf10 transcript levels in the female UGS by TGFbetal
for 7hrs.
P0 female rat UGS were culture overnight under serum free conditions then treated
for 7hrs in the presence or absence of TGFbetal (10ng/ml). VMP+UR and UR were
microdissected after treatment (panel A); the VMP sample was microdissected
with UR attached (VMP+UR). VMP+UR and UR Fgf10 transcript levels were assayed
by RNase protection (panel B), quantified using a phosphoimager and normalised to
cyclophilin (CYCL). The numbers below panel B represent the average transcript
abundance of Fgf10 relative to levels in the VMP+UR cultured in the absence of
TGFbetal (n=3). Fgf10 transcript levels decreased by 1.7 fold in VMP+UR cultured
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Fig 5.4 Regulation of Fgf10 transcript levels in the female UGS by TGFbetal
for 7hrs.
P0 female rat UGS were cultured overnight under serum free conditions then
treated for 7hrs in the presence or absence of TGFbetal (10ng/ml). VMP and
URs were microdissected after treatment (panel A); VMPs were microdissected
so that no UR was attached. VMP and UR Fgf10 transcript levels were assayed
by RNase protection (panel B), quantified using a phosphoimager and normalised to
cyclophilin (CYCL). The numbers below panel B represent the average transcript
abundance of Fgf10 relative to levels in the VMP cultured in the absence of
TGFbetal (n=3). UGS cultured with TGFbetal resulted in a three fold
decrease of Fgf10transcript levels in the VMP. No change was observed in
Fgf10 transcipt levels in the UR.
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control FgflO gene expression in cells located in different parts of the UGS. However
there is still the question of whether testosterone could block the three-fold down-
regulation in VMP organs by TGFbetal. This was not addressed owing to time limits on
this thesis and that the experiments performed on primary VMPC were performed
towards the end of these experiments.
5.2.3 FgflO Transcript Levels in VPs Cultured with TGFbetal
and/or Testosterone
It was shown that TGFbetal regulated FgflO transcript levels both in primary VMPC
and in VMP organ rudiments. Next the effect of TGFbetal and/or testosterone on FgflO
transcript levels was examined in VPs.
5.2.3.1 6-Day Testosterone and TGFbetal Culture
Initially, PO VPs were cultured for six-days in the presence and absence of testosterone
and/or TGFbetal. Whole mount images of VPs, after a six-day culture in the presence
and/or absence of testosterone and/or TGFbetal, are shown on Fig. 5.5A. A six-day
TGFbetal treatment in the absence of testosterone caused a small decrease in FgflO
transcript levels (Fig. 5.5B.). VPs cultured in the presence of testosterone and TGFbetal
showed no significant change in FgflO transcript levels compared to VPs cultured only
in the presence of testosterone. Only small changes were observed in Fgfl0 transcript
levels over this period of time. A noticeable difference in the phenotype of VP
architecture cultured with TGFbetal suggested that differences in epithelial to
mesenchymal ratios may be masking the effect of TGFbetal on FgflO transcript levels
(i.e. if the addition of TGFbetal caused a reduction in the epithelial content then the
ratio of cells that express FgflO to those that do not would increase. This would
indirectly cause an increase in FgflO transcript levels observed by RNase protection
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Fig. 5.5 Regulation of FgflO transcript levels by TGFbetal in VPs cultured for 6 days.
P0 male rat VPs were cultured for six days in the presence and absence of testosterone
(10'8M) and/or TGFbetal (10ng/ml) (Panel A, scale bar = 1mm). VP FgflO transcript
levels were assayed by RNase protection, quantified using a phosphoimager and
normalised to cyclophilin (CYCL). The numbers below panel B represent the average
transcript abundance of FgflO relative to levels in VPs cultured in the absence of
testosterone and TGFbetal (n=3). Panel B, six day TGFbetal treatment in the absence
of testosterone caused a small decrease in FgflO transcript levels. VPs cultured in the
presence of testosterone and TGFbetal showed no significant change in FgflO transcript
levels compared to VPs cultured in the presence of testosterone.
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epithelial to mesenchyme ratio was observed in VPs cultured for 6-days in the presence
of testosterone to that in VPs cultured in the absence of testosterone using CK19 as an
epithelial marker (Thomson et al., 1997). Hence a direct comparison between VPs
cultured with and without testosterone can be made. The results presented here suggest
that testosterone caused a small decrease in FgflO transcript levels over six days. More
recent unpublished data suggests that there is a change in mesenchyme to epithelial ratio
by testosterone using vimentin as a mesenchymal marker (C. Grace and A.A. Thomson,
unpublished). This raises a question of whether there was a change in ratio of cell types.
To overcome this problem VPs were cultured for less time in the presence of
testosterone so less epithelial growth and mesenchymal differentiation would have
occurred.
5.2.3.2 3-Day Culture with Testosterone followed by a Seven Hour
TGFbetal Treatment
On day three of culture, VPs were cultured in the presence and absence of TGFbetal for
seven hours. This was performed as the VPs were larger than those grown for less time
so more RNA could be obtained from fewer organs, and by only culturing VPs for seven
hours with TGFbetal relatively little structural differences were observed between
different treatment groups. This meant any large changes in FgflO transcript levels were
due to direct regulation on the Fgfl0 gene and not due to changes in cell ratios. After
three days in culture, although obvious differences in epithelial branching are apparent
in organs cultured with and without testosterone, VPs visually appeared more similar in
epithelial and mesenchymal ratios than those cultured for six days (Fig. 5.6A). A seven-
hour TGFbetal treatment caused a small decrease in FgflO transcript levels both in the
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Fig 5.6 Regulation of FgflO transcript levels by TGFbetal in VPs cultured for
three days.
P0 male rat VPs were cultured for three days in the presence and absence of
testosterone (108M) then treated for seven hours (panel A) in the presence and
absence of testosterone and/or TGFbetal (1 Ong/ml) (scale bar = 1 mm). VP FgflO
transcript levels were assayed by RNase protection, quantified using a phosphoimager
and normalised to cyclophilin (CYCL). The numbers below panel B represent the
average transcript abundance of FgflO relative to levels in VPs cultured in the
absence of testosterone and TGFbetal (n=2). 7hr TGFbetal treatment caused a
small decrease in FgflO transcript levels in the presence and absence of testosterone.
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5.2.3.3 Three- and Seven-hour TGFbetal Culture
The fold-change of FgflO transcript levels in VPs cultured with TGFbetal for seven
hours was not as large as that observed in primary VMPC and VMP rudiments. There
are several reasons that may account for this. But it may be an effect of factors
produced in the epithelium that also regulated FgflO gene expression. In VPs cultured
overnight there appeared to be less epithelial branching than VPs grown for longer
periods of time (Fig. 5.7A and B compared to Fig. 5.5A and Fig. 5.5B). Again culturing
organ rudiments with testosterone over seven hours was not performed, as testosterone
had no effect on Fgfl0 transcript levels in primary VMPC and had no direct effect on
FgflO transcript expression in the female UGS.
FgflO transcripts levels (Fig. 5.7C) decreased by 1.5-fold in VPs cultured in the
presence of TGFbetal for 3hrs (Fig. 5.7A). FgflO transcript levels decreased by 1.3-fold
(Fig. 5.7D) in VPs cultured in the presence of TGFbetal for 7hrs (Fig. 5.7B). These
fold-changes were not equivalent to those observed in primary VMPC and VMP
rudiments cultured with TGFbetal, but were larger than those seen in VPs with more
epithelium. This suggests epithelium might be inhibiting the effect of TGFbetal on
mesenchymal cells in VPs.
5.3 Summary of Results
Experiments were performed to determine whether Tgfbeta isoforms were expressed
during prostatic development, and if TGFbetal and/or testosterone regulated FgflO gene
expression in organ rudiments. Previous studies have shown that Tgfbeta isoforms were
present in normal prostate, BPH, and prostatic cancer (Danielpour, 1996; Knabbe et ah,




















Fig. 5.7 Regulation of Fgf10transcript levels in VPs by TGFbetal.
PO male rat VPs were cultured and treated for three (panel A) or seven hours
(panel B) in the presence (+) or absence (-) of TGFbetal (10ng/ml) (scale bar =
1mm). VP Fgf10 transcript levels were assayed by RNase protection, quantified
using a phosphoimager and normalised to cyclophilin (CYCL). The numbers
below panel C and D represent the average transcript abundance of Fgf10 relative
to levels in VPs cultured in the absence of TGFbetal (n=2). VPs cultured in the
presence of TGFbetal for 3hrs result in a 1.5 fold decrease in Fgf10transcript
levels (panel C) . VPs cultured in the presence of TGFbetal for 7hrs result in a
1.3 fold decrease in Fgf10 transcript levels (panel D).
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during embryonic and neonatal prostate development. Tgfbeta 1, Tgfbetal and Tgfbetal
transcript levels were analysed in male UGTs and VPs during development of the
prostate. Tgfbetal and Tgfbetal transcript levels were low in the male UGT around the
start of prostate development (el7.5) and increased up to P2. Low levels of Tgfbetal and
Tgfbeta3 transcripts were detected at P6. Tgfbetal transcript levels in the male UGT
were relatively high around the start of prostate development, were lower at el9.5 and
elevated at P2. Lower levels of transcripts were detected at P6. In the VP, Tgfbetal and
Tgfbetal transcript levels peaked at P2 and decreased to P6. Tgfbetal transcript levels
were highest at PO and again decreased to P6. The observed changes in Tgfbetal,
Tgfbetal and Tgfbeta3 transcript levels correlated with the growth pattern of the VP. VP
growth and branching morphogenesis occurs in the early neonatal period, becoming
quiescent after P20. This suggested that TGFbeta-signalling may participate in early VP
development, which agrees with previous results that suggested Tgfbetal, Tgfbeta2, and
Tgfbetal isoforms are associated with fetal UGS tissues and therefore prostatic
morphogenesis (Timme et al., 1994). However, another report suggested Tgfbetal
expression remains constant and Tgfbetal and Tgfbetal are inversely related during
prostatic development (Itoh et al., 1998a). This report examined Tgfbeta expression
patterns at PI, P20, P60 and PI00 and compared values to P20. Our studies examined
levels between el7.5 and P6, when the prostatic growth rate is at its highest, therefore
providing a better picture of how Tgfbeta isoform expression changes with early prostate
oraganogenesis.
Androgens are postulated to regulate FgflO gene expression in the prostate (Lu et al.,
1999). In this chapter it was observed that androgens caused a two-fold increase in
FgflO transcript levels both in the VMP+UR and UR cultured for three days. The
increase in FgflO transcript levels may be a result of androgens either stimulating
proliferation of FgflO expressing cells or promoting URE-mesenchymal interactions
resulting in increased FgflO gene expression (discussed in chapter 8). This would
explain the increase in FgflO transcripts levels in both the VMP+UR and UR and
suggests that testosterone does not directly regulate FgflO transcript levels. The
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experiments performed on primary VMPC (chapter 4) and experiments performed on
prostatic rudiments agree with this hypothesis (Thomson and Cunha, 1999). FgflO
transcript levels were not regulated by androgens in primary VMPC, and while FgflO
transcript levels increased after treatment with testosterone in the SV (and to a lesser
degree in the VP), these changes were not sensitive to anti-androgen treatment
(Thomson and Cunha, 1999). Thus FgflO gene expression was unlikely to be directly
regulated by androgens.
It has previously been shown that TGFbetal repressed FgflO transcript levels in a 3T3
fibroblast cell type (Beer et al., 1997) and in lung mesenchyme cells and lung explants
(Lebeche et al., 1999). We have observed a similar regulation by TGFbetal on FgflO
transcript levels in VMP organ rudiments but not in UR rudiments. FgflO transcript
levels were decreased by a maximum of three-fold in the VMP when cultured for seven
hours with TGFbetal, similar to changes observed in primary VMPC. Also as in
primary VMPC FgflO transcript levels were not regulated by a longer exposure to
TGFbetal in the VMP. This suggests that the effect of TGFbetal was reversible in
organ rudiments similar to what was observed in primary VMPC. TGFbetal did not
affect FgflO transcript levels in the UR under any treatment regimes. This suggested
that FgflO gene expression was regulated by different mechanisms in different parts of
the female UGS or that regulatory signalling from the URE was preventing TGFbetal -
mediated repression of FgflO transcript levels. Also this suggests that TGFbetal
regulation of FgflO transcript levels is VMP/VMPC specific.
To determine if TGFbetal or testosterone might regulate FgflO gene expression in the
VP, they were added together to organ cultures of VPs. Over a six-day culture,
TGFbetal did not appear to regulate FgflO transcript levels in VPs in the presence of
testosterone, but a small decrease in Fgfl0 transcript levels was observed in the absence
of testosterone. FgflO transcript levels were also decreased in VPs cultured with
testosterone alone, which agrees with published data that suggested testosterone does not
directly up-regulate FgflO gene expression in the VP (Thomson and Cunha, 1999).
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A problem resulting from culturing for six days with hormones or growth factors when
examining a factor only expressed in the mesenchyme, is differing final ratios of
mesenchyme to epithelium. No experiments have been performed to address if
TGFbetal changes the ratio of cell types in VPs culture over three and six-days.
However the effect of testosterone on mesenchymal to epithelial ratios has been
examined. It was published that VPs cultured with and without testosterone have similar
levels of CK19 (only a 1.3 fold increase in organs cultured with testosterone) (Thomson
et al., 1997), suggesting that there was very little change in epithelial to mesenchymal
ratio. However recently it was demonstrated that VPs cultured in the absence of
androgens have a higher level of vimentin expression (O.C. Grace and A.A. Thomson,
unpublished); and as vimentin stains mesenchymal cells, VPs cultured in the absence of
testosterone may contain more cells that express FgflO transcripts. These results may
differ as testosterone may regulate the expression of either vimentin or CK19, or cause
differentiation of cells and thus possibly alter their expression. To try and resolve these
problems VPs were cultured for shorter periods of time with testosterone, and then
treated with TGFbetal for seven hours (i.e. the period of time that TGFbetal was shown
to affect FgflO transcript levels in primary VMPC and VMP rudiments). This ensured
that major differences between the ratio of mesenchymal to epithelial cells were not
affecting FgflO transcript levels. After a three-day serum-free culture in the presence or
absence of androgens, the VPs appeared to be of comparable size and therefore they
would more likely have similar mesenchymal to epithelial ratios. Again FgflO transcript
levels were not increased in VPs cultured with testosterone and it was observed that
TGFbetal caused only a small decrease in FgflO transcript levels both in the presence
and absence of testosterone. This suggests that testosterone did not antagonise the
regulation of FgflO transcript levels by TGFbetal.
It was postulated that the effect of TGFbetal on FgflO transcripts levels was inhibited
by factors produced in the epithelium in the prostate, as factors produced in the
epithelium have been proposed to regulate FgflO gene expression during lung
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development (Bellusci et al., 1997b). To test this hypothesis it was decided to treat VPs
with TGFbetal on day one in culture (i.e. when epithelia content appeared to be at its
lowest in our culture system). FgflO transcript levels were consistently repressed over
three- and seven-hours in culture with TGFbetal. The degree of repression was not as
great as what was seen in primary VMPC or the VMP rudiment. Hence in PO VPs,
TGFbetal had a greater effect on FgflO transcript levels than in more developed VPs,
because branching morphogenesis of the epithelium had relatively only just commenced.
In conclusion it was demonstrated that testosterone did not directly regulate FgflO
transcript levels in VP rudiments in vitro, but can indirectly alter levels of FgflO
transcripts in the female UGS by causing a proliferation of mesenchymal cells, and
hence increasing the ratio of FgflO expressing cells to non-expressing cells. TGFbetal
can repress FgflO transcript levels in male and female prostatic rudiments, however the
level of repression is less in the VP compared to the VMP. The major difference
between the VMP and VP is the epithelial content and it is possible that the epithelium
counteracts the effect of TGFbetal on FgflO transcript levels.
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6. Analysis of the Fgfl0 Promoter
6.1 Introduction
To understand the mechanisms responsible for regulating FgflO gene expression,
analysis of the FgflO promoter was performed. Sequences lying 5' to the FgflO
translation start site from mouse, human and sheep were compared using VISTA
analysis to identify a region that may contain the FgflO transcription start site. A fall in
DNA sequence homology potentially indicated the presence of a transcription start site.
An FgflO transcription start site was mapped by RNase protection analysis using
antisense riboprobes designed against the region of promoter identified by VISTA
analysis. VISTA analysis was also used to identify regions of high sequence homology
between mouse and human genomic sequence, 5' to the transcription start site.
Conserved elements of the moused sequence between mouse and human genomic
sequence were placed upstream of pGL3 SV40 promoter to test for enhancer activity.
Using this method two regions were identified, one repressed and the other enhanced
transcription. A deletion analysis of the FgflO promoter was performed to analyse the
activity of the conserved regions in the context of the native FgflO core promoter. A
244 bp DNA fragment, that when deleted reduced FgflO transcription, was examined for
transcription factor binding sites. An Spl site was identified in this region, and was
shown to promote FgflO transcription, and mediate repression of FgflO expression via
TGFbetal.
This project was facilitated by the gift of a 6.6 kb FgflO genomic clone of mouse DNA
isolated by Dr. Justin Grindley. Dr. Grindley also supplied mouse and human FgflO
genomic sequences used in the VISTA analysis, and cloned the mouse regions,
identified as being homologous to human, into the pGL3 SV40 vector. The work
described here was performed in prostate cells in collaboration with Dr. Grindley, and
compliments his studies in lung cells.
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6.2 Results
6.2.1 Identification of an FgflO Transcription Start Site
To identify regions of a mouse FgflO genomic clone that might contain a transcription
start site, a comparison of mouse and human FgflO genomic sequences and sheep cDNA
sequence (GenBank acc no. AF213396) was performed using VISTA analysis (Fig. 6.1).
VISTA is a program for visualizing global DNA sequence alignments of arbitrary length
(Mayor et al., 2000), and the program determines the identity between two DNA
sequences and displays this as a graph. For these studies high sequence conservation
was defined as 50 % or greater. The comparison between mouse and human genomic
sequence, and mouse genomic sequence and sheep cDNA sequence revealed a sharp dip
in homology between -1300 bps and -1500 bps (relative to the translation start site)
(Fig. 6.1). The dip in homology coincided with the 5' end of the sheep cDNA sequence
and was therefore thought to represent a potential transcription start site, assuming that
the cDNA was full length. Riboprobes were designed that flanked this region in the
mouse to determine whether it contained an FgflO transcription start site, and to map the
start site position.
To map the transcription start site RNase protection was used with antisense riboprobes
from six FgflO DNA templates (Fig. 6.2A). DNA templates were synthesised either by
restriction digestion of the FgflO genomic construct or by PCR using primers
complementary to FgflO (see table 2.2), which were cloned into pGEM T-easy or
pBluescript. Probel corresponded to a 457-bp Nhel/PstI fragment 5' to the putative start
site region. Probe2 corresponded to a 488-bp PstI fragment. Probes 3-6 were cloned by
PCR using primers complementary to the FgflO construct (Table 2.2). Labelled probes
were hybridised with 10 pg of total RNA isolated from NIH3T3 cells, el3.5 mouse lung
or P0 mouse VPs (Fig. 6.2B).
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translation start site
Fig. 6.1 Comparison of Fgf10 sequences from three species to identify regions of
homology and potential transcription start sites.
The sheep sequence was obtained from an NCBI blast search on the mouse Fgf10
genomic sequence, using a non-redundant database. Comparison between species
was performed using VISTA analysis and plotted as percentage homology compared
to mouse. Comparison between mouse and human (red line), and mouse and
sheep (blue line) revealed a sharp dip in homologybetween -1300bps and -1500bps
(when ATG is -1 ,+1). The dip in homology represented a potential transcription start
site. Riboprobes were designed flanking this region to determine whether it contained
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Fig. 6.2 Identification of an Fgf10transcription start site by RNase protection assay (RPA).
Panel A. Position of riboprobes on Fgf10 promoter region. Panel B. Riboprobes were prepared
from genomic clones of the mouse Fgf10 sequence.Mouse NIH-3T3, E13.5 lung and PO VP RNA
were hybridised with ^P-labelled antisense riboprobes, shown in panel A. The figure consists of
numerous RPAs exposed for different times and using different cyclophilin probes, which resulted
in background internal protected bands. A boxed area, on panel B, surrounds the region where
cyclophilin background bands occur. The marker lane is representative of the size of probes but
each gel run had its own marker lane. Probe 1, numerous protected bands. Probe 2, numerous
protected bands between 230nts and 270nts in length but no full length probe protection suggesting
no up stream start sites. Probe 3, no full length probe present but protected band observed at about
70nts corresponding to protected bands in probe 2. Probe 4, main protected band at 277nts and
probe 5 protected band at 204nts. Probe 6, full probe length protection shown. The riboprobes
have elucidated a major Fgf10 transcription start site 704nts 5' of the translation start site.
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RNase-protected bands were observed for each riboprobe. The size of RNase-protected
bands was used to calculate the putative transcription start site. To accurately measure
the protected bands in nucleotides the following equation was used:
logy = logc + klogx
where c = intercept and k = slope







As the majority of the protected bands fell between the size markers 200 to 300, this
region was used to calculate the slope (k). The 500 nucleotide marker was taken to
equal 0 and the 300 nucleotide (xi) and 200 nucleotide markers (x2) were measured in
mm from this point, yi and yi respectively.
k = (logy i - logy2) / (logxi - logx2)
When the value of k had been calculated, the intercept (c) was calculated using the
following equation:
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logc = klogxi - logyi
The size of the protected bands was then accurately measured by measuring the distance
(mm) from the 500 nucleotide marker and applying the equation:
logy = logc + klogx
where y = distance in mm of protected bands from the 500 nucleotide marker, c =
calculated intercept, k = calculated slope, and x = the size of the protected band to be
calculated.
The position of the putative transcription start site was calculated by tracing the number
of nucleotides of the protected bands from the 3' end of the probe on the FgflO
sequence. This was performed on each probe in each RNA sample, and the start site
was identified from bands from four independent probes.
Using probe 1, numerous protected bands were observed. Using probe2 numerous
protected bands between 230 nts and 270 nts in length were detected but there was no
full-length probe protection, suggesting that the start site lay within this region and that
no start sites were present upstream of the 5' end of the probe. Probe3 was designed
spanning probe 1 and probe2 to address if the bands observed in these regions were
putative start sites. Using probe3 a protected band of approximately 70 nts was observed
corresponding to a protected band within the numerous bands observed using probe2.
The observed protected band represented a putative transcription start site but it could
not be accurately mapped to a single nucleotide. To map the exact position of the
putative start site, probe4 and probe5 were designed. Probe4 gave a strong protected
band at 277 nts, and probe 5 yielded 204 nts band. The bands observed in probe4 and
probe5 mapped to the same nucleotide in the Fgfl0 sequence, strongly suggesting that
this was a transcription start site. In contrast, the 416 bp probe6 was fully protected
suggesting this probe lay within the transcribed region of the FgflO gene. The same
protection pattern for each probe was detected using NIH3T3 cell, mouse lung and
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mouse VP RNA, demonstrating that this transcription start site for FgflO is in the same
position in NIH3T3 cells, in el3.5 lungs and in PO VPs. The major FgflO transcription
start site (-1, +1; the strongest protected band) was calculated to be 704 nts 5' of the
translation start site and this is shown on Fig. 6.3. However this band did not account
for all the transcripts as the band intensity was not as strong as that observed in the fully
protected probe, suggesting that may be other transcription start sites.
6.2.2 Homologous Regions of the Mouse and Human FgflO
Genomic Sequences
The objective of identifying homologous regions between the mouse and human
genomic sequences was to identify sequences that regulate FgflO transcription.
Conserved segments were defined to be regions in which every contiguous subsegment
of the human sequence was at least 70% identical to the mouse sequence. The
comparable regions were named A to L on the two loci (Fig. 6.4). It was thought these
conserved sequences might represent sequences that regulate FgflO transcription. An
EST (mouse cDNA clone, soares mammary gland; GenBank Acc AI552268) was found
to be contained in region E so this region was thought unlikely to be involved in Fgfl 0
regulation. All the homologous regions in the 5' UTR, except region E (an EST), were
cloned into the pGL3 SV40.
6.2.3 Analysis of Conserved Regions by an Enhancer Assay
As regions of homology may contain sites that regulate Fgfl0 transcription the pGL3
SV40 constructs were co-transfected with a control vector that expressed B-galactosidase
into NIH3T3 cells, primary URSC and primary VMPC (Fig. 6.5) to identify any putative
enhancer or repressor regions. Also all the transfections were performed in media
containing CPSR-1 (controlled process serum replacement-type 1), as CPSR-1 is a
synthetic substitute for serum and does not contain cytokines or steroids that might
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-428
ctacagtgga aaacaagtga acaangggct ccctgtaggg aagggaatgg
ttcccgccgg aaggcacaaa attcggaaag cacgcggaca actcgcgctg
qtggccacgc tgcnaacaca ggacgccqga gccgcaatta ncangactgc
anqctgcqgg qcgctgcccc cacngaagcg gcgaagaaqg gaccgcagcc
cccaqctcan aacaaagqca tcqcqcactc ctctcgccca
Spl
aanatccccc
gccccctccc cqqtnccttc ccccnccctt ttctctqgcg ttcccagcaq
cttagqqttt canatgtccc accgccgttt gaccccttcc cccctttntc
cacccttgca aatgaggttt gaccagcaga ggcagagccc acttttggtt
gaaaagcact gacatttaga ntccaggCTT CAACCTGTTT ACAAGCGGCT
DPE
w +72
TTCCAAGGGA CTTGGAGGTG GAGAGAAGGG CCCAACAAAA CGCCAGCCGC
Fig. 6.3 Sequence of the mouse Fgf10 promoter region
DNA sequence of 500 nucleotides from nucleotide -428 to +72 of the Fgf10
promoter region. The putative Sp1 sites are marked in bold type. The Sp1 site
examined in more detail later in the chapter is marked with an arrow. The CpG
island is underlined from -391 to -117. The major transcriptional start site, identified
by RNase protection, is marked with a blue arrow, and the initiator element (Inr)
sequence is shown in red. The transcribed sequence is shown in capital letters and
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Fig 6.4 Comparison between mouse and human Fgf10 promoter and intron sequences,
Sequences were compared using VISTA analysis and represent a 70 % homology between
sequences (originally performed by Justin Grindley). The diagram represents only 15.2 Kb
of promoter and intronic FgflO genomic sequence including only exon 1 (blue box) of the FgflO gene.
The comparable regions are labelled A to L on the two loci and are represented by boxes; green
(top) and red (bottom) for mouse and human sequences, respectively. The blue line represents
regions that show less than 70 % homology. Region E is an EST (mouse cDNA clone, soares
mammary gland; GenBank Acc AI552268) located by a NCBI Blast search using an EST
database. All the homologous regions, except region E, were cloned into the pGL3 SV40 promoter











Fig. 6.5 Analysis of conserved regions using an enhancer assay.
Domains showing high DNA sequence conservation between the mouse and human FgflO
promoter region were cloned into SV40 pGL3 promoter vector. Constructs were co-transfected
with a Bgal expressing vector into NIH-3T3 (clear bars), URS (chequered bars) and primary
VMPC (solid bars). Results shown are luciferase values normalised for transfection efficiency
(by Bgal assay) and standardised to SV40 luciferase activity. A, five-fold increase in activity in
all three cell types. B, no change in activity. C, two fold increase in activity. D, no change in
activity. F, two-fold down-regulation of activity. G, no change in activity. A+F (region F
cloned 3' of A), no change in activity. Error bars represent SEM.
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affect promoter activity. Luciferase values were normalised for transfection efficiency
(by B-gal assay), and standardised to basal SV40 luciferase activity. Region A increased
the luciferase activity of the SV40 vector five-fold, and region C increased luciferase
activity two-fold, suggesting that these regions act as enhancer regions in the FgflO
promoter in all three cell types. Region F caused a two-fold decrease in luciferase
activity suggesting that it is a repressor region. Regions B, D and G had no effect on the
SV40 promoter vector. To determine if region F could repress activity caused by an
enhancer region isolated from the FgflO promoter, region F was cloned 3' of region A.
Region F inhibited the activity induced by region A, suggesting that region F could
repress FgflO gene transcription induced by an enhancer. To determine if the regions
identified by the SV40 enhancer assay affect the FgflO core promoter in the same
manner, a deletion analysis of the FgflO promoter was performed.
6.2.4 Deletion Analysis of the FgflO Promoter
6.6kb of mouse DNA 5' to the FgflO translation start site, presumed to contain the FgflO
promoter, was cloned into the pGL3 basic vector (Promega) so that the coding region for
FgflO was replaced by a luciferase reporter gene fused at the translation start site. The
plasmid pGL3 was found to have a high basal luciferase activity in our transfection
system, and therefore the FgflO promoter was cloned into pA3Luc. pA3Luc was
originally constructed to prevent cryptic plasmid transcription, that can increase
background activity (Wood et ah, 1989). For our studies it was necessary to modify
pA3Luc (pA3Lucm; section 2.2.6.2.1.) to aid the cloning of the FgflO promoter regions
(Section 2.2.6.2.). Constructs contained the regions of FgflO promoter sequence are
detailed in Fig. 6.6 and Table 2.4.
Promoter constructs were co-transfected with a 6-gal expressing vector into NIH-3T3
and primary VMPC. Luciferase values were normalised for transfection efficiency (by
6-gal assay) and standardised to the Full-length promoter luciferase activity (Fig. 6.6).
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Fig. 6.6 Deletion analysis of the FgflO promoter to identify regulatory elements.
Promoter constructs were cloned into pA3LUC, a luciferase expressing vector, and used in
transfection studies. Constructs contain the following regions of FgflO promoter sequence: Full,
5.8kb; AA, 5.2kb; AA-C, 3.1kb; AA-D, 2.4kb; AA-F, 307bps; and AA-G, 63bps. AA-G A5'UTR,
63bps of DNA 5' and 72bps of DNA 3' to the transcription start site. AF, AF-C, AF-B and AF-A
represent internal 5' DNA deletions from -63 of 2.1kb, 3.5kb, 4.7kb and 5.4kb, respectively.
Promoter constructs were co-transfected with a Bgal expressing vector into NIH-3T3 (clear bars)
and VMP cells (solid bars) and cultured in CPSR-containing media for 36hrs. Results represent
luciferase values normalised for transfection efficiency (by Bgal assay) and standardised to the
Full length promoter luciferase activity. NIH-3T3 cells, 5' to 3' and internal deletions showed no
significant change in activity between constructs. A two-fold down-regulation was observed in
AA-G A5'UTR. VMP cells, 5' to 3' deletions up to AA-F and internal deletions showed no
significant change in activity between constructs. AA-G and AA-G A5'UTR deletions resulted in
a two-fold down-regulation of activity. Error bars represent SEM.
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deletions up to AA-D, and gradually decreased in activity with deletions up to AA-G
A5'UTR. Internal deletions showed no significant change in activity between constructs
in NIH3T3 cells. In primary VMPC, 5' to 3' deletions up to AA-F, and internal
deletions showed no significant change in activity between constructs. AA-G and AA-G
A5'UTR deletions resulted in a two-fold down-regulation of activity. As the effects
observed in primary VMPC were probably more representative of the effect in the
prostate than in NIH3T3 cells, region G was further investigated.
6.2.5 Investigation of Region G
Region G was examined for transcription factor binding sites using GeneJockeyll and
for promoter regions using NIX analysis. NIX analysis is intended as a tool to aid the
identification of interesting regions in Genomic or transcribed nucleic acid sequences
and is found on the website http://www.hgmp.mrc.ac.ulc/Registered/Webapp/nix/.
GeneJockeyll identified a consensus Spl site in region G. Also the unusually high G+C
content of the 5' flanking region to the transcription start site suggested the presence of a
CpG island. To test if this region would qualify as a CpG island the sequence was run
through NIX analysis. A CpG island was predicted starting at -391 and finishing at
-117, containing 62 % G + C content (Fig. 6.3). This region included the 5' end of
region G and the Spl site. CpG islands allow for easy access of transcription factors
(Bird, 1986) increasing the possibility that the Spl site was relevant to the regulation of
FgflO gene expression. Additionally other reports have shown that consensus Spl
binding sites can mediate TGFbetal action (Botella et al., 2001; Brodin et ah, 2000;
Datta et ah, 2000; Li et ah, 1995). FgflO promoter constructs were made to investigate
both the effect of the Spl site on the activity of FgflO promoter constructs and to
determine whether the effect of TGFbetal on FgflO transcript levels is mediated via the
Spl site (Fig. 6.7). Constructs were made by PCR and cloning into pA3Lucm
(described in section 2.2.6.2. and Tables 2.3 and 2.4). Construct +Spl contained the Spl
site and the sequence 3' to the Spl site. Construct ASpl contained only sequence 3' to
the Spl site. Constructs were also made to determine whether deletion of the Spl site
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from within the FgflO sequence would result in any change in activity and if TGFbetal
would mediate its affect on FgflO transcription through this site. As the activity of AA-
D was similar to the activity of the full-length construct, it was decided to delete the Spl
site from AA-D. Construct AA-D ASpl was made by deleting the Spl site from AA-D.
These promoter constructs plus the full length, AA-D, and AA-G (core promoter) were
co-transfected into primary VMPC with a 6-gal expressing vector. Cells were cultured
for 36hrs and treated with and without TGFbetal for 8hrs (Fig. 6.8). TGFbetal
treatment resulted in approximately two-fold down-regulation of activity in the Full,
AA-D and -t-Spl promoter constructs. No down-regulation was observed in the AA-D
ASpl, ASpl and core promoter constructs, with TGFbetal treatment. Deletion of the
Spl site from AA-D resulted in a down-regulation of activity, similar to levels in the
























Fig. 6.7 Fgf10 promoter constructs designed to identify promoter regions which
mediate regulation by TGFbetal.
The constructs in the figure represent PCR products cloned, from the pGL3 Fgf10 promoter
construct, into pA3LUC. An Sp1 site is represented by a red box and red underlined italic
writing (flanking DNA sequences in black type). Full, 5.8kb of DNA 5' to the transcription
start site. AA-D, 2.4kb of DNA 5' to the transcription start site. AA-D ASp1, as AA-D but
with deleted Sp1 site. +Sp1, 214bp of DNA 5' of transcription start site. ASp1, 171 bp of



















0 0.2 0.4 0.6 0.8 1
Activity relative to untreated Full
Promoter
Fig. 6.8 Transfection of pA3LUC promoter constructs to define regions that mediate
regulation by TGFbetal.
Promoter constructs were co-transfected with a Rgal expressing vector into primary VMPC.
Cells were cultured for 36hrs in CPSR-containing media, and treated with (vertical lined
bars) and without (solid bars) TGFbetal (5ng/ml) for 8hrs. Results represent luciferase
values normalised for transfection efficiency (by Rgal assay) and standardised to the full
length promoter luciferase value. The average core promoter activity is represented as a
red dotted line running down the graph. TGFbetal treatment resulted approximately two¬
fold down-regulation of activity in the Full, AA-D and +Sp1 promoter constructs. No down-
regulation was observed in the AA-D ASp1, ASp1 and core promoter constructs when
treated with TGFbetal. Deletion of the Sp1 site from AA-D resulted in a down-regulation of
activity, similar to levels in the core promoter. Deletion of the Sp1 site from +Sp1 resulted in
a small decrease in activity, intermediate between full length and core promoter. Error bars
represent SEM.
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6.3 Summary of Results
Promoter analysis was performed to understand the mechanisms responsible for
regulating FgflO gene expression. A comparison of human and mouse genomic
sequences 5' to the FgflO exonl and sheep cDNA sequence revealed a sharp dip in
homology around 1300 nucleotides 5' of the translation start site. The FgflO
transcription start site was mapped by RNase protection assay. The presence of several
protected bands suggested there was more than one transcription start site for FgflO.
Amongst these bands, a single band was consistently stronger than others with every
probe used, this probably represented the major transcription start site for FgflO.
Analysis of the FgflO promoter revealed that it is a TATA-less promoter. Characteristic
features of TATA-less are the presence of an initiator element (Inr), upstream Spl sites
and downstream promoter elements (DPE). Consensus regions containing these sites
were identified in the FgflO promoter and are shown on Fig. 6.3.
A comparative analysis of mouse and human FgflO genomic sequences revealed that
many regions were highly conserved between human and mouse FgflO promoter
sequences. This suggests that these regions may contain sites that control FgflO gene
expression. To examine if these regions regulated FgflO gene expression two
approaches were adopted; enhancer assays and promoter deletions. Region A (-5492, -
5222) was shown to enhance the activity of an SV40 promoter vector and region F (-
1265, -667) was shown to repress the activity. Region F also inhibited the increase in
activity caused by region A, suggesting that region F could repress FgflO transcription
caused by an enhancer. To determine if the regions identified by the promoter assay
regulated the FgflO core promoter, deletion constructs of the FgflO promoter were
constructed in a luciferase-expressing vector. Deletion of region A or region F did not
significantly change the activity of the FgflO core promoter, suggesting that both regions
did not play a significant part in the regulation of FgflO gene expression. However,
deletion of region G resulted in a two-fold down-regulation of Fgfl 0 activity in primary
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VMPC, although region G had no enhancer activity in SV40 assay. The difference in
results may be an artefact of the cellular in vitro system. However, as the enhancer
assay uses a core promoter that is different to that of Fgfl 0, probably the most accurate
interpretation of these results would be gained from using the Fgfl 0 core promoter and
further investigation of region G. Region G incorporated some of the putative CpG
island, highly suggestive that this region does contain a transcription factor-binding site
that regulates FgflO gene expression. A putative Spl binding site was identified using a
transcription factor binding site search by the computer program GeneJockeyll. Spl
binding sites have been shown to mediate the effect of TGFbetal in some circumstances
(Botella et al., 2001; Li et al., 1995). Hence the repression of FgflO gene expression by
TGFbetal, described in earlier chapters, might be mediated through the Spl site. To
test this theory the Spl site was deleted from promoter constructs and the effect of
TGFbetal on promoter construct activity was tested. Deletion of the Spl site repressed
the activity of the Fgfl0 promoter to levels similar to the activity observed the in Fgfl0
core promoter. Also TGFbetal repressed the activity of the promoter in constructs
containing Spl sites but had no effect on promoter constructs that had the Spl site
removed. The activity of FgflO promoters treated with TGFbetal was similar to the
activity in the FgflO core promoter. These results suggested that the Spl site promotes
FgflO gene expression and TGFbetal represses FgflO gene expression through the Spl
site.
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7 Regulation of VP Growth by TGFbetal
7.1 Introduction
TGFbeta isoforms have been shown to play a role in prostatic regression after androgen
deprivation (Kyprianou and Isaacs, 1988; Kyprianou and Isaacs, 1989; Martikainen et
al., 1990), and TGFbetal has been postulated as being an important factor in stromal-
epithelial interactions during prostate and seminal vesicle development (Itoh et al.,
1998a; Tanji et al., 1994). All three TGFbeta peptides have been localised to prostatic
epithelium and stroma by immunostaining (Perry et al., 1997; Timme et al., 1994) and
their transcripts have been detected in cultured prostate stromal and epithelial cells (Itoh
et al., 1998a; Story et al., 1996). TGFbetal inhibits proliferation of many normal and
transformed cell types (Massague et al., 1992b), including prostatic epithelial cells
(McKeehan and Adams, 1988), but it has been shown to increase proliferation in some
human cancer cell types (Hsu et al., 1994; Kansra et al., 2000; Lamm et al., 1998,
Schroy et al., 1990).
Organ culture of P0 rat VPs was used to address the possible physiological function of
TGFbetal on prostate development. Experiments were designed to determine if
TGFbetal affected the size, prostatic bud number, and proliferation rate of epithelial and
stromal cells in the VP. Also the effect of culturing organ rudiments with testosterone
and TGFbetal on Tgfbetal, Tgfbetal and Tgfbeta3 gene expression was investigated.
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7.2 Results
7.2.1 The Effect of TGFbetal on VP Size
PO VPs were cultured in the presence and absence of TGFbetal and testosterone (Fig.
7.1) to address the potential physiological function of TGFbetal. Whole mount live
images of VPs were captured at the end of culture (Fig. 7.1 A). The images were
imported into NIH Image 1.62f, and the two-dimensional area of VPs was measured and
represented as pixels x 1000. The sizes of the organs were as follows; -T, 95 pixels; -
T+TGFbetal, 75 pixels; +T, 151 pixels; +T+TGFbetal, 103 pixels. TGFbetal inhibited
86 % of testosterone-induced growth. TGFbetal reduced the size of organs grown -T
by 21 % and reduced the size of organs grown +T by 32 %. The two-dimensional area
of VPs cultured with TGFbetal was significantly lower both in the presence and absence
of testosterone after six days (-T+TGFbetal 21% reduction compared to -T, Student's t
test P=4.79e"4; +T+TGFbetal 32% reduction compared to +T, Student's t test P=4.03e~
9)(Fig. 7.IB). This suggests that TGFbetal inhibits prostatic growth and development.
This also suggests that testosterone does not inhibit the effects of TGFbetal on VP
growth although ligand bound AR has been previously shown to inhibit TGFbeta
mediated transcriptional responses (Chipuk et al., 2002).
7.2.2 The Effect of TGFbetal on Epithelial Bud Number
Another way in which the physiological function of TGFbetal was addressed was by
counting the number of epithelial buds (Fig. 7.2). Previous research on the effect of
TGFbetal on branching morphogenesis of VPs counted the number of bud per mm3 over
the whole organ (Itoh et al., 1998a), but this was almost impossible in our system as
individual buds within the VP images were hard to distinguish. It was decided that an
easier way to tell if TGFbetal affected bud number would be to count the number of








Fig. 7.1 The effect of TGFbetal on VP size.
PO rat VPs were cutured for six days in the presence or absence of testosterone (10 M)
and/or TGFbetal (10ng/ml) (scale bar = 1mm). Organs were imaged under lightfield
illumination at the end of culture prior to fixation or freezing for RNA. The data represents
30 organs from each treatment group from 4 independent experiments. Panel A.
Representative pictures of cultured VPs. Panel B. The two dimensional area of VPs
was measured using NIH-image analysis; area represented as pixels was calculated and
plotted on a graph. Addition of TGFbetal to VPs cultured in the presence and absence
of testosterone resulted in a significant reduction in area (-T+TGF 20% reduction compared
































Fig. 7.2 The effect of TGFbetal on epithelial bud number.
VPs from P0 rats were grown for six days in the presence or absence of testosterone (10"8M)
and/or TGFbetal (10ng/ml). 30 organs from 4 independent experiments were measured using
NIH-image. Panel A. Representative pictures of cultured VPs (scale bar = 1mm). The VPs
were magnified to demonstrate bud number. Panel B. The number of epithelial bud tips around
the periphery of organs (shown with arrows, panel A) from each treatment were counted and
shown as bud number per 1000 pixels of perimeter. The addition of TGFbetal to organs
cultured in the absence or presence of testosterone caused significant increases in the number
of epithelial bud tips (-T compared to -T+TGF, Student's t test P=7.89e"6; +T compared to




as a ratio to organ perimeter (bud number/1000 pixels of perimeter (using NIH Image))
so that organs of different sizes could be compared (Fig. 7.2B). The number of buds per
1000 pixels of perimeter were; -T, 36.6; -T+TGFbetal, 46.6, +T, 51.7; +T+TGFbetal,
56. TGFbetal significantly increased the number of buds/1000 pixels of perimeter in
VPs cultured with and without testosterone (-T compared to -T+TGFbetal, Student's t
test P=7.89e"6; +T compared to +T+TGFbetal, Student's t test P=8.30e~4). Again this
suggests that testosterone does not inhibit the effects of TGFbetal on VP growth and
budding.
So, although the two dimensional area of VPs growth with TGFbetal is decreased, the
number of buds in the periphery of the organs is increased, suggesting that TGFbetal
may have differential effects on the proliferation rate of cells within the organ. To
determine if this was occurring the effect of TGFbetal on the proliferation rate of cells
in VPs was investigated.
7.2.3 The Effect of TGFbetal on VP Cell Proliferation
TGFbeta has been demonstrated to have differing effects on the proliferation rate of cells
from different lineages (Massague et al., 1992b). The aim of this part of the thesis was
to determine the effect of TGFbetal on VP cell proliferation, and to determine whether
any changes in cell proliferation correlated with the changes in organ size when treated
with TGFbetal. The effect of TGFbetal on proliferation of epithelial and stromal cells
was examined in P0 VP organ cultures. VPs were cultured for either three days or six
days to examine the effect of TGFbetal at different stages of the culture system. BrdU
was added on the final day of culture, and was detected by immunohistochemistry and
visualised by both fluorescent illumination and con-focal microscopy. Proliferation rate
was measured by counting the number of cells that had incorporated BrdU and
represented as a percentage to total cell number (Table 7.1).
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Table 7.1 showing the percentage BrdU incorporation in proximal and distal cells to urethra after culture
with and without T or TGFbetal for 3 or 6 days









Proximal Distal Proximal Distal Proximal Distal Proximal Distal
-T 20.8+/-1.4 33.8+/-2.5 16.3+/-0.8 22.8+/-1.4 10.4+/-0.9 13+/-1.1 7.8+/-0.6 9.6+/-1.4
-T
+TGFbetal
13.2*+/-0.9 40.9+/-2.0 10.T+/-0.9 21+/-1.3 7.3*+/-0.6 24.6*+/-0.7 3.9*+/-0.5 13.4*+/-0.7
+T 25.6+/-0.9 45.1+/-2.6 15.4+/-1.0 22.3+/-1.0 7.3+/-0.8 26.4+/-1.4 5.9+/-1.0 12.5+/-1.1
+T
+TGFbetal
17.8V/-1.0 47.1+/-1.3 9.3Vi.i 24.7+/-0.7 2.4*+/-0.5 26.3+/-1.1 I.8V0.6 10.8+/-1.0
*
represents significant difference compared to relevant treatment without TGFbetal
7.2.3.1 Three-Day Culture
Lower incorporation of BrdU was observed in the area proximal to urethra in VPs
cultured with TGFbetal and testosterone for three days (Fig. 7.3, Table 7.1). In the
distal region to urethra (Fig. 7.4A), TGFbetal did not significantly change epithelial or
stromal proliferation in the absence or presence of testosterone after three days (Fig.
7.4B) although a small increase in the proliferation of epithelial cells was apparent.
However, in the proximal region TGFbetal significantly reduced epithelial and stromal
proliferation in the VP both in the presence and absence of testosterone (Fig. 7.4C,D)
(epithelium: -T compared to -T+TGFbetal, Student's t test P=5.70e"6; +T compared to
+T+TGFbetal, Student's t test P=1.45e~7) (stroma: -T compared to -T+TGFbetal,
Student's t test P=1.19e"7; +T compared to +T+TGFbetal, Student's t test P=2.11e"5).
This suggested that during the first three days of culture TGFbetal decreased the
proliferation rate of proximal stromal and epithelial cells, but did not significantly affect
the proliferation rate of distal epithelia and stroma. Hence, the VPs two-dimensional
area would be smaller after six-days as observed in a previous result (Fig. 7.1). Next we
assessed whether the proliferation rate of cells in the proximal and distal regions (to
urethra) changed in VPs cultured for six days.
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Fig. 7.3 The effect of TGFbetal on cell proliferation in VPs on day 3 of culture.
VPs were cultured for three days in the presence or absence of testosterone
(10'8M) and/or TGFbetal (10ng/ml). BrdU was added on day three of culture.
Incorporation of BrdU was detected by immunohistochemistry (green) and the
nuclei were counterstained with propidium iodide (red). Immunohistochemistry
was detected under fluorescent illumination at X10 magnification (scale bar =
500pm). This was performed on 8 organs from 3 independent experiments.
VPs cultured with TGFbetal in the presence of testosterone resulted in lower
BrdU incorporation in the area proximal to urethra. No change in BrdU
incorporation was obvious at this magnification in VPs cultured with TGFbetal
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Fig. 7.4 The effect of TGFbetal on proliferation of epithelial and stromal cells in
distal and proximal regions of VPs cultured for 3days
VPs were cultured in the presence and absence of testosterone (10s M) and/or TGFbetal
(10 ng/ml). Proliferation rate was measured by calculating the percentage of cells that
incorporate BrdU, added on day three of culture. Incorporation of BrdU in distal (A) and
proximal (C) regions to urethra were detected by immunohistochemistry (green, yellow
when co-localised to nuclei) and epithelial cells were distinguished by immunohistochemistry
for pan-Cytokeratin (blue). Nuclei were counterstained with propidium iodide (red) (scale bar
= 100 pm). Panel B. Data from the distal region to urethra representing 15 measurements on
8 organs from each treatment group from three independent experiments. TGFbetal did not
significantly change epithelial or stromal proliferation in the absence or presence of
testosterone in the distal region (-T compared to -T+TGF and +T compared to +T+TGF,
Student's t-test P>0.005). Panel D. Data from the proximal region to urethra representing
18 measurements on 9 organs from each treatment group from three independent experiments.
TGFbetal significantly reduced epithelial (-T compared to -T+TGF, Student's t-test P=3.15e3;
+T compared to +T+TGF, Student's t-test P=2.83e 6) and stromal (-T compared to -T+TGF,
Student's t-test P=1,38e5; +T compared to +T+TGF, Student's t-test P=4.63e 4) proliferation




VPs cultured with TGFbetal in the presence and absence of testosterone resulted in a
lower BrdU incorporation in epithelial and stromal cells in the area proximal to urethra
(Fig. 7.5 and Table 7.1). In the distal region TGFbetal significantly increased epithelial
and stromal proliferation in the absence of testosterone (Fig. 7.6A,B) (epithelium: -T
compared to -T+TGFbetal, Student's t test P=l.lle"7) (stroma: -T compared to
^o. :t w
-T+TGFbetal, Student's t test P=2.49e"5). TGFbetal had no significant effect on
A1 "'V^
, epithelial or stromal proliferation in the presence of testosterone (Fig.7.6A,B). This may
be due to testosterone already stimulating cell growth maximally; therefore TGFbetal
may not be able to induce any further increase in proliferation. In the proximal region
TGFbetal significantly reduced epithelial and stromal proliferation both in the presence
and absence of testosterone (Fig. 7.6C,D) (epithelium: -T compared to -T+TGFbetal,
Student's t test P=3.15e"3; +T compared to +T+TGFbetal, Student's t test P=2.83e"6)
(stoma: -T compared to -T+TGFbetal, Student's t test P=1.38e"5; +T compared to
+T+TGFbetal, Student's t test P=4.63e"4). Testosterone also reduced the level of BrdU
incorporation in the proximal region compared to untreated organs, and the addition of
testosterone and TGFbetal caused a greater repression of proliferation.
Hence the effects of TGFbetal on proliferation were not inhibited by testosterone
suggesting the changes in VP growth may be due to changes in the proliferation rate of
cells, and that TGFbetal had differential effects on cell proliferation in different regions
of the VP.
7.2.4 Analysis of Tgfbeta Transcript Levels
Next it was decided to investigate Tgfbeta gene regulation in neonatal prostatic
rudiments, as numerous studies have examined the regulation of Tgfbeta transcript levels
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Fig. 7.5 The effect of TGFbetal on cell proliferation in VPs on day 6 of culture
VPs were cultured for six days in the presence or absence of testosterone (10"8M)
and/or TGFbetal (10ng/ml). BrdU was added on day six of culture. Incorporation
of BrdU was detected by immunohistochemistry (green) and the nuclei were
counterstained with propidium iodide (red). Immunohistochemistry was detected under
fluorescent microscopy (scale bar = 500/vm). This was performed on 9 organs from 3
indepedent experiments. VPs cultured with TGFbetal in the presence or absence of
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Fig. 7.6 The effect of TGFbetal on proliferation of epithelial and stromal cells in VPs cultured
for 6days.
VPs were cultured in the presence or absence of testosterone (10"8M) and/or TGFbetal (10ng/ml).
Proliferation rate was measured by calculating the percentage of cells that incorporated BrdU
added on day 6 of culture. Incorporation of BrdU in the distal (A) and proximal (C) regions were
detected by immunohistochemistry (green, yellow when co-localised with nuclei) and epithelial cells
were distinguished by immunohistochemistry for pan-Cytokeratin (blue). Nuclei were counterstained
with propidium iodide (red) (scale bar = 10Cy/m). The data represents 18 measurements on 9 organs
from each treatment group from 3 independent experiments. Panel B Distal region to urethra.
TGFbetal significantly increased epithelial (-T compared to -T+TGF, Student's t-test P=1.11e~7)
and stromal (-T compared to -T+TGF, Student's t-test P=2.49e"5) proliferation in the absence of
testosterone. TGFbetal had no significant effect on epithelial or stromal proliferation in the
presence of testosterone. Panel D. Proximal region to urethra TGFbetal significantly reduced
epithelial (-T compared to -T+TGF, Student's t-test P=3.15e"3; +T compared to +T+TGF, Student's
t-test P=2.83e~6) and stromal (-T compared to -T+TGF, Student's t-test P=1,38e"5; +T compared to
+T+TGF, Student's t-test P= 4.63e"4) proliferation both in the presence and absence of testosterone.
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expression of TGFbeta ligands (Bacher et al., 1993; Itoh et al., 1998a; Kyprianou and
Isaacs, 1989). TGFbetal has been shown to positively regulate its own expression in
normal and transformed cells (Van Obberghen-Schilling et al., 1988) however, auto-
regulation was not observed in primary prostatic stromal and epithelial cells (Itoh et al.,
1998a). The effect of testosterone and TGFbetal was examined in VPs (Fig. 7.7) and
VMP+UR (Fig 7.8) in organ culture. The long and short-term effects of TGFbetal on
Tgfbeta transcript levels were examined. PO VPs were cultured either for six days in the
presence or absence of testosterone and/or TGFbetal (Fig. 7.7A), or for three days in the
presence or absence of testosterone, then for seven hours with or without TGFbetal (Fig.
7.7B). VMP+UR were cultured either for three days in the absence or presence of
testosterone and/or TGFbetal (Fig. 7.8A) or for three days in serum-free conditions then
treated for seven hours in the presence and absence of testosterone and/or TGFbetal
(Fig. 7.8B). VMP+UR were cultured only for three days because a six-day culture
causes them to appear necrotic, so it was hard to compare the regulation of Tgfbeta
transcript levels in male and female organ rudiments.
7.2.4.1 Analysis of Tgfbeta Transcript Levels in VPs
No change in Tgfbeia transcript levels was observed in VPs cultured for six days in the
presence or absence of testosterone and/or TGFbetal (Fig. 7.7A and table 7.2). Tgfbeta2
transcript levels were lower in VPs cultured with testosterone for three days both in the
presence and absence of TGFbetal for seven hours (Fig. 7.7B). Tgfbetal and Tgfbeta3
transcript levels were higher in VPs cultured with TGFbetal for seven hours, in the
absence of testosterone, but not in the presence of testosterone. This suggests that
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Fig. 7.7 Analysis of Tgfbetat, TgfbetaGL, and TgfbetaQ transcript levels in VPs.
P0 VPs were cultured in the presence and absence of TGFbetal (10ng/ml)
and/or testosterone (108M) for six days (panel A). Also, VPs were cultured for
three days in the presence and absence of testosterone (108M) then treated for
seven hours in the presence or absence of testosterone and/or TGFbetal (10ng/ml)
(Panel B). VP Tgfbeta transcripts were assayed by RNase protection, quantified
using a phosphoimager and normalised to cyclophilin (CYCL). The numbers below
panel A and B represent the average transcript abundance of Tgfbeta isoforms relative
to levels in VPs cultured in the absence of testosterone and TGFbetal (n=2). No
changes in Tgfbeta transcript levels were observed in VPs cultured for 6 days. A 3 day
testosterone treatment caused a small decrease in Tgfbeta2 transcript levels in the
presence and absence of TGFbetal. A 7hr TGFbetal treatmentin the absence of
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Fig. 7.8 Analysis of Tgfbeta], Tgfbeta2, and TgfbetaQ transcript levels in PO female
VMP+UR
PO female VMP+UR were cultured in the presence and absence of TGFbetal
(10ng/ml) and/or testosterone (108M) for three days (panel A). Also, PO female VMP+
UR were cultured for three days in serum free conditions then cultured for seven hours
in the presence or absence of testosterone and/or TGFbetal (10ng/ml) (Panel B).
VMP+UR Tgfbeta transcripts were assayed by RNase protection, quantified using a
phosphoimager and normalised to cyclophilin (CYCL). The numbers below panel A
and B represent the average transcript abundance of Tgfbeta isoforms relative to levels
in VMP+UR cultured in the absence of testosterone and TGFbetal (n=2). Tgfbeta] and
Tgfbeta3 transcript levels decreased by 2- and 3-fold, respectively, when cultured in the
presence of testosterone for 3 days. Tgfbeta2 transcript levels increased by 1.8-fold
when cultured in the presence of testosterone and TGFbetal for 3 days, and increased
by 1.6-fold when cultured in the presence of TGFbetal for 7 hrs.
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7.2.4.2 Analysis of Tgfbeta Transcript Levels in VMP+UR
Tgfbetal and Tgfbeta3 transcript levels were decreased by 2- and 3-fold, respectively, in
VMP+UR cultured in the presence of testosterone for 3 days (Fig. 7.8A and table 7.3).
However no change in these transcript levels was observed when cultured in the
presence of testosterone and TGFbetal, which suggested that TGFbetal inhibited
testosterone action. Over three-days' culture, Tgfbetal transcript levels were increased
in the presence of testosterone and TGFbetal by 1.9-fold. No other changes in Tgfbeta
transcript levels were observed. A seven-hour testosterone treatment of VMP+UR
resulted in a 1.6-fold increase in Tgfbetal transcript levels (Fig. 7.8B). No change in
Tgfbetal and Tgfbetal transcript levels was observed over this treatment period.
Table 7.2 Summary of changes in levels of Tgfbeta transcripts in VPs
Tgfbeta
mRNA
Testosterone TGFbetal Testosterone + TGFbetal




1 118 83 189 103 101 94
2 64 81 112 102 63 96
3 96 88 168 89 97 100
Table 7.3 Summary of changes in levels of Tgfbeta transcripts in VMPs
Tgfbeta
mRNA
Testosterone TGFbetal Testosterone + TGFbetal




1 116 51 112 91 109 116
2 159 91 115 100 131 188
3 101 35 99 88 79 104
* 3 day treatment with testosterone followed by a 7 hr treatment with testosterone and TGFbetal
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7.3 Summary of Results
Experiments were performed to address the function of TGFbetal in prostate
development, and to determine if testosterone and/or TGFbetal regulated the expression
of Tgfbeta transcripts in prostatic rudiments. To address the effect of TGFbetal in
prostatic development, VPs were cultured in the presence and absence of TGFbetal
and/or testosterone for six days. To determine if the changes in VP architecture were
due to testosterone and/or TGFbeta regulating Tgfbeta transcript levels, VP and
VMP+UR were cultured for varying periods of time in the presence and absence of
testosterone and/or TGFbetal. The levels of Tgfbeta transcripts were quantified by
RNase protection assay.
TGFbetal significantly decreased the two-dimensional area of VPs, both in the presence
and absence of testosterone. This suggests that TGFbetal inhibits prostatic growth and
the effect of TGFbetal is not inhibited by testosterone. However, surprisingly
TGFbetal increased the bud number, and increased the proliferation rate of distal (to
urethra) epithelia and stroma, in the absence of testosterone, while it inhibited epithelial
and stromal proliferation in proximal regions. As epithelial cells are more differentiated
in the proximal regions, compared to the distal regions, it could be suggested that
TGFbetal inhibits proliferation of more differentiated cell types while promoting the
proliferation of less differentiated cell types. Also testosterone promotes prostatic cell
differentiation in the proximal epithelial cells and the addition of testosterone and
TGFbetal caused a greater inhibition of proliferation in proximal epithelial cells (67 %)
than of those only cultured with TGFbetal (30 %). Again this suggests that TGFbetal
inhibits proliferation of differentiated cells types.
As numerous studies have demonstrated that testosterone and TGFbetal can regulate
Tgfbeta transcript expression the regulation of Tgfbeta transcripts by testosterone and
TGFbetal was investigated. It was demonstrated that the regulation of Tgfbeta
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transcript levels observed in these studies were similar in the VP or the VMP. These
results will be discussed now in reference to previously published data.
An effect of TGFbetal is its' ability to stimulate Tgfbeta gene expression (Flanders et
al., 1995; Van Obberghen-Schilling et al., 1988). In VPs, the regulation of Tgfbeta
transcripts by TGFbetal was observed over a seven-hour culture but not over six days
(Table 7.2). This suggests that the effect of TGFbetal on Tgfbeta transcript levels is
only short term. No regulation of Tgfbeta transcript levels by TGFbetal was observed in
the VMP, indicating epithelial-mesenchymal interactions might be required for the
changes in Tgfbeta transcript levels observed in the VP.
Another observation is the difference in regulation of Tgfbeta gene expression by
testosterone observed between the developing prostate in this study and the adult
prostate previously studied (Bacher et al., 1993; Itoh et al., 1998a; Kyprianou and Isaacs,
1989). In the adult prostate Tgfbeta transcript levels increased after castration and the
increase in Tgfbeta transcript levels could be repressed by androgens. The rapid changes
in Tgfbeta transcript levels suggested that testosterone may have regulated Tgfbeta
transcription and did not just cause a change in the ratio of number of cells expressing
Tgfbeta transcripts. In addition, Ttoh et al. (1998) demonstrated that Tgfbeta transcript
levels were not regulated in isolated stromal or epithelial cells by testosterone,
suggesting that the regulation of Tgfbeta transcript levels by testosterone requires
stromal-epithelial interactions. In our experiments testosterone did not repress Tgfbeta
transcript levels in the VP suggesting that Tgfbeta transcript levels are regulated using
different mechanisms in developing compared to adult VPs. Also this suggests that
mesenchymal-epithelial interactions observed in the developing prostate are different to
stromal-epithelial interactions in the adult prostate. However, interestingly, Tgfbeta 1
and Tgfbeta3 transcript levels were repressed in the VMP, which was similar to changes
observed in the adult VP, suggesting that certain developmental mechanisms of
regulation are maintained in adulthood.
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Previous data has shown that complex interactions between testosterone and TGFbeta
signaling may exist (Chipuk et al., 2002; Hayes et al., 2001; Kang et al., 2001), and
these interactions will be discussed in context to data observed in this thesis. TGFbetal
downstream signaling factor, Smad3, has been demonstrated to bind to AR and inhibit
AR-mediated transcription (Hayes et al., 2001). The inhibition of AR-mediated
transcriptional changes was demonstrated in our system as TGFbetal inhibited the effect
of testosterone in the VMP. Also Smad3 has been shown to function as a co-regulator to
enhance AR-mediated transactivation (Kang et al., 2001). Again this may be relevant to
the VMP as Tgfbeta2 transcripts levels increased only in the presence of testosterone and
TGFbetal. AR has also been shown to repress TGFbeta signaling (Chipuk et al., 2002)
and this effect may be apparent in the VP in regard to some genes.
It has previously been demonstrated that Tgfbeta 1 and Tgjbetai (but not Tgfbeta2) were
regulated by the Spl transcription factor, indicating differential transcriptional
regulation of the Tgfbeta genes (Geiser et al., 1993). Differential regulation of Tgfbeta
genes was observed in both cultured VMPs and VPs. As the Spl transcription factor has
already been shown to regulate Tgfbetai and Tgfbetai this suggests that Spl may be
involved in the regulation of the Tgfbeta genes in the VMP and VP. Hence it could be
suggested that the transcription factor Spl may be involved in regulating Tgfbeta
transcript levels in prostate development. In fact the regulation of FgflO transcript
levels by TGFbetal was shown to involve the Spl transcription factor binding site in the
FgflO promoter and Spl has been shown to be involved in TGFbeta signaling pathways
(Brodin et al., 2000; Feng et al., 2000b; Li et al., 1998). This suggests that complex
pathways may be regulating the growth and development of the VP that involved the
Spl transcription factor.
The difference in Tgfbeta transcript regulation between male and female prostatic
rudiments becomes more apparent when comparing the regulation of Tgfbeta transcript
levels in the VP to the VMP+UR using Table 7.2 and 7.3. The major difference between
the VMP and VP is the budding and branching of epithelial and differentiation of stroma
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in the VP. This suggests that epithelial/stromal interactions are regulating or are
required for TGFbetal and testosterone regulation of Tgfbeta transcript levels. These
observations also suggest that the in vivo effects of androgens and TGFbetal on Tgfbeta
gene expression are regulated indirectly through a complex networks of growth factor
signaling pathways between stroma and epithelial cells, and that differences occur in
gene regulatory pathways between male and female and developmental and adult
prostatic rudiments.
In conclusion it has been shown that TGFbetal regulates VP growth and branching
morphogenesis and that an increase in epithelial bud number is not a result of increased
proliferation of epithelial cells. It has also been demonstrated that TGFbetal has
differing effects on stromal and epithelial cell proliferation in the proximal compared to
distal regions to urethra in the VP. TGFbetal and testosterone regulated Tgfbetal and
TgfbetaS transcript levels differently than Tgfbetal transcript levels, indicating
differential regulation of Tgfbeta isoforms. As a previous report has shown that
testosterone and TGFbetal do not regulate Tgfbeta transcript levels in isolated prostate
stromal and epithelial cells (Itoh et al., 1998a) it can be suggested that the regulation of
transcripts in prostatic rudiments requires or is due to mesenchymal-epithelial
interactions. Hence the regulation of Tgfbeta transcript levels in prostatic rudiments may
involve complex networks of epithelial-mesenchymal interactions. Also it was
demonstrated that testosterone repressed TGFbetal transcriptional changes in the VP,
and TGFbetal inhibited testosterone transcriptional responses in the VMP. However
testosterone did not inhibit the changes induced by TGFbetal in the growth of the VP
suggesting that the regulation of Tgfbeta transcripts by testosterone and TGFbetal are
not the main causative agents observed in changes in VP phenotype.
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8 Discussion
The aim of this thesis was to investigate the regulation of FgflO gene expression in
prostatic development. A primary stromal cell system from the VMP (primary VMPC)
was established and characterised and proposed a suitable in vitro model for these
studies. Hence, the regulation of FgflO transcript levels by TGFbetal and testosterone
was initially investigated in primary VMPC. As TGFbetal repressed FgflO transcript
levels in primary VMPC, these studies were extended into organ cultures of VMP and
UR, and VP. Primary VMPC were also used to analyse the FgflO promoter to identify
regions that regulated FgflO gene expression and any regions of the promoter that
mediated TGFbetal action. Owing to the regulation of FgflO transcript levels by
TGFbetal and the effect of TGFbetal on VP growth (Itoh et al., 1998a), FGF10 and
TGFbetal appear to play opposing roles in prostate development. The function of
TGFbetal in prostate development, and the regulation of Tgfbeta transcript levels by
testosterone and TGFbetal were addressed in organ cultures of VP and VMP. The
regulation of FgflO and Tgfbeta gene expression by TGFbetal and testosterone proved
complex, possibly involving interactions between epithelial and stromal cells.
8.1 Primary VMPC
Prostate organogenesis involves numerous interactions between epithelial and
mesenchymal cells (Chung et al., 1991; Cunha et al., 1983; Tenniswood, 1986). These
interactions induce ductal budding and branching morphogenesis of the prostate.
Investigation of these poorly understood developmental processes is important, as
inappropriate ductal branching occurs in prostatic disease (McNeal, 1988). Prostatic cell
lines have been used to investigate the regulation of factors thought to be involved in
prostate development and disease (Gerdes et al., 1998; Itoh et al., 1998a; Karan et al.,
2002; Wilding et al., 1989). However the majority of research has focused on cell lines
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derived from the epithelium, as most tumours arise in glandular epithelial cells (Gmyrek
et al., 2001; Peehl and Stamey, 1986; Tang et al., 1999). However the inductive
component of prostate budding and development is the mesenchyme/stromal tissue
(Cunha and Lung, 1978; Lasnitzki and Mizuno, 1980; Shannon and Cunha, 1983;
Takeda and Mizuno, 1984; Takeda et al., 1985). As a result, recent research has focused
on prostate stromal cells as an important component in regulation of epithelial
mitogenesis and differentiation in prostate cancer (Hall et al., 2002; Tuxhorn et al.,
2002a; Tuxhorn et al., 2002b). One factor expressed in neonatal stromal tissue and
known to regulate prostate growth and epithelial proliferation is FGF10 (Thomson and
Cunha, 1999). FGF10 is therefore an important factor involved in prostate development
and it may also be involved in prostate cancer. The aim of this thesis was to examine
regulation of FgflO gene expression during prostate development. Hence for these
studies, a stromal cell type that expressed FgflO and that was derived from the inductive
tissue was required. Stromal cells in the VP have been shown to express FgflO
transcripts (Thomson and Cunha, 1999) and therefore the VP is an obvious candidate for
disassociation into primary stromal cells. However, the rat male urogenital structures
cannot be visibly subdivided into a bladder and a definite urogenital sinus until el7
(Hayward et al., 1996a). It would be desirable not to include non-inductive tissue in the
dissection, and accurate dissection of the VP without including non-VP urogenital sinus
is difficult until distinct VP structures are visible in the rat at el9. However by el9
solid cords of epithelium have been seen growing from the UGE (Hayward et al.,
1996a). The removal of the epithelial buds from VPs to obtain a cell suspension of only
stromal cells would be difficult owing the size of the organ. Also, epithelial budding is
associated with stromal cell differentiation in the VP (Hayward et al., 1996b) and in this
thesis it was demonstrated that the presence of epithelium may effect the regulation of
FgflO. Thus VP tissue was deemed unsuitable, as a cell type was required that had not
been subjected to differentiation in response to epithelium.
The VP develops from UGE budding into a discrete pad of mesenchyme, called the
VMP. A female VMP has been identified, and prostatic budding can be induced in the
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female VMP in the presence of testosterone (Lasnitzki and Mizuno, 1977; Takeda et al.,
1986; Timms et al., 1995). FgflO transcripts have been localised to both the male and
the female VMP by in situ hybridisation (Thomson and Cunha, 1999) and RNase
protection (Fig. 3.11). Therefore, the VMP is made up of a cell type that expresses
FgflO, has not differentiated in response to epithelium and is capable of inducing
prostate-like budding. Primary cultures of VMPC were tested to see if these cells were a
good model for studying endogenous FgflO gene regulation.
In order to validate the use of primary VMPC in studies of FgflO gene regulation and to
compare FgflO promoter construct activity in FgflO expressing cells to non-FgflO
expressing cells, primary VMPC were compared to primary cells derived from non-
FgflO expressing tissue that cannot induce prostate development. It is known that non-
VMP URS (dissected from the caudal region of the urethra) is not capable of inducing
prostate organogenesis (Timms et al., 1995), and does not express FgflO (Thomson and
Cunha, 1999). Therefore primary VMPC were compared to primary URSC.
The PO female VMP is relatively small and in close contact with UR, and a smooth
muscle layer separates the VMP from the UR (Thomson et al., 2002). The VMP is SM-
negative in vivo but the micro-dissected VMP included some of the smooth muscle layer
from the UR (shown by western blotting in figure 3.9). Analysis of primary VMPC
revealed that all cells expressed SM a actin, a smooth muscle marker. This suggested
either that only the cells that expressed SM a actin plated out or that non-SM a actin
expressing cells expressed SM a actin upon explant. The dissected VMP would have
consisted of a heterogeneous population of mesenchymal and SM a actin cells. It was
more likely that mesenchymal cells began to express SM a actin on disassociation and
plating out, as the majority of the cells in the micro-dissected tissue would have been
from the VMP. However, to further confirm that primary VMPC are of VMP origin a
comparison of primary VMPC and VMP was performed. Primary VMPC were also
compared to primary URSC and UR as a comparison to non-VMP derived cells and
tissue.
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A key difference between primary VMPC and URSC is the rate of cell senescence. In
past literature it has been suggested that the number of cell divisions in vitro is directly
associated with the number of cell divisions in vivo (Hayflick, 1965; Martin et ah, 1970).
As the VMP eventually disappears after about P12 in the female it could be suggested
that the number of cell divisions in a female VMP would be considerably less than cells
in the URS. Hence the number of cell divisions in culture would be lower in primary
VMPC than URSC, which is reflected in cells in culture. There could be other reasons
for the lower number of cell divisions such as the loss of a VMP survival factor on
explant. Overall, it is likely that the main source of primary VMPC were VMP cells and
not SM cells.
Another key difference between primary VMPC and URSC is the expression pattern of
Tgfbeta transcripts. Previous research has shown that Tgfbeta transcripts are expressed
in cells derived from prostate tissue (Itoh et ah, 1998a; Story et ah, 1996), and through
inhibiting the growth of both epithelial and stromal cells TGFbeta has been proposed as
having dramatic effects on the prostate (Ilio et ah, 1995; Martikainen et ah, 1990; Story
et ah, 1993; Sutkowski et ah, 1992). Differential transcriptional regulation of Tgfbeta
genes has been previously shown (Geiser et ah, 1993), and targeted disruption of
Tgfbeta genes result in different phenotypes (reviewed in (Dunker and Krieglstein,
2000)), suggesting that TGFbeta isoforms may have different roles during development.
Our results demonstrated that primary VMPC and URSC expressed different levels of
Tgfbetal, Tgfbeta.2 and Tgfbeta?) transcripts, and the transcript levels were similar to
levels expressed in the organ rudiments from which they were derived. Thus we believe
our primary cells are a good reflection of the in vivo rudiments. This also suggested that
the different Tgfbeta isoforms could have different roles in development of the female
UGS to the female VMP e.g. as Tgfbeta? was more highly expressed in the VMP than
the UR (Fig. 3.10) thus Tgfbeta? may be involved in the formation of the VMP. The
difference in Tgfbeta isoform expression between primary VMPC and URSC also
suggested that primary VMPC were derived from the VMP and not UR.
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The idea of comparing primary VMPC to primary URSC was mainly based on the fact
that the URS was shown not to express FgflO transcripts by in situ hybridisation
(Thomson and Cunha, 1999). However, RNase protection assay revealed that low levels
of FgflO transcripts were expressed in the URS. FgflO transcripts were also expressed
in primary URSC at similar levels to primary VMPC (Fig. 3.11). The elevated
expression of FgflO transcripts in primary URSC may be a wound response to the cells
being disassociated from the URS, as FgflO may be a primary factor involved in the
process of wound healing (Tagashira et al., 1997). However, some reports suggest that
FGF10 is not involved in wound healing (Beer et al., 1997). The levels of FgflO
transcripts in the wounding process decreased after the initial increase after injury
(Tagashira et al., 1997), and this was reflected in cells in culture. The levels of FgflO
transcripts in primary URSC decreased after the second passage while levels of FgflO in
primary VMPC did not change with passage number. This further suggested that the
increase in FgflO transcript levels in primary URSC was a response to disassociation of
the URS, while the FgflO transcripts were expressed in primary VMPC because of the
expression already observed in the VMP rudiment. Also it was impossible to tell which
cells in the URS expressed FgflO, and whether the FgflO expressing cells were the only
cells to survive on plating out or if these cells were overgrowing the other cells. Another
possible explanation for the increase in FgflO transcripts levels may be that factors
produced in the epithelium are regulating its expression. As the URS is in close contact
with URE, factors produced by the URE may have repressed FgflO transcript expression
in the URS. When URS cells were disassociated and plated out they were no longer in
contact with URE cells, therefore the repression on FgflO transcript levels by URE no
longer occurred hence expression of FgflO transcripts was increased. Recently,
regulation of FgflO transcript levels was investigated in the lung (Bellusci et al., 1997b)
and FgflO transcript levels were repressed by factors produced in the epithelium, which
correlates with the hypothesis described above for the prostate. Also in lung studies it
was observed that in the absence of epithelium in vitro, mesenchymal cells have a
marked increase in the FgflO transcript levels (Lebeche et al., 1999). It was speculated
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that epithelial cells in the intact lung secrete factors that are inhibitory for FgflO.
Collectively this data suggests that FgflO gene expression in the lung could be regulated
by factors produced in the epithelium and as factors controlling branching
morphogenesis in the lung and prostate have proved to be similar this mechanism may
be carried through to regulation of factors in the prostate. Also as epithelia may repress
FgflO transcript levels you would expect more FgflO transcripts in the PO VMP
compared to the PO VP. In fact this was demonstrated in Fig. 3.11; the VMP expressed
four times more FgflO transcripts than the VP.
Primary URSC were meant to act as a negative control for promoter analysis i.e. cells
that do not express FgflO. The fact that primary URSC expressed FgflO transcripts
raised the question of whether primary URSC could have been used in experiments
addressing the regulation of FgflO gene expression as well as primary VMPC.
However, FgflO gene expression decreases in primary URSC after the second passage.
This suggested that primary URSC could be used at passage three in the promoter
analysis (i.e. when the cells did not express FgflO transcripts), but at this passage the
URSC were hard to transfect. The decrease in FgflO transcript levels after the second
passage in primary URSC also suggested that FgflO gene expression might have been
regulated by different factors to FgflO gene expression in primary VMPC. Also through
the characterisation of primary VMPC and comparing them to primary URSC it became
apparent that the two cell types had key differences that were characteristic to the
rudiment from which they were derived. Therefore primary URSC may prove to be a
useful cell type to examine and compare FgflO promoter construct activity at early
passage dates, although whether this would say anything about regulation of FgflO in
the prostate is unclear.
In conclusion primary VMPC were a good, but not perfect, model to examine the
regulation of FgflO transcript levels because 1) they express FgflO transcripts, 2) the
number of cell divisions may be representative of the life span of the VMP, 3) the
Tgfbeta transcripts expression pattern was similar to that of the VMP, 4) they expressed
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AR (described in chapter 3), and 5) they represent a cell type derived from a pad of
mesenchyme that can induce prostate organogenesis. However as primary VMPC
started to senesce after passage number one it was concluded that any experiments
would be performed before or at this passage number.
8.2 Regulation of FgflO Transcript Levels
Experiments were performed to determine whether testosterone and/or TGFbetal
regulated FgflO transcript levels in cells and prostatic organ rudiments.
8.2.1 The Effect of Testosterone
Previous studies have shown that androgen/AR action in mesenchymal cells is essential
for prostate development (Cunha and Lung, 1978; Lasnitzki and Mizuno, 1980; Shannon
and Cunha, 1983; Takeda and Mizuno, 1984; Takeda et al., 1985). Many studies have
attempted to identify paracrine factors that are stimulated by testosterone and that
promote prostate development (Finch et al., 1995a; Lu et al., 1999; Peehl and Rubin,
1995; Sugimura et al., 1996; Yan et al., 1992). FGF10 has been shown to function as a
mesenchymal paracrine regulator of epithelial growth and branching morphogenesis in
the VP (Thomson and Cunha, 1999). FgflO gene expression has been shown to be
regulated by testosterone in cells in vitro and has been proposed to be a mediator of
androgen action (Lu et al., 1999). However, there is some controversy concerning the
regulation of FgflO gene expression by testosterone (Thomson, 2001), hence it was
decided to further investigate this in our culture system. Data presented here suggested
that testosterone did not regulate FgflO transcript levels in primary VMPC cultured in
the presence of testosterone for either 7 or 48 hours. Also, culturing VPs in the presence
of testosterone for either three or six days did not regulate FgflO transcript levels.
Taken together these results confirmed data published by Thomson and Cunha
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(Thomson and Cunha, 1999). However, an increase in FgflO transcript levels in
response to testosterone was observed in NIH3T3 cells and in the female UGS.
FgflO transcript levels increased two-fold in NIH3T3 cells cultured for 48 hours in the
presence of testosterone. This increase was only observed in the presence of FCS
suggesting that testosterone was acting in conjunction with a factor within the serum.
NIH3T3 cells lack AR shown by immunohistochemistry and western blotting (Fig.
4.1A,B); therefore the change in FgflO transcript levels caused by testosterone must
have occurred through an AR independent pathway. One such pathway may involve the
human sex hormone-binding globulin (SHBG). It has been shown that biologically
active steroids activated receptor-bound SHBG to cause a response in LNCaP cells,
demonstrating a mode of action for steroid hormones that did not require interaction
with a steroid receptor (Nakhla et al., 1990). This study demonstrated that when LNCaP
cells were prebound with SHBG, addition of DHT resulted in a dose dependent increase
in intracellular cAMP. SHBG globulin in the absence of DHT or DHT in the absence of
SHBG was without effect. More recently it has been demonstrated that the ability of
oestradiol to induce cAMP in breast cancer cells (MCF-7) is not due to the ligand-bound
oestrogen receptor, but rather it was mediated via FCS (Fortunati et al., 1996; Fortunati
et al., 1999). In addition it was shown that SHBG triggers the cAMP pathway in MCF-7
cells at physiologic concentrations. The evidence points to a similar effect observed in
NIH3T3 cells. However, this was not further investigated in this thesis, as the effect did
not occur in primary VMPC that represented a developmental prostate cell type.
As mentioned previously an increase in FgflO transcript levels was also observed in the
female UGS cultured with testosterone. FgflO transcript levels increased in both the
VMP+UR and UR rudiments of the female UGS, when cultured in the presence of
testosterone for three days. It was proposed that FgflO gene expression might not be
directly regulated by androgens, and the observed elevated expression could be a result
of androgens stimulating proliferation of FgflO expressing cells. This would explain the
increase in FgflO transcript levels in both the VMP+UR and UR. Also this is the likely
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explanation owing to the fact that an increase in VMP size (i.e. in cells that express
FgflO) was obvious in UGSs cultured with androgens after three days (personal
communication S.Freestone). Other explanations for the change in FgflO transcript
levels involve the differentiation of cells in the female UGS. Testosterone may be
regulating cellular differentiation that may result in cells that express a higher level of
FgflO transcripts. Testosterone has also been shown to affect the differentiation of SM
cells in the female UGS (Thomson et al., 2002). In cultures of female UGS androgens
regulated the thickness of the SM layer resulting in a 2.4-fold reduction in thickness. It
is possible that FgflO positive mesenchyme may differentiate into SM, but the presence
of testosterone prevents this differentiation therefore there is more mesenchyme that
expresses FgflO transcripts. These processes propose an indirect pathway that
androgens may regulate FgflO transcript levels in the female UGS.
8.2.2 The Effect of TGFbetal
The TGFbeta peptides are members of a large superfamily of highly conserved
cytokines (Massague, 1998) that have been implicated in prostate development (Itoh et
al., 1998a; Timme et al., 1994). Analysis of Tgfbeta transcript levels between el7.5 and
P6 suggested that TGFbeta-signalling might participate in early VP development. These
results agreed with previous data suggesting Tgfbeta isoforms are associated with fetal
UGS tissues and prostate morphogenesis (Timme et al., 1994). A previous report
suggested Tgfbetal expression remains constant, and Tgfbetal and Tgfbeta3 expression
are inversely related during prostate development (Itoh et al., 1998a). This report
examined Tgfbeta expression patterns at PI, P20, P60 and P100 and compared values to
P20. My studies examined levels during the neonatal period, when the complex
processes of branching had relatively just commenced (Sugimura et al., 1986b),
therefore providing more complete picture of how Tgfbeta isoform expression might
correlate with early prostate development. Levels of Tgfbetal and Tgfbeta3 transcripts
were increased and decreased at similar stages throughout prostate development, while
Tgfbeta2 did not follow the same expression pattern. Differential transcriptional
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regulation of Tgfbeta genes has previously been shown by promoter analysis (Geiser et
al., 1993). Our results suggest that the regulation of Tgfbetal and Tgfbetal gene
expression was regulated differently to Tgfbetal gene expression during prostate
development.
The expression pattern of Tgfbeta isoforms suggested that TGFbeta plays an important
role in prostate development. TGFbeta has been shown to inhibit prostate growth (Itoh
et al., 1998a) playing an opposing role to FGF10, which has been shown to promote
growth and development (Thomson and Cunha, 1999). As TGFbeta 1 repressed FgflO
transcript levels in non-prostate cell lines (Beer et al., 1997; Lebeche et al., 1999), it was
decided to investigate whether TGFbetal regulated FgflO transcript levels in the
prostate. Data presented here showed that FgflO transcripts levels were reduced by
fourteen-fold in primary VMPC cultured in the presence of TGFbetal for three hours.
This repression was reversible, and after 48 hours FgflO transcript levels had reverted
back to normal levels. Repression of FgflO transcript levels was also observed in
NIH3T3 cells but this effect was less reversible. In that regard the result in NIH3T3
cells was different to what Beer et al. demonstrated, as their experiments showed that
FgflO transcript levels started to recover after eight hours in culture with TGFbeta (Beer
et al., 1997). This may simply be a result of using different cell lines. The reversible
effect of TGFbetal on FgflO gene expression in primary VMPC might have involved
complex interactions of TGFbeta-signalling pathways (discussed in chapter 1). The
reversible effect of TGFbeta on FgflO transcript levels observed in primary VMPC may
have been cause by an increase in inhibitory SMAD expression resulting in negative
feedback signalling that prevents TGFbetal action. Also the regulation of FgflO
transcript levels might not be a direct effect of SMAD induction but may be mediated
via other TGFbeta-inducible genes. One such gene is TGFbeta-inducible early gene
(TIEG). TIEG transcript levels increase rapidly after TGFbeta treatment but decrease
after 4 hours (Cook et al., 1998; Subramaniam et al., 1995). Also TIEG has been shown
to inhibit gene transcription (Cook et al., 1998; Yajima et al., 1997). The pattern of
TIEG expression after TGFbeta treatment is highly suggestive that TIEG may repress
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FgflO gene transcription when initially induced but when levels of TIEG drop less
repression occurs and FgflO transcript levels may return to normal. Future studies could
examine the induction and kinetics of TIEG and SMAD expression in primary VMPC to
determine which correlates with FgflO transcript changes.
As TGFbetal negatively regulated FgflO transcript levels in primary VMPC, we next
extended our analysis to VMP rudiments grown in vitro. A similar regulation of FgflO
transcript levels by TGFbetal was observed in VMP organ rudiments, but not in UR
organ rudiments. FgflO transcript levels were decreased a maximum of three-fold in the
VMP over seven hours which was comparable to the regulation of FgflO transcript
levels in primary VMPC at the same time point. The regulation of FgflO transcript
levels by TGFbetal in the VMP was not investigated at three hours as this length of time
was postulated as not being long enough for TGFbetal to penetrate and affect FgflO
gene expression.
The presence of epithelium may inhibit the regulation of FgflO transcript levels by
TGFbetal, as epithelial cells have been proposed to produce factors that regulate FgflO
transcript levels in the mesenchyme (Bellusci et al., 1997b). If this hypothesis is true,
then no or very little repression of FgflO transcript levels would be observed in the VP
depending on the extent of epithelial budding. In fact the highest level of repression of
FgflO transcript levels by TGFbetal in the VP was observed on day one of culture,
when epithelial branching was relatively low, and this repression was only half the level
observed in the VMP. As the extent of epithelial branching increased, even less
TGFbetal-mediated repression of FgflO transcript levels occurred. This data is highly
suggestive that the epithelium is inhibiting the repression of FgflO transcript levels by
TGFbetal in the VP. This theory also may explain why TGFbetal did not regulate
FgflO transcript levels in the UR, as URS is in close contact with URE. If there are
more buds then regulation of FgflO may be more tightly controlled. Also the effect of
TGFbetal on FgflO transcript levels is reduced as VPs develop suggesting that the effect
is temporal i.e. as the VP develops the effect of TGFbetal on FgflO transcript levels is
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progressively reduced. This hypothesis is substantiated as FgflO may play a dual role in
rat prostate development like branchless (bnl), an Fgf homologue, may play during
Drosophila tracheal branch formation. Bnl regulates tracheal branching in two ways, by
guiding tracheal cell migration and then inducing later programs of tracheal branching at
the ends of growing primary branches (Sutherland et al., 1996). FgflO may play a
similar role in rat prostate development, by inducing bud outgrowth and later promoting
and guiding branching morphogenesis. Hence it is possible that different molecules
regulate FgflO during these different stages of development, and TGFbetal may repress
FgflO transcript levels during early bud outgrowth and not during branching
morphogenesis. This may explain why TGFbetal only regulates FgflO transcripts
during early prostate development in the VP.
Androgens promote the growth and development of the prostate and TGFbetal
negatively regulates this process, suggesting that interactions between androgen and
TGFbeta signalling pathways may play significant roles during the development of the
prostate. Recent reports have identified Smad3 as an AR coregulator, and that this
interaction may either enhance (Kang et al., 2001) or inhibit (Hayes et al., 2001) AR-
mediated transcription. Also AR has been shown to repress TGFbeta signalling through
interactions with Smad3 (Chipuk et al., 2002), suggesting that androgens can inhibit
TGFbeta-mediated transcription. TGFbetal was shown to repress FgflO transcript
levels in primary VMPC, and the addition of androgens inhibited this effect, indicating
that androgens can inhibit TGFbeta-mediated transcription in prostate stromal cells. This
suggests that complex interactions between androgen and TGFbeta-signalling may
regulate prostate development.
8.2.3 Fgfl0 Promoter Analysis
Promoter analysis is a useful tool for the identification of factors involved in regulating
genes implicated in prostate development (Bloom et al., 1996; Fasciana et al., 1996;
Fenton et al., 1996; Finch et al., 1995b). Hence, a method of addressing the regulation
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of FgflO gene expression was to analyse the FgflO promoter. The first stage of
characterising the FgflO promoter was to map the transcription start site. 6 kb of
genomic sequence 5' to the translation start site was searched using NIX analysis for any
putative TATA-containing promoters. No characteristic TATA-promoters were
identified, so genomic sequences that were 5' to the FgflO translation start site (mouse
and human), and a cDNA sequence (sheep) for FgflO were compared using VISTA
analysis. A comparison between genomic sequences was performed as the percentage
identity between sequences might fall 5' to the transcription start site, i.e. in non-
transcribed sequences, and between genomic and cDNA, as the 5' end of cDNA should
lie on a transcription start site. In fact, the sequence identity fell in the same promoter
region (approximately 1300 nts 5' of the translation start site) in the comparison between
mouse and human, and mouse and sheep. Hence, this region might contain a putative
transcription start site. Riboprobes were designed from -1438 to -981 (probe 1), and
from -981 to -469 (probe2) (5' of the translation start site), to map transcription start
sites. RNase-digested bands were observed using both riboprobes and no fully protected
band was observed using probe2, therefore FgflO transcription was unlikely to start
between -1438 and -981, and more likely to start 3' of this region. However to verify
that the RNase-digested bands observed in probe 1 were not transcription start sites a
further riboprobe (probe3) was cloned spanning probe 1 and probe2, from -1131 to -631.
An RNase-digested band of approximately 70 nts in length was observed which was
highly suggestive that the RNase-digested bands detected using probe2 (between -700
and -770) represented a transcription start site. Probe4 (from -841 to -427) and probe5
(from -841 to -500) were cloned to exactly identify which nucleotide represented the
transcription start site, and probe6 was cloned from sequence 3' to the transcription start
site as a control riboprobe that should be fully protected. Numerous protected bands
were observed using probe4 and probe5 suggesting that there was more than one
transcription start site for FgflO. Amongst these bands, a single band was consistently
stronger than others with every probe used; this probably represented the major
transcription start site for FgflO.
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Analysis of the FgflO promoter revealed that it is a TATA-less promoter. Many
promoters do not contain consensus TATA boxes and TATA-less promoters can either
retain the ability to direct transcription initiation from a specific nucleotide or direct
transcription initiation through multiple sites (Smale, 1997). The FgflO promoter seems
to direct transcription initiation through multiple sites. No TATA box seemed to be
present upstream of this site. It has been shown that TATA-lacking promoters may
contain an element called an initiator (Inr) and the Inr can overlap the transcription start
site of both TATA-containing and TATA-lacking promoters (Smale, 1997). The first
functionally derived consensus sequence for Inr activity was derived from a mutant
analysis of over 80 generated Inr (Javahery et al., 1994). A loose consensus sequence of
(C/T)(C/T)A+1N(T/A)(C/T)(C/T) was revealed. The Inr of the FgflO promoter
(GGCTTCA) was not similar to the published consensus sequences, however other
typical features of TATA-less promoters were identified.
Further promoter analysis revealed a GC-rich region (63 %), including Spl consensus
sites in the vicinity of the transcription initiation site. A similar region was also
identified in the human promoter, with a GC-rich region (64 %) in the vicinity of the
transcription start site, however an identical Spl consensus site was not found. These
features are typical of TATA-less promoters with multiple transcription initiation sites
(Pugh and Tjian, 1990). Also the GC-rich region was reminiscent of CpG islands. CpG
islands can be 0.5-5 kilobases in size with a characteristically high G+C content (60-70
%). Initially CpG islands were identified as short stretches of DNA that contained a
nucleosome-free region allowing for easy access for transcription factors (Bird, 1986).
Approximately half of all mouse genes, mainly house keeping genes, and about 40 % of
genes with a tissue-restricted pattern (i.e. FgflO) contain CpG islands (Antequera and
Bird, 1993). As CpG islands allow for easy access to transcription factors, the putative
CpG island in the FgflO promoter could possibly harbour sites responsible for regulation
of FgflO gene expression. This region was confirmed as being a putative CpG island
using NIX analysis.
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Another characteristic of TATA-less promoters is the presence of a downstream
promoter element (DPE). Burke and Kadonaga (1996) identified a conserved element
about 30 bp downstream of the transcription start sites in a large number of Drosophila
genes. A consensus sequence for the DPE was suggested to be (A/G)G(A/T)CGTG
(Burke and Kadonaga, 1996). A similar sequence was identified (GGACTTG) in the
FgflO promoter exactly 30 bp downstream of the transcription start site. Overall
although the Inr consensus sequence does not exactly match the FgflO transcription start
site sequence, other characteristic features of the promoter suggest that this site is most
probably the major transcription start site.
Many regions of the FgflO promoter were highly conserved between mouse and human,
and these conserved regions 5' to the transcription start site might contain regulatory
elements. The conserved regions include the area containing the putative CpG island,
and in conjunction with Dr. Justin Grindley these regions were characterised. The
conserved regions were characterised by two methods, by cloning them into an enhancer
vector and by deleting the regions from the FgflO promoter. Two regions (A and F) of
the FgflO promoter were shown to regulate the activity of SV40 enhancer vector, but
when these regions were deleted from the FgflO promoter sequence in pA3Lucm no
change in promoter activity was observed. This suggests these regions have no direct
effect on Fgfl 0 transcription in the context of the Fgfl0 promoter. In contrast region G
(which contained the putative CpG island) had no effect on the SV40 enhancer vector,
but when deleted from the FgflO promoter FgflO transcription was repressed. As this
region was identified as being a putative CpG island capable of harbouring transcription
factor binding sites, and when deleted from promoter constructs altered FgflO
transcription, it can be suggested that region G is highly likely to contain sites that
regulate FgflO gene expression. Region G was analysed used GeneJockey II and a
putative Spl binding site was identified.
Certain genes have been shown to be Spl-dependent and the Spl site involved
participated in transcription initiation regardless of whether they contained TATA or
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TATA-less promoters (Botella et al., 2001; Brodin et al., 2000; Datta et al., 2000; Feng
et al., 2000a; Moustakas and Kardassis, 1998). Hence as FgflO transcription was
repressed when the Spl site (with surrounding regions) was deleted from the FgflO
promoter construct, it is highly likely that the Spl site was participating in FgflO
transcription. Also studies have shown that regulation of gene expression by TGFbeta
involves interactions of the Spl transcription factor and Spl binding sites (Bloom et al.,
1996; Botella et al., 2001; Brodin et al., 2000; Datta et al., 2000; Feng et al., 2000b;
Geiser et al., 1993; Li et al., 1998; Li et al., 1995). As TGFbetal repressed FgflO
transcript levels in cells and organs it was highly likely that the consensus Spl site in
region G might be involved in regulating FgflO gene transcription. To test these
hypotheses, FgflO promoter constructs were transfected into primary VMPC and treated
with TGFbeta 1. The Spl site was deleted from the FgflO promoter in two types of
constructs to address the effect on promoter activity and TGFbetal-mediated repression.
Initially the Spl binding site was 5' deleted leaving all the 3' sequence in pA3Lucm and
its activity was compared to the activity in promoter constructs containing the Spl site.
However this might not address whether regions 5' and in close proximity to the
putative Spl binding site regulated FgflO gene expression. As the activity of FgflO
promoter constructs did not change up to AA-G, it was decided to delete the Spl site
from AA-D. AA-D contained enough sequence 3' of the Spl site to harbour possible
areas involved in FgflO regulation and it was easier to clone this region than the Spl site
deleted from the full length construct. The Spl site seemed to mediate TGFbetal
repression of FgflO gene expression to levels observed in the core promoter. However
only a two-fold reduction in activity was observed in the presence of TGFbetal but
TGFbetal repressed FgflO transcript levels by up to fourteen-fold in primary VMPC.
Although there was only a two-fold decrease in levels, these levels were the same as
levels observed in constructs containing only the core promoter suggesting that
TGFbetal inhibited the majority, if not all, of FgflO's promoter activity, but not basal
activity. The difference between the regulation of promoter activity and endogenous
FgflO transcript levels by TGFbetal was probably due to the limitations of the
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transfection. Also binding sites that may mediate TGFbetal action could be found in
other parts of the FgflO promoter that were not studied in this thesis.
The deletion of the Spl site from AA-D resulted in a reduction in basal activity of the
FgflO promoter, again to similar levels observed in the core promoter, suggesting that
the Spl site was also involved in mediating basal transcriptional activity. In construct
-Spl, i.e. the Spl site was 5' deleted, the activity was reduced to a lesser degree than
observed in AA-DASpl, raising the question of whether FgflO gene expression was
mediated though the Spl site. However ASpl only represents a small part of the
promoter while AA-DASpl represents a larger proportion of the promoter, leading to the
conclusion that the effect observed in AA-DASpl was probably a more accurate
assessment of the function of the Spl site. It is not known why there was a difference
between ASpl and AA-DASpl activity in transfected cells but it may be a result of
cryptic sites in the plasmid that may have altered the regulation of transcription in the
ASpl plasmid construct. However this explanation is difficult to justify as the same
vector was used for each promoter construct and therefore they contained the same
potential 'cryptic sites'.
In conclusion we have identified a promoter whose basal transcriptional activity is
regulated by Spl. Numerous other studies have identified similar regions of promoters
that regulate transcriptional activity (Botella et al., 2001; Brodin et al., 2000; Datta et al.,
2000; Feng et al., 2000a; Moustakas and Kardassis, 1998), however the majority of these
studies demonstrated that TGFbeta signalling induced transcription while our results
showed that TGFbeta inhibited FgflO transcription. This may be due to the increase in
TIEG proteins (briefly described in chapter 1). TIEGs are induced by presence of
TGFbeta (Cook et al., 1998; Subramaniam et al., 1995) and may cause a repression of
gene transcription (Tachibana et al., 1997; Tau et al., 1998; Yajima et al., 1997). TIEGs
also have the ability to bind to GC-rich regions, like Spl sites (Cook et al., 1999; Cook
et al., 1998; Yajima et al., 1997) therefore they may mediate their effect via competing
for binding with Spl. By competing for binding and thus preventing Spl mediated
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transcription, TIEG may reduce FgflO transcript levels. The regulation of FgflO
transcript levels by TGFbetal is transient and FgflO transcript levels begin to return to
normal levels after seven hours in culture (chapter 4). However TIEG transcript levels
increase rapidly in cells after treatment with TGFbeta and levels return to normal after 4
hours in culture (Cook et al., 1998; Subramaniam et al., 1995). The change in transcript
levels of TIEG and FgflO are therefore inversely related; as TIEG transcripts increase
FgflO transcripts decrease. This is suggestive that TGFbetal may be regulating FgflO
transcript levels via the induction of TIEG. This proposes a novel way in which
TGFbetal may mediate FgflO gene transcription and gene expression. However the
expression and regulation of TIEG in primary VMPC and the binding of TIEG in
competition to Spl to the FgflO promoter needs to be further investigated to verify this
hypothesis.
8.3 Regulation of VP Development by TGFbetal
Numerous growth factors have been identified as mediators of mesenchymal-epithelial
interactions in prostate development (Finch et al., 1995a; Peehl and Rubin, 1995;
Thomson and Cunha, 1999; Thomson et al., 1997; Timme et al., 1994). TGFbeta has
been proposed to be one such factor, and it has been shown that TGFbetal can inhibit
prostate growth (Itoh et al., 1998b; Tanji et al., 1994). It has also been suggested that
TGFbetal probably plays a significant role in the induction of prostatic budding (Timme
et al., 1994). As FGF10 can promote prostate growth and is an important factor for
prostate development (Thomson and Cunha, 1999), and TGFbetal can regulate FgflO
transcript levels (shown in chapters 2 and 3), it can be suggested that TGFbetal and
FGF10 may play opposing roles in development of the prostate. So next the effect of
TGFbetal on VP growth and development was investigated.
The role of TGFbetal in the growth and development of the neonatal VP was
investigated using an organ culture system. TGFbetal was shown to reduce the area of
VPs confirming TGFbetal as an inhibitor of prostate growth, but TGFbetal also
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increased the number of epithelial buds around the periphery of the organs. This
suggested that TGFbetal might have multiple roles in prostate growth and development.
Inhibition of growth of the VP by TGFbeta has been previously demonstrated (Itoh et
al., 1998a). Itoh et al. (1998) also demonstrated the ability of TGFbeta to inhibit ductal
branching morphogenesis. However, in our study androgens and TGFbetal were found
to promote the number of buds suggesting that TGFbetal might promote branching
morphogenesis. Itoh et al. (1998) examined the number of branching ducts throughout
the organs using a two-dimensional image, while our data determined the number of
buds around the periphery of the organs. This method was used because it was decided
that it was too difficult to determine the number of branching ducts, but counting the
number of buds around the periphery of VPs was an accurate and easy way of
comparing the effect of TGFbetal on branching morphogenesis. Hence, the different
results may reflect the different methodologies.
It has previously been shown that the TGFbetal-mediated transcriptional changes could
be inhibited by testosterone in cell lines (Fig. 4.8) (Chipuk et al., 2002) and in organ
culture (Fig. 7.7). In the current study the changes in growth induced by TGFbetal in the
VP were not inhibited by testosterone, suggesting the effects caused by TGFbetal were
not transcriptional responses that were regulated by this mechanism. This proposes that
the transcriptional changes, described in this thesis, caused by TGFbetal and that were
inhibited by testosterone were not fully responsible for the changes in growth induced by
TGFbetal.
To determine if the changes in size and bud number of VPs were due to TGFbetal
regulating the proliferation rate of cells, proliferative index was calculated by BrdU
incorporation. TGFbetal has been well documented as inhibiting cell proliferation
(Blanchere et al., 2001; Bretland et al., 2001; Ilio et al., 1995; Wilding et al., 1989), but
TGFbetal has also been shown to increase the proliferation rate of cells (Hsu et al.,
1994; Kansra et al., 2000; Lamm et al., 1998; Schroy et al., 1990). The increase in
proliferation rate by TGFbetal has been associated with undifferentiated cell types (Hsu
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et al., 1994; Kansra et al., 2000; Lamm et al., 1998; Schroy et al., 1990), suggesting that
the proliferation rate of undifferentiated cells may be stimulated by TGFbetal while the
proliferation rate of more differentiated cells are inhibited by TGFbetal. It was
demonstrated that TGFbetal had a similar effect in cells at different stages of
differentiation in the VP (Fig 7.6). TGFbetal increased the proliferation of relatively
undifferentiated cells but inhibited proliferation of differentiated cells. Also testosterone
is known to promote differentiation of prostate epithelial cells, and it was demonstrated
that after six days the inhibition of proliferation in the proximal region by TGFbetal was
greater in organs cultured with testosterone than those cultured without testosterone.
Hence this result strongly suggests that TGFbetal inhibits the proliferation of
differentiated cell types while promoting proliferation of undifferentiated cell types.
The changes in cell proliferation rate, in different regions of VPs cultured with
TGFbetal, also correlated with the change in their two-dimensional size. Although
TGFbetal increased the proliferation rate of cells this was only a significant increase
after six days in culture. In contrast the inhibition of cell proliferation in the proximal
regions was apparent at all time points examined. This suggests that overall the organs
cultured with TGFbetal should be smaller than those cultured with vehicle, which is
representative of what was demonstrated. Also the increase in proliferation was only
observed in the absence of testosterone. TGFbetal might not have increased the rate of
proliferation in cells in the presence of testosterone as the maximum proliferation rate
might have been reached in response to testosterone in this system. However this
observation might explain why the difference in size between VPs cultured with
TGFbetal was greater in VPs cultured in the presence of testosterone (32 % decrease)
than those cultured in the absence of testosterone (21 % decrease).
It was also shown that bud number increased in VPs cultured with TGFbetal in the
presence and absence of testosterone, but cell proliferation was only increased in the
absence of testosterone. This suggests that an increase in bud number was not related to
an increase in proliferation rate of epithelial cells, which agrees with previous data that
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has shown that increased cell proliferation is not a prerequisite for budding in lung
explants (Nogawa et ah, 1998).
The regulation of Tgfbeta gene expression in the prostate has previously been
investigated in adult prostates and prostate cells lines (Itoh et ah, 1998a; Kyprianou and
Isaacs, 1989), but none have addressed it during neonatal prostate development. The
regulation of Tgfbeta transcript levels was investigated to determine if any changes in
transcripts levels could be correlated to the changes observed in VP morphology. To
investigate the regulation of Tgfbeta transcript levels male and female prostatic organ
rudiments were cultured with TGFbetal and/or testosterone. However, the comparison
between the changes in Tgfbeta transcript levels in the VMP and VP is difficult owing to
the different lengths of time the organ rudiments were cultured, but Table 7.2 and 7.3
were designed for an easier comparison of results. We have demonstrated that both
TGFbetal and testosterone can regulate the levels of Tgfbeta transcripts in cultured
organ rudiments. However the pattern of gene regulation was different between male
and female organ rudiments and on the length of time in culture. This suggests that
epithelial interaction in the male rudiment may be affecting the regulation of Tgfbeta
transcripts, and that the regulation of transcripts is dynamic.
Overall these results suggest that the interactions between TGFbetal and testosterone
regulate the growth and development of prostatic rudiments. The changes in phenotype
of the VP induced by TGFbetal were not inhibited by the presence of testosterone. This
suggests that the transcriptional regulation of Tgfbeta transcripts observed in these
experiments may not be fully responsible for the changes observed in the architecture of
the VP induced by TGFbetal. However TGFbetal regulated both FgflO and Tgfbeta
transcript levels over seven hours in VPs, and the resultant changes may lead to the
changes in growth and development observed in this thesis. In fact a preliminary study
(where VPs were treated with TGFbetal for seven hours, TGFbetal was then removed
and organs were further grown with or without testosterone for six days), suggested that
short-term TGFbetal treatment of VPs would lead to the same changes in morphology
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as observed over six days. However owing to limited time and technical problems
associated with this approach this was not examined further. More research is needed to
investigate this hypothesis.
8.4 Summary
In conclusion, it has been demonstrated that primary VMPC were a good, but not
perfect, model to examine the regulation of FgflO transcript levels. TGFbetal repressed
FgflO transcript levels in primary VMPC. The regulation was rapid and reversible, with
maximum repression at three hours. TGFbetal was also shown to regulate FgflO
transcript levels in VMP but not in UR organ rudiments grown in vitro. TGFbetal also
repressed FgflO transcript levels in the VP, but the repression was to a much lesser
extent than in the VMP, and primary VMPC and the effect was temporal. It has been
proposed that the regulation of FgflO transcript levels is strictly controlled by the
presence of the epithelium in the VP, and that the presence of epithelial buds inhibited
the TGFbetal-mediated repression of FgflO transcript levels. As the epithelium
becomes more branched less repression of FgflO transcript levels (in response to
TGFbetal) was observed suggesting that the epithelium was decreasing the effect of
TGFbetal. Regulation of FgflO gene expression was also studied by the
characterization of the FgflO promoter. Using this method an Spl binding site was
identified that, when deleted from the promoter, caused a decrease in promoter activity
suggesting the Spl site was involved in FgflO transcription. Also TGFbetal was found
to decrease FgflO promoter activity through the consensus Spl site, thus identifying a
binding site in the FgflO promoter that was mediating the effect of TGFbetal.
It was demonstrated that Tgfbeta 1, Tgfbetal, and Tgjbetah transcript expression
correlated with growth and development of the prostate, indicating a potential role for
TGFbeta isoforms in prostatic development. TGFbetal inhibited growth of the VP and
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had differential effects on cell proliferation. Also TGFbetal and testosterone regulated
Tgfbeta transcript levels in organ rudiments. The changes in phenotype of VP cultured
with TGFbetal was not inhibited by testosterone, but the regulation of TGFbetal-
mediated transcriptional responses were inhibited by testosterone. This suggests that the
TGFbetal-mediated transcriptional changes examined in this thesis did not fully cause
the changes in VP phenotype. However the short-term effects of TGFbetal on VPs
might have caused a change in branching morphogenesis at an early stage of
development that affected the patterning of growth. This suggests that the changes in
FgflO and Tgfbeta transcript levels might have in part been responsible for the changes
in VP phenotype. Further research is needed to clarify this hypothesis.
Overall I have demonstrated that TGFbetal regulates FgflO transcript levels in the
prostate and that this effect is temporal and may be dependent on the presence of
epithelium. It has also been demonstrated that Tgfbeta isoforms are expressed during
periods of prostatic growth and may therefore play a role in prostate development.
TGFbetal was shown to inhibit prostate growth. However although TGFbetal inhibited
cell proliferation in the proximal region to urethra of the VP, surprisingly, TGFbetal
stimulated cell proliferation in the distal region of the VP. As FGF10 promotes prostate
growth and TGFbetal inhibits it, we can conclude that TGFbetal plays an antagonistic
role to FGF10 during prostate development.
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